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Abstract 
Human cytomegalovirus (HCMV) infection is recognized as the major cause of 
morbidity and mortality in patients who receive hematopoietic stem cell transplant 
(HSCT). Currently, four antiviral drugs, Ganciclovir, Valganciclovir, Foscarnet and 
Cidofovir are used to prevent and treat HCMV infection and diseases. However, prolonged 
antiviral therapy, which is often necessary, may lead to antiviral resistance associated with 
the development of mutations in the phosphokinase (UL97) and/or DNA polymerase 
(UL54) viral genes. The characterization of HCMV drug resistance mutations is an 
important issue, improving the management of patients with alternative treatments. This 
study aims to characterize HCMV UL97 and UL54 mutations in twenty two patients with 
HCMV infection submitted to allogeneic HSCT at the Portuguese Oncology Institute of 
Porto (IPO Porto). To characterize HCMV mutations, DNA fragments of both UL97 and 
UL54 were amplified by nested PCR and sequenced for genetic characterization. The 
genetic information was compared with the reference HCMV strains and described as 
resistance mutations, polymorphisms or unknown mutations. Resistance mutations were 
identified in seven patients (32%): five (23%) harbored HCMV resistance mutations in 
UL97 (C592G, A594V, L595W and C603W) and two (9%) harbored HCMV resistance 
mutations in UL54 (P522S and L957F). These UL97 resistance mutations are amongst the 
most frequently detected mutations in HCMV. UL54 gene was less frequently mutated and 
its mutations were detected in the absence of UL97 mutations. The P522S mutation is one 
of the most frequent UL54 gene mutations while L957F mutation has only been reported 
on laboratory strains, until now. Several polymorphisms were also found in both genes in 
combination with the resistance mutations. Unknown mutations in UL97 and/or in UL54 
were also found, which may play an important role in the emergence of antiviral resistance. 
Resistance mutations, which lead to an impaired response to the therapy, confer different 
resistance levels which are an important factor that influence patient’s outcome. Other 
factors rather than the level of resistance may have been important in the definition of this 
outcome, and the presence of polymorphisms and unknown mutations may help modulate 
the drug-resistance level induced by resistance mutations. 
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Resumo 
A infecção pelo citomegalovírus humano (HCMV) é reconhecida como a principal 
causa de morbilidade e mortalidade em doentes que recebem transplante de células 
estaminais hematopoéticas (HSCT). Atualmente, existem quatro fármacos antivirais 
(Ganciclovir, Valganciclovir, Foscarnet e Cidofovir) para prevenir e tratar a infecção e 
doenças causadas pelo HCMV. Contudo, uma terapia antiviral prolongada pode levar à 
resistência antiviral associada ao desenvolvimento de mutações nos genes virais 
fosfocinase (UL97) e/ou DNA polimerase (UL54). A caracterização das mutações de 
resistência aos fármacos anti-HCMV é importante no sentido de melhorar o tratamento dos 
doentes. Este estudo teve como objectivo caracterizar as mutações nos genes UL97 e UL54 
em vinte e dois doentes com infecção HCMV, que foram submetidos a HSCT alogénico, 
no Instituto Portugês de Oncologia do Porto. Os genes UL97 e UL54 foram amplificados 
por nested PCR e sequenciados para caracterização genética. A informação genética foi 
comparada com estirpes HCMV de referência e descrita como mutações de resistência, 
polimorfismos ou mutações de fenótipo desconhecido. Foram identificadas mutações de 
resistência em sete doentes  (32%): cinco (23%) continham  mutações no UL97 (C592G, 
A594V, L595W e C603W) e dois (9%) continham mutações no UL54 (P522S e L957F). 
As mutações de resistência encontradas no gene UL97 estão entre as mutações mais 
frequentes nas estirpes resistentes. As mutações do UL54 foram detectadas na ausência de 
mutações no UL97 e numa frequência menor. A mutação P522S é uma das mais frequentes 
no UL54 e a mutação L957F apenas tem sido reportada em estirpes laboratoriais. Vários 
polimorfismos foram encontados em ambos os genes, em combinação com as mutações de 
resistência. Adicionalmente, também foram identificadas mutações de fenótipo 
desconhecido, as quais poderão ser importantes no aparecimento da resistência antiviral. 
As mutações de resistência, que conferem diferentes níveis de resistência, levaram a uma 
resposta inadequada à terapia com impacto no outcome dos pacientes. Outros factores 
podem também ter sido importantes para o outcome dos doentes, sendo que a presença de 
polimorfismos e mutações de fenótipo desconhecido poderão ter ajudado a modular o nível 
de resistência das mutações. 
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Chapter 1  
Literature’s Review 
1.1. Human Cytomegalovirus (HCMV) 
In 1881, Ribbert described the presence of large intranuclear inclusions in kidney 
sections of a stillborn infant with congenital syphilis, who thought at that time that were 
caused by protozoal infections [1, 2]. These typical morphological alterations, known as 
“cytomegalic inclusions”, were also reported by several authors during the early 1900s, 
and were attributed to either syphilitic or protozoan infection [3]. Nevertheless, it was only 
in 1921 that Goodpasture and Talbert have suggested that these “cytomegalic inclusions” 
could be caused by a viral agent [1, 4, 5]. In fact they suggested that the occurrence of 
these morphologic alterations in the liver and kidney without the presence of inflammatory 
signs appeared to indicate that the causal agent could be transported by the bloodstream [1, 
4, 5]. Furthermore, in 1950, Smith and Vellios also showed that this infection could be 
spread in the utero [4]. 
Despite the evidences for a viral association, it was only in 1956 that Smith et al. 
and Rowe et al. followed by Weller et al., in 1957, were able to isolate human CMV 
strains from the human salivary gland [4]. Later in 1960, Weller et al. proposed the term 
“cytomegalovirus” [1, 4]. Since then, human cytomegalovirus (HCMV) has been 
recognized as one of the most common opportunistic pathogens, especially found in 
immunocompromised patients as human immunodeficiency virus (HIV)-infected or 
transplanted patients [2, 4]. 
1.1.1. General characteristics  
HCMV is a ubiquitous virus that belongs to the Herpesviridae family [6, 7] sharing 
with other herpesviruses a similar virion structure (icosahedral nucleocapsid, surrounding 
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tegument layer, and an envelope containing embedded viral glycoprotein complexes), a 
double-stranded DNA genome, kinetics of viral gene expression, persistence for the 
lifetime of the host after primary infection, reactivation from latency, and reinfection  [8-
14]. Within Herpesviridae family, HCMV belongs to the betaherpesvirinae subfamily and 
is alternatively known as Human Herpesvirus 5 (HHV-5) [12]. It is considered the 
betaherpesvirus prototype due to the tropism for salivary glands, the restricted host range 
and the slow replication that leads to slow spread of infectious particles in cell culture [8, 
15, 16]. Even though the immune system keeps HCMV infections under control, a total 
HCMV clearance is rarely achieved, and the viral genome remains in a latent state [13, 17]. 
In fact, members of betaherpesvirinae subfamily are characterized by latent infections 
which are maintained in myeloid lineage cells [6]. Especially in cases of immune 
suppression, the reactivation of HCMV from latency is a key step in the pathogenesis of 
HCMV infection [6, 10-12, 17]. 
1.1.2. Structural characteristics  
The mature HCMV virion particle has between 150 and 200 nm of diameter and is 
structurally more complex when compared to other members of the Herpesviridae family 
[1, 7, 18]. Structurally, a mature virion consists of a double-stranded linear DNA genome 
within a 100 nm diameter complex icosahedral nucleocapsid, surrounded by a lipid 
envelope containing embedded viral glycoprotein complexes [6, 18, 19]. Between the 
nucleocapsid and the envelope there is the tegument, an amorphous structure with some 
degree of organization which contains viral phosphoproteins – Figure 1 [6, 18, 20]. 
 
Figure 1: Structure of a mature HCMV virion. dsDNA – double stranded DNA is packaged in an nucleocapsid, surrounded by the 
tegument layer, and enclosed in the host-derived lipid envelope studded with virally encoded glycoproteins. Adapted from [6]. 
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HCMV-infected cell cultures are characterized by the production of infectious 
virions and two other types of particles: noninfectious enveloped particles (NIEPS) that are 
very similar to infectious virions but lack viral genomes packaged within the icosahedral 
nucleocapsid; and dense bodies (DB) that are composed by several tegument proteins, but 
lack an assembled nucleocapsid and viral genome. Depending upon the viral strain and the 
number of infectious cycles in culture,  the ratios of the three forms of HCMV particles 
released from infected cells vary [8, 18, 20].  
The virion structural proteins, mainly proteins of the capsid, have been described as 
having homology to other herpes virus [7]. The capsid is an icosahedral structure 
consisting of 12 pentons, 150 hexons, and 320 triplexes of proteins that self-assemble into 
an icosahedral structure [7]. Of the more than thirty viral proteins found in the complete 
infectious virion, at least four proteins constitute the capsid: major capsid protein (pUL86); 
minor capsid protein (pUL85); the minor capsid protein-binding protein (pUL46); and the 
small capsid protein (pUL48-49) [7, 18, 21]. The pUL86 is the most abundant protein 
component of the capsid (960 copies) and forms the penton and hexons of the icosahedral 
capsid. The pUL85 (two copies) and pUL46 (one copy), form the triplexes that are located 
between the pentons and hexons. The smallest capsid protein (pUL48-49) has been shown 
to decorate the hexons of the capsid and is essential for the assembly of infectious virions, 
perhaps through interactions with tegument proteins [7, 22]. 
Among herpesviruses, HCMV has the largest coding capacity for glycoproteins. At 
least 57 potential glycoproteins are encoded by AD169 laboratory strain, while clinical 
isolates and Toledo laboratory strain, contain an additional 13 open reading frames (ORFs) 
that may also encode glycoproteins [23-25]. While some glycoproteins are proposed to 
play specialized functional roles tailored to replication and pathogenic features in the 
biology of HCMV infection, others are likely functionally redundant [24, 25]. The 
phospholipid envelope contains 6 genes encoded glycoproteins: gpUL55 (gB), gpUL73 
(gN), gpUL74 (gO), gpUL75 (gH), UL100 (gM), and gpUL115 (gL). These glycoproteins 
play essential roles in virus entry into host cells, cell-to-cell interaction and virion 
maturation [25-27]. Studies have revealed that the gB, gN, gM, gL and gH glycoproteins 
have an essential role for the production of infectious virus, in which an disruption of 
ORFs results in the failure to produce infectious progeny [7, 21]. Only gO is dispensable 
for viral growth in culture fibrobasts [21]. The glycoproteins of the six major glycoprotein-
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encoding genes, associate to form three glycoprotein complexes: gCI, composed of 
homodimeric gB molecules linked by disulfide bonds; gCII, comprises gM, a type III 
membrane protein, and gN, a type I membrane protein; and gCIII, composed of gH 
heterotrimer plus gO and gL [7, 23-25, 28]. These glycoprotein complexes are highly 
conserved within herpesviruses and function as membrane glycoproteins. At least two 
glycoprotein complexes (gCI and gCIII) are required for viral entry into cells [27]. While 
gCI appears to be the primary glycoprotein involved in attachment to the cell, gCIII is 
implicated in HCMV and host cell membrane fusion [21]. Very little is known about the 
role of components of the gCII complex, which have been identified as heparin binding 
proteins of the envelope [23]. 
The remaining 20-25 structural proteins are enclosed in the tegument layer of 
HCMV virions, which is characterized by an amorphous layer between the nucleocapsid 
and the envelope [18, 20]. The tegument appears to be formed by the sequential addition of 
proteins collected from the nucleus and the cytoplasm of infected cells. Some are 
expressed only in the nucleus (ppUL69), others only in the cytoplasm (ppUL32/pp150 or 
ppUL99/pp28), and others (ppUL53 and ppUL83/pp65) are expressed in the nucleus but 
are often found in the cytoplasm [29].  
Most tegument proteins are phosphorylated and are highly immunogenic [18, 20]. 
There are five predominant proteins in the tegument: the basic phosphoprotein ppUL32, 
the high molecular weight protein ppUL48, the high molecular weight-binding protein 
ppUL47, the  upper matrix protein ppUL82 and the lower matrix protein ppUL83 [30], 
while more than 20 proteins have been identified at lower concentrations, including gene 
products of UL99, UL97, UL26, UL35 and UL88 [31]. Due to its large amounts, pp65 is 
the target antigen in antigenemia assays for rapid diagnosis of HCMV clinical infections 
[21]. The tegument proteins are thought to be involved in the maturation of virions, 
influence viral and cellular events in the early stages of infection, such as release of viral 
DNA from disassembling virus particles or the regulation of viral and cellular gene 
promoters [7, 18, 20, 21]. The tegument ppUL99/pp28 protein appears to be essential for 
virus replication by providing an essential function for virion envelopment, while pUL94 
contributes for the secondary envelopment of virions [32, 33]. Furthermore, ppUL69 and 
ppUL82/pp71 are transactivators of both viral and cellular gene expression contributing for 
the dysregulation of cycle progression [7, 20]. pp71 has been shown to transactivate 
immediate early viral promoters as well as target cellular retinoblastoma (Rb) family 
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members for degradation and ppUL69 has been shown to restrict cell cycle progression 
[21, 34, 35]. 
1.1.3. Genetic characteristics 
The HCMV genome is the largest of all herpesviruses with approximately 230 000 
basepairs (bp) [1, 19, 36, 37].  The organization of the viral genome consists of two 
covalently linked segments, (UL as unique long and US as unique short) bounded by 
repeat sequences located internally (internal repeat sequences binding the long and short 
segments, IRL and IRS, respectively) and terminally (terminal repeat bounding the long 
and short segments, TRL and TRS, respectively) - Figure 2 [11, 19, 37-39].   
 
 
Figure 2: Structural components of the HCMV genome. UL and US indicate unique long and unique short regions, respectively. Repeat 
sequences are denoted by: TR - terminal repeat, IR – internal repeat. Positions of genes of interest are indicated by dotted lines. Arrows 
show the direction of the open reading frame (ORF) for each gene. Adapted from [19]. 
 
Like the genome of other herpes virus, both segments can undergo inversion, 
resulting in four isomers of the viral genome [1, 7, 21, 39, 40]. Inversion of UL and US 
regions is mediated by direct repeat elements (a, b, c) at the genome termini and by 
inverted repeat elements at the UL-US junction (a´, b´, c´) - Figure 3 [21, 39]. 
 
Figure 3: Structure of the four HCMV genome isomers, which are produced  by inversion of UL and US regions [21]. 
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The HCMV genome contains a single origin of replication, and like all human 
herpesviruses encodes a complete package of genes required for viral DNA replication 
including the DNA polymerase gene (UL54) [19, 36].  
Viral genes conserved between different betaherpesviruses are most frequently 
found in the UL region of the genome, whereas genes located within the US region in 
general, encode functions that are specific for betaherpesviruses, including the host 
restriction of HCMV [7]. A significant number of genes in the UL region encode proteins 
that likely play key roles in the tissue and cellular distribution of the virus in vivo, yet are 
dispensable for in vitro replication [7].  
The number of virus genes encoded by the genome of HCMV is greater than in 
other herpesviruses, but it remains unclear how many ORFs are expressed [40]. In fact, 
depending on the virus strain and the used prediction method, the HCMV genome has been 
estimated to encode between 192 and 252 ORFs [41]. Studies have assigned functional 
roles to some HCMV ORFs, nevertheless, the products of more than 50 HCMV ORFs have 
been considered dispensable for productive replication in vitro [21, 42]. Approximately 
25% of the herpesvirus-conserved ORFs appear to encode functions related to viral DNA 
metabolism and replication, whereas the remaining 75% are thought to be involved in the 
maturation and structural organization of virions [21]. 
The AD169 laboratory strain was the first and the only completely sequenced 
HCMV strain, nevertheless it seems to have shorter genome than do many clinical isolates 
[36]. Analysis of its genome has revealed that it encodes 225 ORFs of about 100 or more 
amino acids (aa) residues in length, named according to the region and the numerical order 
in which they occur [19, 42]. There have been described the existence of unique ORFs, 
UL1-154 (with some ORFs receiving fractional designations such as UL21.5) and US1-36; 
and also repeated ORFs, J1L/J1I/J1S, TRL1-14/IRL1-14; and IRS1 plus TRS1 - Figure 4 
[42]. Additional ORFs have been identified in two laboratory strains (Towne and Toledo) 
and in clinical isolates [42]. The Toledo strain, as well as some clinical isolates contains an 
additional 15 kilobases (kb) of DNA that is absent in the genomes of AD169 and Towne 
strains [19, 36, 41]. This large block of DNA seems to contain 19 genes encoding for viral 
glycoproteins and other specialized functions [36, 41].  
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Figure 4: Schematic diagram of the linear, double-stranded DNA of HCMV. Repeated genes (J1L/J1I/J1S, TRL1-14/IRL1-14) and 
partially repeated genes (IRS1 and TRS1) are represented by rectangles, whereas unique gene blocks (UL1-UL154 and US1-US36) are 
designated by a line [42]. 
1.2. HCMV Infection 
1.2.1. Epidemiology 
HCMV is a common virus with unknown seasonal predominance and its 
epidemiology varies in different regions of the world and between socioeconomic and age 
groups [1, 43, 44]. Generally, the prevalence of HCMV infection is higher in developing 
countries and among persons of lower socioeconomic status in developed nations [1, 45]. 
HCMV infection is considered important in certain risk groups such as 
immunocompromised individuals and pregnant women [43, 45].  
The incidence of HCMV infection in the general population ranges from 36 to 90%, 
but the overall seroprevalence in developed countries is estimated to be in the range of 30–
70% [44, 46]. HCMV infection gradually increases with age, showing the lifelong risk of 
acquiring HCMV infection [1, 43, 45]. The prevalence of HCMV seropositivity in younger 
age varies according the social standing, being higher in lower economic classes [41, 47].  
Racial differences have also been described, with higher seroprevalence found in African 
Americans and Hispanics than in Caucasians [1, 45]. An increased seroprevalence of 
HCMV has also been described in women attending sexually transmitted disease clinics 
and in young homosexual males [1, 44].  
1.2.2. Source of Transmission 
HCMV is easily transmitted orally, through sexual intercourse, breastfeeding, 
placental transfer, blood transfusion or transplantation [44, 46]. The unsuspecting host is 
thus able to spread the virus both vertically and horizontally [1, 21, 48], since it is excreted 
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through body fluids (urine, saliva, tears, semen, milk, and cervical secretions) for months 
to years. [12, 43, 48]. 
Vertical transmission of HCMV can occur in three different ways: transplacental, 
intrapartum or breastfeeding [1]. Transplacental transmission can occur both in women 
infected for the first time during pregnancy and those infected long before conception [21]. 
A primary infection in the first 16 weeks of pregnancy is associated with higher rate of 
damage in fetal development [43]. Infection during delivery is due to shedding from the 
vagina or cervix, followed by ingestion of infected secretions by the offspring [21]. 
Breastfeeding is considered the most common mode of transmission to children and plays 
an important role in the epidemiology of HCMV infection as the virus is reactivated during 
lactation in nearly every seropositive mother [1, 43, 48].  
Epidemiologic studies support the classification of HCMV as a sexually transmitted 
infection, consistent with excretion of this virus in cervical secretions, vaginal fluid, and 
semen [1]. Furthermore, HCMV has also been described as capable of being transmitted 
through blood or transplants [1]. The association between the acquisition of HCMV 
primary infection and blood transfusion was first suggested in 1960 as it is assumed that 
the virus is latent in the blood cells of healthy donors and is reactivated following 
transfusion when they encounter an allogeneic stimulus [1, 21].  
1.2.3. Infection and replication Cycle 
HCMV infection starts with the attachment of HCMV membrane glycoproteins to 
the host cell surface receptors by a pH-independent mechanism [1, 3, 20, 21, 37] followed 
by the uncoated of viral capsids and rapid translocation of viral DNA into the nucleus – 
Figure 5 [3, 21].  
The mechanism by which HCMV entry proceeds is cell type-dependent and occurs 
via fusion with the plasma membrane (on fibroblasts) or by acid-mediated endocytosis (in 
epithelial and endothelial cells). Both pathways require the viral gH/gL complex, however 
further characterization indicates that while gCIII (gH/gO/gL) is involved in binding of 
HCMV to fibroblasts, a complex consisting of gH/gL/UL128-131 plays a significant role 
in attachment and entry into epithelial and endothelial cells [1, 7, 20, 49].  
Virus attachment and penetration are fast and efficient in both permissive and 
nonpermissime cell types [3, 21, 49]. The viral glycoprotein B (gB), encoded by UL55 
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gene, is the primary viral ligand that interacts with two separate binding sites: the heparin 
sulfate proteoglycans and a non-heparin receptor [21]. During the initial virus-cell 
interactions, HCMV attaches to the cell surface by low-binding of gB to heparan sulfate 
proteoglycans. The subsequent interaction of gB with its non-heparin receptor increases the 
stability of HCMV bind to cell surface [21]. However, the fusion of the viral envelope with 
the cell membrane to allow viral penetration is thought to require a further event mediated 
by the heteroligomeric gCIII (gH/gL/gO) complex with unidentified receptors  - Figure 5 
[7, 27].  
After translocation into the nucleus, viral mRNA is transcribed and the transcripts 
exported from the nucleus to be translated by cellular machinery [3, 50]. Nevertheless, 
while some translated viral gene products are solely cytoplasmic proteins, others may 
return to the nucleus to regulate viral replication and cellular control [3, 50]. DNA 
replication, capsid assembly and DNA packaging occurs in the nucleus and viral assembly, 
which includes tegumentation and envelopment of new viral capsids, occur in the 
cytoplasm- Figure 5 [3, 51].   
Similar to other herpesviruses, HCMV DNA replication begins 16 to 24 hours after 
infection [37] involving temporally ordered viral gene expression [12, 19, 37, 38]. The first 
transcribed viral genes are the immediate early (IE or α) genes, which are mainly 
transcriptional regulators, and have the ability to be transcribed in the absence of de novo 
protein synthesis, and are assumed to carry out key regulatory functions in permissive as 
well as in latent infection [1, 3, 19, 37, 38]. Expression of these genes is required for the 
transcription of early genes (E or β) [3, 12, 19, 37, 38]. Early genes are divided into two 
subclasses (β1/E and β2/E-L) and encode multiple proteins required for synthesis, 
processing and repair of DNA, capsid assembly, encapsidation, and establishment of 
immune evasion in the productively infected cell [1, 8, 12, 19, 37, 38]. HCMV replication 
occurs after circularization of DNA and DNA synthesis starts by rolling circle replication 
which can undergo genomic inversion [47]. HCMV genome, unlike other herpesviruses, 
does not encode deoxyribonucleotide (dNTPs) biosynthesis enzymes, thus it has developed 
strategies to stimulate the biochemical pathways involved in the biosynthesis of DNA 
precursors [21]. This feature is considered crucial for its productive replication in the 
quiescent or terminally differentiated non-dividing cells [21]. Several trans acting factors 
are required for origin (oriLyt)-dependent DNA replication which include the six 
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herpesvirus-conserved ORFs that provide the core replication proteins for viral DNA 
replication [8]. Among them, the single-stranded DNA-binding protein ppUL57 prevents 
the reannealing of DNA strands, followed by the unwinding by the helicase-primase 
complex, composed by primase (pUL70), helicase (pUL102) and primase-associated 
protein (pUL105) encoded by UL70, UL102, and UL105, respectively. The DNA 
polymerase processivity factor pUL44, encoded by UL44, prevents the dissociation of 
DNA polymerase pUL54, which is encoded by UL54, from the template [8, 19, 38]. The 
amino acid sequences of all of these proteins are highly conserved among HCMV strains 
and pUL54 3’-5’exonuclease activity (proofreading) is responsible for the high fidelity of 
the replication, which results in a low mutation rate [19]. The Late (L or γ) proteins are the 
last class of gene products expressed during HCMV replication and can be divided into 
two classes: gamma 1/leaky-late (γ1) and gamma 2/true-late (γ2) [8, 38]. Proteins encoded 
by these genes have mainly structural roles and contribute to the assembly and 
morphogenesis of the virion [1, 3, 12, 19, 37, 38]. Their transcription begins more than 24 
hours after infection and requires prior viral DNA replication [37]. The late genes UL94, 
UL99, and also UL32 tegument proteins are essential for late events in virion assembly in 
the cytoplasm [32, 52].  
The growth cycle of HCMV is relatively slow and viruses are not released until 72 
to 96 hours [37]. Despite the fact that the precise molecular events of capsid assembly and 
DNA packaging are not yet understood, these processes are thought to occur in the nucleus 
– Figure 5 [53]. Three distinct capsid types, termed A, B, and C, are found in HCMV-
infected cells [53]. The packaging of the DNA genome leads to the egress of the capsid 
scaffold and gives rise to a mature capsid - Figure 5 [21, 51]. Errors in packaging can 
result in cytoplasmic accumulation of non-infectious enveloped viral particles containing 
capsids lacking scaffold or DNA and capsids with only scaffold protein cores [54]. In fact, 
experiments revealed an important role for UL97 kinase (pUL97) in capsid assembly [19, 
55]. Optimal nuclear egress requires active pUL97 and its detection correlates with 
abnormal subcellular distribution of viral structural protein assembly sites, both in the 
nucleus and in perinuclear structures, and consequent reduction in viral yield [19, 55]. 
Capsids are initially assembly through budding at the nuclear membrane, where they 
acquire a primary envelope derived from its inner leaflet. Then, they cross the lumen, fuse 
with the outer leaflet of the nuclear membrane or the endoplasmic reticulum (ER) 
membrane, lose their primary envelope, and move into the cytoplasm, where HCMV virion 
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particles acquire their tegument - Figure 5 [21]. Final envelopment of tegument-coated 
HCMV capsids occurs into a Golgi-derived secretory vacuole specifically destined for the 
plasma membrane and not marked for degradation in lysosomes or endosomes [14, 21]. 
Finally, the egress of infectious viral particles occurs by the fusion of secretory vacuoles 
containing HCMV viral particles with the cell membrane after transport via the vesicle 
trafficking pathways - Figure 5 [14, 21]. 
 
 
Figure 5: HCMV Life Cycle. 1) HCMV attachment to the cell membrane with penetration via endocytosis or fusion at the plasma 
membrane; 2) Virion contents are released into the cytoplasm; 3) nucleocapsids are translocated into the nucleus, where viral DNA is 
released; 4) Viral replication and maturation follow the stimulation and parallel accumulation of viral synthesis function; 5) the 
encapsulation of replicated viral DNA as capsids, which are then transported from the nucleus to the cytoplasm; 6) envelopment of 
tegument-coated HCMV capsids occurs into a Golgi-derived secretory vacuole in the cytoplasm; 7) egress process that leads to virion 
release by exocytosis at the plasma membrane. Adapted from [6]. 
1.2.4. HCMV Infection and Disease 
HCMV infection is in the majority of cases asymptomatic, since the virus is 
maintained in a state of latency or low level shedding that is clinically undetectable [13, 
19, 46]. Symptomatic infections in immunocompetent individuals are rare [4]. However, 
the groups at higher risk of HCMV infection and associated disease development are 
individuals with compromised or immature immune systems, including those infected with 
HIV, transplant recipients and congenitally-infected infants. In these patient groups, 
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HCMV infection can lead to HCMV-associated disease resulting in significant morbidity 
and mortality [8, 16].  
Infants infected in utero are at risk for several congenital abnormalities and 
sensorineural hearing loss [13, 36, 40, 45, 46]. In patients who have acquired immune 
deficiency syndrome (AIDS) most commonly developed HCMV retinitis that leads to 
vision loss [13, 36, 46]. In transplant recipients, HCMV has both direct effects, resulting 
from viral invasion of organ systems, and indirect effects on the immune systems [46, 56]. 
The direct effects of HCMV primary infection or reactivation in organs are the 
development of end-organ diseases such as pneumonia, hepatitis, pancreatitis, 
gastrointestinal disease, retinitis, encephalitis, colitis, esophageal ulcers and others [13, 21, 
36, 56]. Regarding the indirect effects, they are often associated with increased risk of 
other infections, bacterial and fungal, and promote acute graft rejection [46]. In fact, 
HCMV has repeatedly been associated with rejection after solid-organ transplantation and 
with graft-versus-host disease (GVHD) after hematopoietic stem cell transplant (HSCT) 
[19, 36, 56]. 
1.3. HCMV and HSCT 
1.3.1. Epidemiology and Characteristics 
HCMV infection is the leading viral cause of morbidity and mortality in patients 
who receive hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) 
(including kidney, liver, heart, heart-lung) [36, 46]. 
Studies have described that HSCT recipients have a higher prevalence of HCMV 
infection and associated diseases than SOT recipients [16, 57]. The incidence of HCMV 
infection following allogeneic HSCT (allo-HSCT) ranges from 32% to 70%, varying with 
the serological status of the recipient (R) and donor (D) [21]. Its incidence in seronegative 
recipients with seropositive donors (D+/R-) is lower than in seropositive recipients with 
seropositive donors (D+/R+), suggesting a transfer of adoptive immunity from donor to 
recipient. Thus, the most critical event is reactivation of a latent virus in seropositive 
recipients [15, 21, 46, 58-60]. In seronegative recipients, transmission mostly occurs 
through larger quantities of blood products that they receive [21]. 
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A recent study from Portugal showed that 60.3% of allogeneic HSCT patients 
developed HCMV infection, mainly viral reactivations rather than primary infections 
(96.2% vs 3.8%, respectively) [61]. Typically, HCMV infection/reactivation appears 
within the first 100 days after transplant, both in allogeneic and autologous recipients, and 
affects mainly the lungs and the gastrointestinal tract [60, 61]. In HSCT recipients, late-
onset HCMV disease (disease occurring >100 days after transplant) is similar to that 
observed in SOT patients, but with higher mortality [60, 62, 63]. Nevertheless, the increase 
in late-onset HCMV infections may be due to effective antiviral prophylaxis or preemptive 
treatment during the first 100 days after transplantation [58, 63, 64], by inhibiting the 
development of HCMV-specific T-cell lymphocyte response [62, 64, 65]. In fact, while 
prophylaxis and pre-emptive therapy are effective for the prevention of the HCMV disease 
during the antiviral treatment, cessation of therapy can result in the emergence of late-onset 
HCMV disease [58, 63].  
1.3.2. Risk Factors 
The risk of developing HCMV reactivation or disease in HSCT patients is 
associated with the type of transplant and its associated-complications [59, 61, 64, 65]. 
Indeed, not all individuals are at the same risk as it varies with age, underlying disease, 
source of stem cells, donor/recipient (D/R) HCMV serological status, type of 
immunosuppression, and occurrence of graft-versus-host disease (GVDH) [36, 58, 59, 61, 
64-67]. Moreover, the risk factors for HCMV infection vary during the transplantation 
period and while some can be predicted prior the transplant, other are dependent on the 
outcome of the transplant - Figure 6 [58-60, 64, 65]. 
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Figure 6: Conditions associated with the risk of developing HCMV infection, reactivation, or disease in each of the following phase of 
therapy in HSCT patients. Adapted from [65]. 
1.3.2.1.  Before Transplantation 
The risk factors that can be used prior transplantation to predict the occurrence of a 
HCMV reactivation/disease may be divided in host factors and transplant-related factors - 
Figure 6. Considering the host factors, it has been demonstrated that older ages represents a 
risk factor for developing HCMV reactivation/disease and for transplant-related mortality 
(TRM) [59, 61, 65]. The underlying disease and its treatment has not been specifically 
studied as a risk factor for development of HCMV reactivation/disease after HSCT, 
nevertheless, it has been demonstrated that the disease stage at the time of transplant is a 
highly significant predictor of mortality and that a diagnosis of chronic myelogenous 
leukemia in patients receiving T cells depleted from a HCMV–positive donor could 
represent a negative prognostic factor [59, 61, 65]. Furthermore, HCMV serostatus is 
considered mandatory in all transplant recipients and donors to evaluate the risk of HCMV 
reactivation/disease [58, 61, 66, 68, 69]. In autologous HSCT (auto-HSCT) recipients the 
probability of HCMV infection has been reported to be nearly 60% in seropositive patients 
and 23% in seronegative patients, however, the risk of developing HCMV 
reactivation/disease is lower than in allogeneic HSCT recipients [36, 65]. In allogeneic 
HSCT recipients, the risk of developing HCMV reactivation/disease has been reported as 
Before transplant 
• Host factors 
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• Underlying disease 
• Seropositivy status (donor and 
recipient) 
• Transplant-related factors 
• T-cell depletion 
• Autologous vs allogeneic 
• Human leukocyte antigen (HLA)-
match vs non-match donors 
• Immnunosuppresion 
• Source of stem cells  
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After transplant 
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• Immune reconstitution 
 
• Other viral infections  
 
• Other Opportunistic infections: 
parasitic, bacterial and fungal 
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5% of seronegative patients with seropositive donors (D+/R-), 14% of seropositive patients 
with seronegative donors (D-/R+), and 12% of seropositive patients with seropositive 
donors (D+/R+) [17, 59, 60, 65, 69]. Thus, the reactivation of HCMV occurs in nearly 80% 
of HCMV-seropositive recipients and 28% of seronegative recipients who receive a graft 
from a seropositive donor [65, 68]. Ljungman et al. suggests that seronegative patients that 
received grafts from seropositive donors have improved outcome [70], and in contrast, 
seropositive patients who receive grafts from seronegative donors have an increased risk of 
both repeated HCMV reactivation and disease [17, 59, 60, 65, 69]. Furthermore, 
seronegative recipients receiving transplant from seronegative donors have a very low risk 
of primary infection and a lower HCMV-related mortality [58, 59, 68].  
Regarding the transplant-related factors, the type of transplant, Human leukocyte 
antigen (HLA) status, immunosuppression regimen, source of stem cells and T-cell 
depletion are considered important in the definition of risk for HCMV reactivation or 
disease - Figure 6 [17, 58, 60, 62, 64, 65, 67, 68]. Recipients of T cell-depleted allografts 
are the patients predominantly affected by HCMV reactivation, a rapid onset of HCMV-
related symptoms, and a higher rate of fatal infections that may occur during the first 30 
days after HSCT [58, 64, 66]. The risk of HCMV reactivation/disease is higher in 
recipients of transplants from an unrelated donor than in recipients of a related donor. 
However, in the allogeneic HSCT patients the risk of HCMV reactivation or disease is 
higher compared with patients receiving autologous HSCT [58, 60, 65, 66].  In recipients 
of unrelated or mismatched donor transplants, the increased risk of HCMV 
reactivation/disease is associated with a higher risk for HCMV-associated death and TRM, 
with higher mortality occurring in HCMV-positive patients receiving a transplant from 
negative donors [65]. Ljungman et al. also showed that allogeneic HSCT from seropositive 
donors was associated with better survival than from seronegative donors when the donors 
were unrelated, but not when the donors were HLA-identical siblings [70]. More 
aggressive chemotherapy regimens in transplant candidates have led to an increased 
infection of HCMV before transplantation [62]. Recipients of non-myeloablative stem cell 
transplants have a reduced risk of early HCMV infection and disease compared with 
standard myeloablative regimens [68]. However, they are also at an increased risk of late 
HCMV disease, mostly related to the use of antithymocyte globulin (ATG) or 
alemtuzumab (anti-CD52 monoclonal antibody) during conditioning chemotherapy [17, 
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60, 62]. A randomized study has showed, somewhat unexpectedly, that peripheral blood 
stem cell transplantation has not been associated with less HCMV infection and disease 
when compared to marrow transplantation [71]. However, in a non-randomized study, has 
been observed a moderate reduction in HCMV disease [72]. Cord blood transplantation is 
associated with similar rates of HCMV infection and has generated new populations of 
patients at high risk for HCMV reactivation and disease [60, 62]. However, blood products 
transfusion represents the main risk factor for HCMV acquisition in HCMV-negative 
patients receiving bone marrow from a HCMV-negative donor [65].   
1.3.2.2. After Transplantation 
Amongst the post-transplant related risk factors for HCMV reactivation or disease 
are the immune reconstitution, the development of GVDH, immunosuppression regime and 
the development of other infections - Figure 6 [17, 59, 60, 62, 64, 65, 68]. The 
development of HCMV disease occurs especially in HSCT recipients submitted to highly 
immunosuppressive regimens used to prevent rejection of the transplant, in particular those 
that lead to prolonged lymphocytopenia such as the use of fludarabine or analogues as well 
as alemtuzumab [60, 62].  In fact, the severity of the end-organ disease caused by HCMV 
is related to the degree of immune suppression [36, 60]. Furthermore, the immune 
reconstitution is also a significant factor, since while in SOT the host has the immune 
system working very early, in HSCT recipients the time to reach immune reconstitution 
may vary a lot [17, 64, 65]. Furthermore, allogeneic HSCT recipients, in contrast to 
autologous HSCT patients, are at a much higher risk of active HCMV infection because of 
the delayed recovery of T- and B-cell functions [17, 64]. In fact, studies have found 
HCMV-specific cytotoxic T-lymphocytes regeneration is dependent on HCMV serologic 
status, with both CD4+ and CD8+ T lymphocytes to be required for complete restoration 
of immunity [65]. However, the inability to control HCMV reactivation after allogeneic 
Bone Marrow Transplant (BMT) has been mainly associated with impaired function of 
antigen-specific CD8+ T cells rather than an inability to recover a sufficient numbers of 
HCMV-specific T cells [65]. In addition, it has been demonstrated that CD4+ T-helper 
cells regenerate relatively slowly following allogeneic BMT with subsequent limited help 
for CD8+ T cells to control HCMV replication and have observed lower HCMV-specific 
CD8 T-cell numbers during viral replication [17]. Therefore, HCMV pneumonia during the 
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first 120 days after HSCT is much more severe and life-threatening than it is in a patient 
after renal transplantation [36]. 
Another risk factor for HCMV reactivation or disease is the development of GVHD 
after transplantation and has been shown that acute and chronic GVHD significantly 
increases the risk of HCMV infection [17, 64, 65]. Moreover, patients that develop chronic 
GVHD (cGVHD), which is characterized by a severe combined cellular and humoral 
immunodeficiency, and acute GVHD (aGVHD), are at a prolonged risk to develop late-
onset HCMV disease [60, 62, 64, 65].  
Other viral infections, such as Human herpesvirus 6 (HHV6), Human herpesvirus 7 
(HHV7) and Epstein Barr virus (EBV) have been implicated as risk factors for progression 
from active HCMV infection to HCMV disease and with reactivation of HCMV by 
suppressing the development of HCMV-specific immune responses [65]. In addition to 
viral infections, other opportunistic infections such as parasitic, bacterial, and fungal also 
emerge as common causes of HCMV reactivation/disease [58].  
1.3.3. Clinical Features 
HCMV end-organ disease is classified as of early onset (<100 days after transplant) 
or late onset (>100 days after transplant) [36, 60]. Pneumonia and gastrointestinal 
involvement are the most frequently described diseases caused by HCMV in HSCT 
recipients; nevertheless, there are other documented conditions such as hepatitis, retinitis, 
encephalitis, hemorrhagic cystitis, unexplained fever, endothelial damage, and thrombotic 
microangiopathy [17, 36, 55, 58, 60, 68]. 
The interstitial pneumonia caused by HCMV is the most common life-threatening 
infectious complication of allogeneic HSCT, defined by the presence of pulmonary 
disease, combined with HCMV found in bronchoalveolar lavage fluid or lung tissue 
samples. It is still a potentially fatal disease, which usually occurs within the first 120 days 
after transplantation, with decreasing incidence and severity after the initiation of routine 
antiviral prophylaxis or pre-emptive therapy after HSCT [17, 36, 65, 68]. The incidence of 
HCMV pneumonia ranges from 10% to 30% in allogeneic HSCT recipients and from 1% 
to 6% in autologous HSCT recipients. It has been described that 69% of cases occur early 
and 31% late after transplant [17]. HCMV pneumonia is associated with the following risk 
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factors: prolonged deficiency in HCMV-specific cytotoxic T-lymphocyte activity, recipient 
seropositivity, older age, presence of acute GVHD, use of cyclosporine (CsA) as GVHD 
prophylaxis, and the underlying disease [17, 36, 65].  Lymphocytopenia, male gender, and 
severe acute GVHD are also often referred as contributing for severe HCMV pneumonia 
[17, 36, 65].  
Gastrointestinal (GI) HCMV disease has been described both in autologous and 
allogeneic HSCT as a combination of clinical symptoms in gastrointestinal tract, findings 
of macroscopic mucosal lesions at endoscopy, and the symptoms vary depending on the 
location of the disease [17, 36, 65]. It is characterized by an erosive and/or an ulcerative 
condition that can occur at any location in the GI tract, from mouth to rectum [36, 65]. The 
incidence rates for GI HCMV disease are of 2% at 2 years after HSCT, with higher 
frequency in allogeneic than in autologous HSCT recipients [17]. The risk factors for the 
development of GI HCMV disease include allogeneic transplantation, use of steroids, the 
presence of intestinal acute GVHD and the HCMV-seropositive recipients [17, 65]. 
1.4. HCMV infection management 
1.4.1. Anti-HCMV Drugs 
Currently, four antiviral drugs are used to prevent/treat HCMV infection and 
diseases. These antiviral drugs act by inhibiting effective HCMV DNA synthesis and have 
been shown to be effective in the prevention and/or treatment of HCMV infection and 
diseases: Ganciclovir (GCV), Valganciclovir (VGCV), Cidofovir (CDV) and Foscarnet 
(FOS) - Figure 7 [40, 46, 73-76]. Despite their clinical utility being limited by the efficacy, 
limited oral bioavailability, development of resistance in clinical practice, and associated 
toxicities, these drugs have been used to treat many forms of HCMV disease in 
immunocompromised patients [40, 46].  
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Figure 7: Action mechanisms of systemic antivirals approved for treatment of HCMV infection. GCV/VGCV requires phosphorylation 
by the phosphokinase (pUL97). After monophosphorylation by pUL97, the cellular kinases add two additional phosphates. GCV 
triphosphate is the active form of the drug incorporated into viral DNA by the viral DNA polymerase (pUL54). CDV is a 
monophosphate analog and does not require initial viral phosphorylation. Cellular kinases add additional phosphates to produce CDV 
diphosphate, which is incorporated into the viral DNA by pUL54 leading to termination of viral DNA replication. FOS is a 
pyrophosphate analog, which does not require activation and is not incorporated into the growing viral DNA chain. It blocks directly the 
release of pyrophosphate by pUL54 and therefore resulting in chain termination. Adapted from [19, 77]. 
1.4.1.1. Ganciclovir and Valganciclovir 
Ganciclovir (GCV) or (9-[1, 3-dyhydroxy-2-propoxymethyl] guanine) was the first 
antiviral agent approved for the treatment of HCMV infection/disease, and remains the 
first-line treatment for HCMV infection/disease in immunocompromised patients [36, 46, 
77, 78]. It is an inactive nucleoside analogue of guanosine and homologue of acyclovir 
(ACV) [10, 36, 40, 77]. GCV is converted to GCV triphosphate that is the active form of 
drug by a multistep process dependent on both viral and cellular enzymes - Figure 7 and 
Table I [19, 46, 78-80]. The two target viral proteins involved in GCV anabolism are: 
UL97 and UL54 [19, 40, 78]. The UL97 gene of HCMV encodes a viral protein kinase that 
phosphorylates GCV to GCV monophosphate [10, 36, 40, 46, 77-79, 81]. Two subsequent 
phosphorylation steps are performed by host cellular kinases that result in the formation of 
the GCV triphosphate metabolite, which is a competitive inhibitor of the natural substrate 
(deoxyguanosine triphosphate) for the viral DNA polymerase encoded by UL54 - Figure 7 
and Table I  [77, 78, 82]. GCV is not an absolute chain terminator, and short fragments of 
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HCMV DNA continue to be synthesized [36, 80], nevertheless its effects result from the 
ability to difficult and slow the elongation of viral DNA [36, 46, 81]. 
GCV has been shown to reduce the severity of HCMV retinitis, gastrointestinal 
disease and, to a lesser extent, pneumonia in SOT, HSCT and AIDS patients [21, 36, 40, 
46]. GCV was initially approved by Food and Drug Administration (FDA) in 1989 for 
intravenous (IV) use [19, 46, 79]. Nevertheless, and despite its high bioavailability and 
therapeutic efficacy, IV use is limited since hospitalization is required for administration 
[46, 75]. Moreover, GCV use is limited by the occurrence of hematologic side effects, 
primarily neutropenia, and thrombocytopenia, mainly in the early phases of HSCT - Table 
I [17, 36, 46, 65, 68]. An oral capsule released in 1994 represented a major advance for 
treatment of HCMV retinitis, but could only be used as maintenance therapy, as the low 
bioavailability of the oral formulation was considered insufficient for induction therapy 
[19, 46, 79]. GCV poor oral bioavailability (5.6%) leads to the development of 
Valganciclovir (VGCV), a L-valyl ester prodrug which after oral administration is rapidly 
metabolized in the liver and intestinal wall - Table I [19, 36, 40, 46, 67, 77, 79]. The 
adverse effects of VGCV are similar to those of GCV, mainly, neutropenia and 
thrombocytopenia - Table I [36, 46, 67]. Nevertheless, VGCV has a much better 
bioavailability (60%) and is a suitable replacement for IV GCV in many clinical 
applications [19, 36, 40, 46, 67, 77, 79]. Thus, given the convenience to treat patients 
without hospitalization, VGCV tends to be widely used among transplant recipients, not 
only for prophylaxis, but also for preemptive and maintenance therapy [46, 67, 73].  
Although GCV and VGCV have been effective in prevention and treatment of 
HCMV disease, the emergence of GCV/VGCV-resistant HCMV strains has posed a more 
significant threat due to an aggressive disease course and a greater mortality risk. 
Treatment options for these strains are limited, with FOS being recommended as the initial 
treatment option followed by CDV; nevertheless, these agents are known to have 
substantial side effects, the most notable of which is nephrotoxicity - Table I [83]. 
1.4.1.2. Foscarnet 
Foscarnet (FOS) a pyrophosphate analogue, with the chemical name of 
phosphonoformic acid, which reversibly, and noncompetitively, inhibits the activity of the 
HCMV DNA polymerase - Table I [36, 40, 82]. FOS does not require intracellular 
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activation to exert its antiviral activity and is not incorporated into the growing viral DNA 
chain [19, 40, 77, 78, 80-82]. This noncompetitive inhibitor reversibly blocks the 
pyrophosphate binding site of the viral DNA polymerase and inhibits the cleavage of 
pyrophosphate from deoxynucleoside triphosphates - Figure 7 and Table I [19, 40, 46, 77-
81]. FOS is administered as large volume intravenous solution since it must be present in 
high concentrations inside the cell to remain in contact with the viral DNA polymerase and 
inhibit DNA replication; hence, when the intracellular concentration decreases viral DNA 
synthesis resumes [10, 19, 36]. 
FOS was FDA approved in 1991 [10, 19] and despite its utility has been associated 
with nephrotoxicity and metabolic toxicity as well as renal failure, hypocalcemia, 
hypomagnesemia and hypophosphatemia - Table I [10, 36, 46]. Due to its side effects, FOS 
is considered a second-line therapy, preferred over GCV especially in patients with 
myelosupression or weak graft after HSCT, to treat patients with AIDS and HCMV reti-
nitis who are failing GCV therapy due to viral resistance, or those who cannot be treated 
with GCV due to dose-limiting neutropenia or leucopenia [17, 36, 46, 68]. Furthermore, 
some studies refer that patients must be on long-term maintenance regimens with IV FOS 
to prevent the relapse or progression of HCMV disease [21, 36].  
1.4.1.3. Cidofovir 
Cidofovir (CDV) is a monophosphate nucleotide analogue, with the chemical name 
([S]-1-[3-hydroxy-2-phosphonylmethoxypropyl] cytosine) [36, 40, 46, 78, 80].  Because a 
single phosphate-like group is already present in this monophosphate analog, CDV does 
not require initial phosphorylation by pUL97 kinase but is dependent on diphosphorylation 
by cellular kinases for activation - Figure 7 and Table I [19, 40, 80, 81]. Cellular kinases 
add the additional phosphate group to CDV, converting it into CDV diphosphate, an 
analog of deoxycytosine [46, 77, 81]. Similarly to GCV, the incorporation of CDV-
diphosphate into viral DNA causes a slowing and subsequent cessation of HCMV DNA 
replication - Figure 7 and Table I [77, 78, 81]. Sequential incorporation of two CDV 
molecules completely inhibits further synthesis of HCMV DNA since it cannot be excised 
by pUL54 3-to-5 exonuclease activity [84].  
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CDV was FDA approved in 1996 as an IV formulation for the treatment of a broad- 
range of DNA viruses infections, including all the herpesviruses [40, 68]. CDV oral 
bioavailability is less than 5% [19, 46]; nevertheless it has a very long intracellular half-life 
when compared with GCV and FOS [36, 68]. Despite its efficacy as an anti-HCMV agent, 
due to the poor oral bioavailability and concerns about dose-related nephrotoxicity, lipid 
ester analogs, including as hexadecyloxypropyl-CDV (CMX001) and octadecyloxyethyl-
CDV, are being tested against herpesviruses – Table I [46].  
CDV has excellent activity against HCMV and has been reported to be effective in 
the treatment of HCMV retinitis in AIDS patients [40, 46] . CDV has also been studied for 
HCMV infection and disease in allogeneic HSCT [36], however, it has several side-effect 
such as nephrotoxicity and myelosuppression [17, 46, 68], and therefore it is considered a 
third-line agent for HCMV infection – Table I [17].  
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Table I: Antiviral agents used to prevent/ treat HCMV infection and disease. Adapted from [17]. 
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1.4.2. Current Strategies 
The strategy for HCMV infection prevention in seronegative HSCT recipients starts 
by the selection of blood products from HCMV seronegative donors or use leukocyte-
reduced blood products [58, 60, 64, 68]. However, antiviral prophylaxis and viral 
monitoring with pre-emptive therapy are currently the two strategies used for prevention of 
HCMV infection and disease in high-risk patients [58, 60, 62, 64, 65, 67]. Overall, 
intravenous GCV and oral VGCV are preferred as first-line agents for both prophylaxis 
and preemptive treatment, largely because of their lower toxicities than those of FOS and 
CDV [68, 74].  
HCMV prophylaxis begins prior to transplantations and is continued for a post-
transplant period that usually rounds 100 days [19]. It is conceptually attractive because it 
is simple, may not require viral monitoring, and may prevent both direct and indirect 
effects of HCMV infection [62, 68]. This therapy has been more used in SOT recipients 
than in HSCT [17, 36]. Randomized studies have shown that the long-term (3 to 4 months) 
use of GCV-based prophylaxis, among HCMV-seropositive HSCT recipients, is effective 
in suppressing early HCMV disease. However, the incidence of bacterial and fungal 
infections and occurrence of late HCMV disease was increased [85, 86]. A possible 
mechanism for late HCMV disease in prophylactic therapy is the delayed recovery 
HCMV-specific T cell responses due to efficient suppression of HCMV by GCV [58].  
Furthermore, there are some toxic effects of anti-HCMV drugs that influence the 
use/efficacy of prophylactic treatment [58, 60, 62]. GCV has been associated with bone 
marrow depression and this has led to a reduction on the use of GCV-based prophylaxis 
[17]. The use of other drugs in HCMV prophylaxis has been reduced and FOS has been 
used for HCMV prophylaxis in pilot studies only [60, 64]. Furthermore, some studies 
suggest that HCMV prophylaxis, despite useful in some cases, is a high-cost strategy that 
exposes all patients to drug toxicity, selection of viruses and development of antiviral 
resistance, and increases the risk of late-onset HCMV infection and disease [87]. 
Preemptive antiviral therapy is based in two parts: monitoring HCMV 
infection/reactivation and early intervention in patients when HCMV infection/reactivation 
is detected [58, 62, 68]. There are several strategies for HCMV monitoring, especially 
those based in the pp65 antigenemia or HCMV DNA viral load (by real-time quantitative 
polymerase chain reaction (RT-qPCR)), and the sensitivity of tests is crucial for the 
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effective detection of HCMV prior to disease development [10, 58-60, 62, 64, 68, 79, 88, 
89]. Preemptive treatment is applied after the first positive and lasts until day 100 after 
transplantation or resolution of symptoms or a HCMV-negative test result, which usually 
result in 2-4 weeks duration of therapy [88, 89]. Then, a maintenance period of therapy is 
usually used and varies according to the patient (disease response, risk factors-risk of 
relapse and side effects of the therapy) [17]. Both GCV and FOS can be used for 
preemptive therapy, with similar efficacy against HCMV, but with different toxicity 
profiles [60, 62, 65, 68, 90]. The combination of GCV and FOS has been used with high 
efficacy in patients with a high viral load [90, 91]. Nevertheless, oral VGCV has also been 
reported in substitution of IV GCV for HCMV infections after HSCT [60, 67, 73]. CDV 
was found to be effective as second-line therapy especially to rescue patients failing 
antiviral therapy with GCV, FOS, or both [62, 80, 90] . This approach has the advantage 
that only patients at highest risk for HCMV disease will get treatment, reducing the risk of 
side-effects [59, 67]. Preemptive therapy for HCMV has shown to reduce the risk for 
HCMV disease and improve survival [59, 62, 67]. However, its efficacy is dependent on 
the sensitivity of the monitoring assay [58].  
Preemptive therapy guided by pp65 antigenemia and/or real-time quantitative PCR 
(RT-qPCR) assays is now more widely used than prophylactic therapy as a strategy against 
HCMV after allogeneic HSCT because of the bone marrow toxicities of the current anti-
HCMV drugs [58, 59]. In fact, PCR-based antiviral therapy was demonstrated to reduce 
the incidence of HCMV disease and the risk for HCMV associated mortality [59, 88], 
while that antigenemia-based preemptive therapy was found to be as effective as GCV 
prophylaxis in preventing HCMV disease [89]. However, RT-qPCR assays have largely 
replaced the pp65 antigenemia assay for guidance of preemptive antiviral therapy [92]. 
     The treatment for end-organ disease is longer with 2-4 weeks of induction, followed 
by maintenance therapy for several weeks [17, 68]. The standard recommended therapy for 
HCMV pneumonia consists in IV GCV or FOS as an alternative agent in combination with 
high-dose intravenous immune globulin (IVIGs) [17, 58, 68]. For other HCMV diseases, 
such as Gastrointestinal (GI) or central nervous systems (CNS), IV GCV (or FOS) alone is 
the most frequent approach [58]. Decreasing immunosuppression is crucial to the treatment 
of HCMV end-organ disease, however, it must be balanced against the risk of acute GVHD 
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[17]. Furthermore, the decision to stop therapy or switch to maintenance therapy should be 
made based on the individual patient response to therapy [58]. 
1.5. HCMV drug resistance 
The emergence of HCMV resistance to one or more antiviral agents is associated 
with treatment failure and progression of HCMV disease in immunocompromised patients, 
complicating therapeutic and clinical management [73, 74, 93, 94]. Drug resistance may be 
suspected if persistent or increasing viral loads or overt HCMV disease occurs after two or 
more weeks of therapy [19, 68, 74, 93, 95, 96]. 
The rates of HCMV drug resistance vary widely depending on the type of patients, 
ranging between 5.0-12.5% for SOT recipients and <4.0% for HSCT recipients. In HIV-
infected patients, resistance has been reported in >20% of patients before the availability of 
highly active antiretroviral therapy (HAART) and in 9% after HAART [19, 40, 74, 79].  
In immunocompromised patients, several risk factors have been identified for the 
emergence of HCMV resistance to antiviral agents [19, 40, 68, 73, 77, 93, 95, 97, 98]. The 
risk factors may be divided in different categories: 1) patient and disease related factors; 2) 
treatment-related factors; and 3) viral factors [19, 40, 68, 73, 77, 93, 95, 97, 98]. Regarding 
the patient and the disease related factors, SOT, underlying disease, type and degree of 
host immunosuppression and the occurrence of HCMV disease have been described as 
influencing the risk of drug resistance [40, 95, 96, 98]. Prolonged antiviral therapy, 
suboptimal antiviral concentrations due to poor compliance or low drug absorption and 
limited oral bioavailability are important risk factors in the emergence of HCMV drug 
resistance [40, 46, 68, 73, 96]. The viral factors that appear to play a role in the 
development of drug resistance are: the establishment of lifelong latency, which allows for 
later reactivation under the conditions of immunosuppression; the slow lytic replication 
cycle; higher viral load at the start of the therapy; and the viral DNA polymerase, which 
has a proofreading function and is responsible for the high fidelity of the replication, which 
results in a low mutation rate  [19, 73].  
Actually, it is known that the molecular mechanisms of HCMV resistance to 
antiviral drugs result from the evolution of single or multiple mutations in the viral 
phosphokinase (UL97) and DNA polymerase (UL54) genes that confer various levels of 
resistance [19, 73, 82, 95, 96]. Moreover, the continuous administration of a drug to which 
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resistance has been developed can lead to accumulation of multiple drug resistance 
mutations [74, 96, 99, 100]. The level of resistance of each mutation is expressed as the 
ratio of the half maximal inhibitory concentration (IC50) of the mutant to that of drug –
sensitive wild-type (IC50 of mutant/IC50 of wild type ratio) [19, 101]. 
The resistance to GCV/VGCV has been associated with mutations in UL97, UL54, 
or both viral genes in laboratory and/or clinical HCMV isolates [78, 97, 102]. However, 
mutations in UL54 DNA polymerase are less common than mutations in the UL97 gene 
[82, 103]. Despite of the majority of UL54 mutations that confer resistance to GCV/VGCV 
also confer it to CDV and/or FOS [19, 82, 96, 99, 103], there are also mutations UL54 that 
confer only to the GCV/VGCV - Table I [98, 104, 105]. Moreover, resistance to FOS or 
CDV in laboratory and/or clinical isolates has been mapped to amino acid substitutions in 
pUL54. Cross-resistance between GCV, CDV and FOS has been reported in pUL54, in 
laboratory and/or clinical isolates, with both genotypic and phenotypic resistance - Table I, 
Attachment I and II [19, 78, 97, 102]. 
HCMV drug-resistance can be determined by phenotype or genotype assays [19, 
40, 75, 95, 98, 106]. Phenotype assays are time-consuming whereas genotype assays are 
faster and easier to perform, however, the mutations detected through genotype assay may 
be hard to interpret [19, 40, 75, 97, 98, 106, 107]. Thus, the discrimination between 
polymorphisms (sequence variants not reducing drug susceptibility) and resistance-
conferring mutations is determined by recombinant phenotyping (marker transfer) assays 
[101, 106]. 
1.5.1. UL97 Mutations 
UL97 is on the position 97 of the unique long region of HCMV genome and is a β2 
delayed early gene encoding for the viral phosphokinase pUL97 [19, 55, 97]. The pUL97 
amino acid sequence contains serine/threonine kinase functional motifs conserved in 
different host species including yeast, bovine, rat and human [19, 55]. This protein 
undergoes auto phosphorylation, which is required for subsequent phosphorylation of 
serine and threonine residues of various cellular and viral proteins, and is required for 
efficient HCMV replication [19, 77, 98].  
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Structurally, pUL97 can be divided into different conserved functional regions: I, 
II, III, VIB, VII, VIII and IX [40, 55, 77, 98]. Codons defined for each regions are as 
follows: region I, 338 to 345; region II, catalytic lysine 355; region III, glutamate 380; 
region VIB, 453 to 462; region VII, 481 to 483; region VIII, 520 to 527; and region IX, 
574 to 579 [19, 55]. While region I is responsible for adenosine triphosphate (ATP) 
binding, regions II, III, VIB and VII are involved in the phosphate transfer and region IX is 
essential for substrate binding - Figure 8 [55, 95]. 
 
 
Figure 8: UL97 structure and functional domains. Adapted from [19, 55, 77, 95]. 
 
pUL97 kinase has a crucial role in the phosphorylation of the GCV, which is 
necessary for generation of its active forms and consequent inhibition of viral DNA 
polymerase [40, 55]. Hence, mutations in UL97 that impair this phosphorylation in virus-
infected cells are the preferred mechanism of viral resistance [58, 62]. UL97 mutations, 
which are clustered over a relatively small genomic region, confer resistance to 
GCV/VGCV, but do not affect susceptibility to FOS or CDV [40, 55, 74]. 
Mutations that confer resistance to GCV/VGCV are typically amino acid 
substitutions or short (1- to 17-amino-acid) in-frame deletions that change the ATP binding 
site or the phosphate transfer site altering its ability to phosphorylate GCV, but without 
impair its function in viral replication [19, 55, 75, 95, 98, 108]. Approximately 95% of 
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GCV/VGCV-resistant HCMV strains contain one or more mutations in UL97 [68, 78, 81, 
94, 108-110]. GCV/VGCV resistance mutations are strongly clustered at codons 460 
(region VIB), 520 (region VIII), and 590-607 (nonfunctional region), with three specific 
codons (460, 594, and 595) accounting for approximately 70% of GCV/VGCV-resistant 
HCMV strains [19, 40, 55, 77, 81, 108-110]. Mutations at codons 460 and 520 are located 
at conserved kinase domains more likely to be critical to overall kinase function, which 
probably explains the more limited range of mutations observed at these sites [19, 55]. The 
codon segment 590–607 is dispensable for viral replication. Nevertheless, mutations in this 
region impair the recognition of GCV as a substrate while preserving the normal biological 
functions [19, 55]. In fact, in this region it may be observed a large variety of amino acid 
substitutions and deletions that confer different degrees of resistance – Attachment I [19, 
55, 101]. Furthermore, the impact of each mutation in GCV/VGCV-resistance is different 
and the GCV/VGCV IC50 has been shown by recombinant phenotyping for a great 
majority of them [95, 97].  
By revising the literature regarding the UL97 mutations in immunocompromised 
patients, including transplantation recipients and patients with AIDS, it was found that the 
most common UL97 mutations associated with GCV/VGCV resistance are M460I/V, 
H520Q, C592G, A594V, L595F/S/W and C603W [107-111]. In fact, one or more of these 
canonical mutations appear in over 80% of GCV/VGCV-resistant isolates [55]. All of 
these mutations have been described by recombinant phenotyping to confer a 5- to 16-fold 
increased GCV/VGCV IC50 [77, 97, 101, 108, 112], except C592G, which has been 
referred as preferentially selected in situations where the virus is exposed to low GCV 
concentrations such as when oral therapy is insufficiently absorbed or bioavailable – 
Attachment I [55, 77, 107, 108]. 
Although the dominance of these seven canonical mutations as laboratory markers 
of GCV/VGCV resistance is confirmed by all recent clinical studies, a variety of 
uncommon resistance mutations are known to occur in different UL97 codons [77, 98, 
107]. Amino acid substitutions F342S, V356G, L405P, D456N, M460T, V466G, C480R 
C518Y, P521L, C592F, A594E/G/P/T, L595T, E596G/Y, K599T, C603R, C607T/Y, 
I610T, A613V and the deletion variants (del355, del591-594, del590-600, del591-607, 
del595, del595-603, del601-603, del617) are uncommon resistant mutations that were 
reported to confer at least a 2-fold reduction in susceptibility to GCV/VGCV in phenotypic 
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assays [96, 101, 108, 113-124]. Some of these mutations (L405P, V466G, A594E/P/T, 
L595T, E596G, I610T and A613V) confer low-grade resistance (2-4x increased IC50) , 
while others (F342S, del355, V356G, D456N, M460T, C480R, C518Y, P521L, del591-
594, del590-600, del591-607, C592F, A594G, del595, del595-603, E596Y, K599T, 
del601-603, C603R, C607T/Y, and del617) confer a moderate to high GCV/VGCV 
resistance (5-32x increased IC50) [95-97, 101, 108, 113-125]. Nevertheless, reductions in 
susceptibility of <2-fold have been reported to be clinically significant [97, 108]. For 
example, the mutations, del600, C603S, C607F and E655K have been shown to confer a 
<2-fold reduction in phenotypic assays [19, 96, 101, 108, 126]. Despite the lack of a clear 
resistance phenotype, the amino acid substitutions, C603S and C607F, occur at a 
conserved site where other mutations have been shown to be associated with 
ganciclovir/valganciclovir resistance. All of these mutations have been shown to be 
associated with GCV/VGCV resistance and have been also observed in patients failing 
treatment or prophylaxis – Attachment I [97, 108, 126].  
In addition, there are also other mutations (M460L, del590-603, del594-595, 
del596, G598S, K599E, del601 and T601M) that appear to confer significant GCV/VGCV 
resistance based on recombinant phenotyping, but do not have an IC50 value reported in 
comparison to a wild-type reference – Attachment I [127-133].  
Many other UL97 sequence changes found in clinical isolates have not been yet 
phenotyped by marker transference, mainly because the size of the HCMV genome makes 
its site-specific mutagenesis technically nontrivial [101]. So far, despite have been 
observed in patients failing treatment or prophylaxis, there is no published data to 
characterize the phenotype of the mutations E596D, G598V, K599M, C603Y and C607S, 
which occur at the same position as a confirmed resistance-associated amino acid 
substitutions and were found in the HCMV UL97 gene together with the mutations 
conferring resistance to GCV/VGCV [97, 129]. Moreover, V498I, A590T, A591D, N597I, 
C606D and deletion variants  del600-601, del601-602 and del597-603 are other mutations 
of unknown phenotype but also observed in patients failing treatment or prophylaxis and 
all, except the del597-603, were found in the HCMV UL97 gene together with the 
mutations conferring resistance to GCV/VGCV [73, 97, 129, 134, 135]. 
UL97 natural polymorphism mainly focused on codon range 460-607, where all 
known GCV/VGCV resistance mutations are located [55]. Some amino acid positions of 
UL97 can be involved in both natural polymorphism and antiviral resistance [136]. For 
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example, K599T was previously reported to induce GCV/VGCV resistance [115] whereas 
K599R has been assessed as a polymorphism [101]. Similarly, V466G, but not V466M, 
confers resistance to GCV/VGCV [101, 122, 136]. Despite of amino acid substitution 
V466M being considered, by various authors, as a natural polymorphism, this mutation has 
also been observed in patients failing treatment or prophylaxis [97, 137]. Other sequence 
changes as H469Y, A478V, A588V, L600I, M615V, G623S, T659I, and V665I were 
found to confer no significant GCV/VGCV resistance [55, 101, 122]. Nevertheless, some 
natural polymorphisms may modulate the drug-resistance level provided by other 
mutations [100, 136]. Indeed, it has been evidenced by marker transfer that D605E change 
does not confer any GCV/VGCV resistance and did not affect the resistance conferred by 
several common UL97 resistance mutations [55]. Nevertheless, some authors suggest that 
the D605E mutation could “partially or totally compensate” for the effect of the 
GCV/VGCV resistance, conferred by the common mutation M460V [100, 106]. 
Additionally, a study using vaccinia recombinants viruses concluded that D605E partially 
reversed the GCV/VGCV resistance conferred by the unusual A594P mutation [106, 113]. 
Similarly, N510S mutation has been identified in phenotypically GCV/VGCV sensitive 
HCMV clinical isolates and it has been also shown not to confer significant GCV/VGCV 
resistance [101, 136]. This N510S mutation has also been evidenced in a clinical isolate 
harboring the 591–594 deletion associated with resistance, leading to the hypothesis that 
N510S mutation may be involved in the modulation of GCV/VGCV resistance induced by 
the 591–594 deletion [136]. However, Chou and its collaborators showed that the level of 
GCV/VGCV resistance of 591–594 deletion was not higher than the clinical isolate 
harboring the 591–594 deletion alone [108]. 
Finally, there are some mutations described in vitro studies (G340V, A442V, 
L446R, and F523C) that lead technically to GCV/VGCV resistance, but are not expected 
to occur in clinical isolates since such mutations impair biological function by the loss of 
autophosphorylation and thus promote a severe growth deficiency [19]. 
1.5.2. UL54 Mutations 
The UL54 gene is a β2 delayed early gene located on the position 54 of the unique 
long region of HCMV genome which encodes for the HCMV DNA polymerase (pUL54), a 
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relatively large protein (140 kDa) composed by 1242 amino acids [97]. Both DNA and 
amino acid sequence analysis revealed that the UL54 gene has significant homology to the 
pol genes of other herpesviruses, such as herpes simplex virus type 1 (HSV-1) and EBV, 
but also with DNA polymerases encoded by a wide range of organisms [81, 97].  
There are two extremely important functions in viral polymerases that share strong 
homology in different species: the 3´-5´ exonuclease activity (Exo I through III) and 
polymerization (I through VII). Although it has been proposed that the Exo I to III motifs 
constitute the 3´ to 5´ exonuclease site of the enzyme, enzymatic analyses of purified 
mutated HCMV DNA pol proteins (L501F and K513N) suggest that the N-terminal portion 
of a Delta-region (∂-region) C also participates in this enzyme activity [19, 77]. This ∂-
region C is also found among herpesvirus polymerases and is also shared with some 
mammalian and yeast delta DNA polymerases [19, 77]. Despite the specific role of each 
region, it has been shown that the two enzymatic functions may not behave independently 
in herpesviruses and may, indeed, overlap [77]. In fact, there is an overlap of Exo II with 
polymerization region IV and of Exo III with ∂-region C - Figure 9 [19]. 
 
 
Figure 9: UL54 structure and functional domains. Adapted from [19, 77, 95]. 
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pUL54 is the central enzyme involved in viral DNA replication and the primary 
drug target for current therapies (GCV/VGCV, FOS and CDV)  [75, 76, 97]. The three 
possible mechanisms of resistance that have been postulated for the substrates (GCV 
triphosphate and CDV diphosphate) of DNA pol enzyme are: 1) a decreased affinity of the 
enzyme for the inhibitor; 2) a decreased selective incorporation of the inhibitor into the 
elongating DNA chain; or 3) an enhanced selective excision from the DNA chain of the 
incorporated inhibitors [19, 77]. In case of FOS, which is not incorporated into the 
elongating DNA, only the first mechanism of resistance (decreased affinity of the enzyme) 
would apply [19, 77].  
UL54 mutations, which are clustered over a much larger area, can confer resistance 
to all current dugs and may emerge after prolonged therapy to increase the level of 
resistance conferred by a pre-existing UL97 mutation [87, 98]. Although is uncommon, it 
has been reported the appearance of a resistance UL54 mutation in the absence of a UL97 
mutation [19, 78, 138, 139]. Indeed, the combination of mutations in pUL97 and pUL54 
resulted in greater reduction in susceptibility to GCV/VGCV than in isolates with only one 
mutation [112, 140, 141]. For example, the UL54 mutations A809V, T813S, and G841A, 
which showed similar phenotypes of low-grade GCV/VGCV resistance, when combined 
with the UL97 C592G mutation, result in a significant increase in GCV/VGCV resistance 
[141]. Similar results were found for the combination of UL54 del981-2 and UL97 C592G, 
and UL54 L773V and UL97 C607Y, conferring higher GCV/VGCV resistance than either 
mutation alone – Attachment I and II [112, 140].  
The majority of resistance mutations in UL54 occur within the conserved regions of 
homology and many occur at amino acid residues highly conserved among enzymes from 
herpesvirus and from unrelated organisms [19]. Thus, the particular resistance phenotype 
largely correlates with its location within the genome [40, 75, 77, 78]. Moreover, multiple 
UL54 mutations are additive and cause resistance to multiple antiviral agents [78]. 
Mutations that confer resistance to GCV/VGCV and CDV are most often found within the 
exonuclease domains (conserved region IV and the N-terminal extremity of ∂-region C) 
and region V (C-terminus), whereas mutations located within the C-terminal extremity of 
∂-region C and within or next to conserved regions II and VI, seem to be mostly involved 
in FOS resistance [40, 77, 78, 98]. Deletion of codons 981-982 in region V causes 
resistance to GCV, CDV, and FOS [40, 77, 78], while mutations within conserved region 
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III can be associated with resistance to any single agent or combination of agents – 
Attachment II  [77]. No drug resistance mutations have so far been detected in regions I 
and VII [19]. Conversely, the majority amino acid polymorphisms that are not associated 
with drug resistance occur at residues outside the conserved regions [19, 78]. However, 
polymorphisms in this gene are relatively common which makes it more complicated to 
distinguish them from true resistance mutations. In fact, two polymorphisms (E506K in ∂-
Region C and R785S in region VI) may be associated with resistance since they lay within 
conserved regions [139]. Although position 506 lay within a conserved region, there is 
high amino acid variability at this position amongst the herpesvirus DNA polymerase, 
which supports the theory that E506K may be a natural variant [139].  
Several studies have documented the emergence of a wide variety and distribution 
of mutations (amino acid substitutions and deletions) in drug-resistant HCMV clinical 
isolates from immunocompromised patients including transplantation recipients and 
patients with AIDS – Attachment II [82, 96, 103, 105, 116, 123, 126, 134, 138, 140, 142-
150]. The D542E and K805Q are the single mutations which confer resistance only to 
CDV [96, 116, 148, 151, 152]; while L802V, P829S, L862F and L957F, are the mutations 
that confer resistance only to GCV/VGCV [98, 105]; and the mutations that confer 
resistance just to FOS are N495K, S585A, D588E, F595I, A692S, T700A, V715M, 
E756D/Q, W780V, T838A, M844T and V946L [75, 96, 98, 105, 116, 138, 140, 143, 149-
151, 153-155]. Nevertheless, the majority of the UL54 mutations that confer resistance to 
GCV/VGCV also confer it to CDV and/or FOS, therefore cross-resistance between 
GCV/VGCV and CDV and/or FOS has been reported for several amino acid substitutions 
and two deletions [19, 78, 95-97, 102]. However, cross-resistance between GCV/VGCV 
and CDV has been reported more frequently than between the GCV/VGCV and FOS [19, 
78, 95-97, 102]. Among the most frequent mutations associated with drug resistance are 
T503I, P522S, L545S and A987G [73, 74, 82, 96, 116, 134, 139, 140, 145, 153, 156] 
which confer resistance to GCV and CDV; V781I, L802M, and A809V which confer 
resistance to GCV and FOS [74, 96, 104, 111, 116, 134, 140, 145, 153, 155-157]; and 
V715M which confers resistance to FOS [94, 96, 134, 140, 156, 158, 159]. In addition, 
there are some frequent mutations that confer resistance to all three drugs (D588N, Q578H 
and A834P) [74, 82, 96, 103, 140, 145] Although the dominance of these mutations, a 
variety of uncommon resistance mutations have also been reported in both laboratory and 
clinical strains – Attachment II [19, 78, 95-97, 102].  
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As in UL97, the impact on drug resistance of each mutation in UL54 is variable and 
has been demonstrated by several recombinant phenotyping studies– Attachment II. The 
D301N, N408D/K/S, N410K, F412C/L/S/V, D413A/E/N, P488R, K500N, L501I, T503I, 
K513E/N/R, L516R, I521T, P522A/S, V526L, C539G/R, L545S/W, A987G and del524 
are reported to confer ≥ 2-fold reduction in susceptibility to GCV and CDV [19, 95, 97, 
105, 126, 143, 144, 151, 160-162]. With except for D413E, K500N and V526L all other 
mutations exhibit greater resistance to CDV than to GCV [95, 97, 105, 126, 143, 144, 151, 
160-162]. Similarly, there are mutations with cross-resistance (≥2-fold reduction) to GCV 
and FOS (D515E/Y, V776M, V781I, V787A/L, L802M, A809V and G841S), and the 
majority exhibit a greater resistance to FOS than to GCV [95, 97, 105, 122, 141, 146, 151, 
155]. The Q578H, D588N, E756K, L773V, V812L, T813S, A834P, G841A and del 981–
982 confer a ≥2-fold reduction for all three drugs, however the del 981–982 exhibit a 
greater resistance to GCV than to FOS and CDV – Attachment II [97, 105, 140, 141, 143, 
160, 161, 163]. 
Considering the mutations in UL54 that confer higher rate of GCV/VGCV-
resistance, D413A, L501I, K513N and deletion of codons 981 to 982 have been associated 
with a 6- to 8-fold increased resistance [19, 97, 112, 142, 143, 151, 163, 164]; for CDV-
resistance, N408K, F412C/S/V, D413A/N, K513N/R, C539R, D542E and A987G  have 
been associated with a 10- to 21-fold decrease in CDV susceptibility [19, 95, 97, 105, 148, 
151, 160, 161]; and for FOS, D588N, V715M, E756K, L802M, A809V, T821I and A834P 
seem to confer 5.5- to 21-fold increased resistance [19, 95, 97, 105, 141, 143, 151, 152, 
160]. In addition, there are some mutations that confer a <2-fold reduction in susceptibility 
to HCMV-antiviral drugs in phenotypic assays and that have been found in both laboratory 
and clinical isolates (A505V, T552N, Q578L, I726T/V, W780V, L802V, T821I, M844V 
and L872F) – Attachment II [97, 98, 105, 140, 146, 149]. 
Despite of some UL54 mutations have little direct impact on HCMV susceptibility 
to drugs, they may increase the effect of other mutations, either by directly enhancing 
resistance or indirectly by increasing viral fitness (viral replication kinetics) [97, 98, 105, 
152, 160]. For example, the HCMV DNA polymerase mutation K805Q improved the viral 
fitness of the mutation T821I associated with high levels of resistance to FOS [152]. It has 
also been shown that the N408K mutation, in combination with A834P, partially 
reconstituted the replication impairment of recombinant virus containing only A834P 
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[160]. This suggests that perturbation of both DNA polymerization (A834P) and 
exonuclease (N408K) activities contributes to antiviral resistance and altered replication 
kinetics in these mutant strains [160]. Additionally, the combination N408K+A834P also 
increased GCV/VGCV and CDV resistance compared to the levels of resistance of the 
virus containing only the A834P mutation [160]. Others combinations, such as 
N408D/L957F and L545S/P829S showed FOS resistance whereas the single mutations did 
not [98, 105]. The mutation L957F is also apparently able to modulate the FOS resistance 
level conferred by mutation T552N alone [105]. Some studies have suggested decreased 
viral fitness of HCMV strains with drug-resistant mutations (K513N, D588N, T838A,) 
[155, 164] and a reduction of infectious virus yield of N495K, T700A and V715M [154, 
159]. This is expected to be caused by the occurrence of these mutations within conserved 
regions and also because resistance to FOS is associated with a slower replication of 
HCMV – Attachment II [159].  
Moreover, there are some natural polymorphisms on the sequence of UL54 of 
which the impact on resistance is unknown. For example, the P522L polymorphism, 
located at the same position as confirmed resistance-associated mutation (P522S), has also 
been observed in patients failing treatment or prophylaxis [97]. In addition, E315D, 
D879G and A972V polymorphisms have also been observed in multiple patients failing 
treatment or prophylaxis [73, 97]. 
Furthermore, there are several other amino acid substitution (i.e. M393R/K, L501F, 
L516M, P608S, T610M, A614S, G629S, I722V, Y751H, S880L, S897P and R1052C) 
found in clinical isolates that have not been phenotyped by marker transfer yet [73, 102, 
104, 116, 138, 145, 165]. A number of other mutations observed after in vitro or in vivo 
drug exposure have not been confirmed, and they illustrate the potential diversity and 
distribution of pol mutations, which may not be the same in laboratory strains as in clinical 
isolates [19]. 
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Chapter 2  
Objectives 
Important studies showed that HCMV drug resistance mutations are associated with 
a poor outcome and with a significant patient morbidity and mortality. Indeed, the 
characterization of HCMV drug resistance mutations has contributed to the progress of the 
HCMV therapy and to understand the basic biological functions of virus-encoded products 
that serve as antiviral drug targets. Thus, the fast detection of these HCMV drug-resistance 
strains, directly from patients, is an important issue, improving an early management of 
patients with alternative treatments. 
2.1. Main Objective 
The main objective of this dissertation was to characterize HCMV mutations on 
allogeneic HSCT patients and correlate with patient’s response to treatment.  
2.2. Secondary Objectives 
For this dissertation we have defined the following secondary objectives: 
1. Characterize HCMV mutations in UL97 and UL54; 
2. Correlate HCMV mutations with antiviral treatment response; 
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Chapter 3  
Patients and Methods 
3.1. Type of Study and Population 
We have performed a retrospective study in a cohort of patients with different 
haematological malignancies submitted to allogeneic Hematopoietic Stem Cell Transplant 
(allo-HSCT), between 2010 and 2014, at the Bone Marrow Transplant Service from 
Portuguese Institute of Oncology of Porto (IPO Porto). Cases were selected for mutation 
analysis if had more than one of the following: 1) reactivation prior 30 days after 
transplant; 2) viral load at first positive detection >10
4
 or > 5 positive cells; 3) more than 1 
month of HCMV positivity; 4) under preemptive treatment for more than 2 weeks with no 
significant decrease or increase of HCMV. 
This study was approved by the local ethical committee (CES IPO: 73/2015) and 
did not interfere with routine procedures decided by clinicians – Attachment VI.  
3.2. HCMV infection monitoring  
Anti-HCMV prophylaxis was not performed. However, herpesvirus prophylaxis 
was performed with acyclovir (5 mg/kg/dose, every eighth hours) for four weeks. All 
patients undergoing allogeneic HSCT were monitored after transplant for active HCMV 
infection using either: 1) pp65 antigenemia (pp65-Ag) assay, based on detection of HCMV 
pp65 antigen in infected cells using the C10/C11 monoclonal antibody cocktail (IQ 
Products®, Groningen, Netherlands); or 2) when White Blood Cells (WBC) count was 
<1000/mL by a real-time quantitative polymerase chain reaction  (RT-qPCR), which 
amplifies a region from the exon 4 of the HCMV major immediate early antigen (MIEA), 
using the Q-CMV Complete Kit (EliTech Group®, Puteaux, France). Briefly, the 
monitoring was performed in peripheral blood samples starting at the day of the transplant 
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with bi-weekly analysis up to 100 days after transplant, weekly up to 180 days, bi-monthly 
up to 1year, and after the first year on routine evaluations.  
3.3. Management of post-allo-HSCT HCMV infection   
All patients were followed post-transplant using a preemptive strategy for HCMV 
infection/disease prevention. Preemptive therapy was initiated after two consecutive 
positive results for HCMV, either by pp65-Ag (≥ 1 antigen-positive cell 
per 5,0x10
4
 polymorphonuclear leukocytes (PMNL)) or by RT-qPCR (viral load ≥1000 
copies/mL). Preemptive anti-HCMV therapy is initiated with either Ganciclovir (GCV) or 
oral Valganciclovir (VGCV). VGCV is used as first-line treatment at a dose of 900 mg 
twice a day (12h/12h) during 2-3 consecutive weeks. In the context of gastrointestinal 
intolerance, oral VGCV is replaced by GCV as second-line treatment: GCV at a dose of 5 
mg/kg twice a day (12h/12h) by 2-3 consecutive weeks. Patients with severe VGCV or 
GCV-associated complications or with no laboratory response were treated with 
intravenous foscarnet (FOS) as third-line treatment, at a dose of 60 mg/mg/8h. Antiviral 
doses are closely monitored according to patients` renal function. After two consecutive 
negative results for HCMV, patients start maintenance therapy with VGCV 450 mg once a 
day; or GCV 5 mg/kg once a day during 5 days per week; or FOS at a dose of 90 mg/kg 
once a day during 5 days per week until day +100 or day +180 in high risk patients. 
3.4. Data collection and analysis 
The patient’s demographic characteristics (gender, age), clinicopathological data 
(underlying diseases, stem cell source, HLA status, conditioning regimen and HCMV 
donor/recipient serostatus) and treatment information (strategy: prophylactic or 
preemptive; type of antiviral: VGCV, GCV, FOS or CDV; dose and duration) of 22 
patients were collected from individual clinical records by a clinician and are described in 
Table IV. 
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3.4.1. Variable definitions 
Hematological diseases were classified into the following categories: acute 
leukemia; chronic myeloproliferative disorders; chronic lymphoproliferative disorders; 
Myelodysplatic/Myeloproliferative diseases; aplastic anemia; and others.  
HCMV infection was defined as a positive result in either pp65 antigenemia (≥ 1 
antigen-positive cell per 5,0x10
4
 polymorphonuclear leukocytes) or RT-qPCR (viral load 
in whole blood sample ≥100 copies/mL). Time to infection (TTI) was defined as the 
difference between the day of allogeneic HSCT and the day of first HCMV positive result. 
Early HCMV infection was defined as occurring before 100 days after allogeneic HSCT, 
whereas late HCMV infection was defined as occurring after 100 days after allogeneic 
HSCT. The end of an infection episode was defined as the first of two consecutive days 
with negative result. Recurrent HCMV infection was defined as a new detection by pp65 
antigenemia assay at least four weeks after the clearance of the preceding episode. If a 
positive result was obtained within the four weeks after clearance, it was considered to be 
the same episode of the previous HCMV infection. The duration of infection (DOI) was 
defined for the first HCMV infection episode as the difference between the day of the first 
positive HCMV result and the day of the last positive HCMV result (that is, the positive 
result preceding four consecutive negative results during biweekly monitoring). 
3.5. HCMV genotyping 
3.5.1. Sample processing and nucleic acids extraction 
Peripheral blood samples collected in ethylenediaminetetraacetic acid (EDTA)-
containing tubes used for HCMV diagnosis were used for Nucleic Acid (NA) extraction 
and genotyping of HCMV.  
Nucleic acids extraction was performed using Magna Pure Compact Nucleic Acid 
Kit (Roche, Indianapolis, USA) according to manufacturer`s instructions. To validate the 
extraction method, nucleic acids quality was assessed by measuring the absorbance at 
260/280nm using an UV/Visible spectrophotometer and its purity assessed by the ratio of 
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the values of absorbance at 260/280nm. The presence of genomic DNA was tested with a 
PCR protocol for amplification of cyclin D1 gene [166].  
3.5.2. HCMV genotypic antiviral resistance 
HCMV genotypic antiviral resistance test was based on the analysis of UL97 and 
UL54 mutations.  The protocols for amplification of UL97 and UL54 were adapted from 
published manuscripts and given by Professor David Boutolleau [73, 136]. The 
amplification and sequencing conditions, which were used to characterize the UL97 and 
UL54 mutations, are reported bellow. 
3.5.2.1. Amplification of HCMV full-length UL97 gene 
The protocol for UL97 amplification is based in a Nested-PCR reaction. The first 
PCR, which amplified a fragment of 2389 bp, was performed in a 50 µL of PCR reaction 
mix containing 1x buffer, 0.3 mM dNTPs, 0.3 µM of forward and reverse outer primers 
(Table II), 1U DNA polymerase (KAPA Hifi HotStart DNA Polymerase, 
KAPABIOSYSTEMS, Boston, Massachusetts, United States) and 2 µL of test DNA. The 
amplification conditions were as follows: initial denaturation at 94ºC  for 5 min, 40 cycles 
of amplification followed by denaturation at 98ºC for 20s, annealing at 60.4ºC for 20s, and 
extension at 72ºC for 60s, then final extension at 72ºC for 5 min.  
The second PCR amplifies a 2288 bp fragment of UL97 using the inner primers 
(Table II) in a 50 µL reaction mix with the same conditions as the first PCR and with 0.2 
µL of the first PCR product. The amplification conditions were: initial denaturation at 94ºC 
for 5 min, 30 cycles of amplification followed by denaturation at 98ºC for 20s, annealing at 
58.7ºC for 20s, and extension at 72ºC for 60s, then final extension at 72ºC for 5 min. This 
PCR amplifies the full-length UL97 sequence, including all of the known GCV/VGCV-
resistance mutation sites from codons 342-708. 
PCR products were analyzed by electrophoresis with a 0.5% (w/v) agarose gel 
stained by ethidium bromide and visualized under UV light – Figure 10. PCR products 
resulting from the nested PCR were purified using the Qiagen QIAquick Gel Extraction 
Kit (QIAGEN GmbH, Hilden, Germany). 
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Figure 10: Second PCR product with 2288 bp indicates the presence of the amplification product of HCMV UL97 gene. 1-4: samples; 
M-marker; C+: Positive Control; C-: Negative Control. 
3.5.2.2. Amplification of HCMV partial UL54 gene 
The protocol for UL54 amplification is also based in a Nested-PCR technology. 
The first reaction was performed in a 25 µL of reaction mix containing 1x buffer rich GC, 
0.2 mM dNTPs, 0.3 μM forward and reverse outer primers (Table III), 1U DNA 
polymerase (KAPA Hifi HotStart DNA Polymerase, KAPABIOSYSTEMS, Boston, 
Massachusetts, United States) and 1 µL of DNA. The amplification conditions were:  
initial denaturation at 94ºC for 5min followed by 40 cycles at 94ºC for 20s (denaturation), 
60.4ºC for 20s (annealing), and 72ºC for 60s (extension), and a final extension at 72ºC for 
5 min. This PCR reaction amplifies a fragment of 2576 bp of the HCMV UL54.  
The second PCR was performed using the inner primers (Table III) in similar 
conditions to the first PCR and 0.1 µL of first round PCR product. The amplification 
conditions were: initial denaturation at 94ºC for 5 min, followed by 30 cycles of 94ºC for 
20s (denaturation), 60.4ºC for 20s (annealing), and 72ºC for 60s (extension), and a final 
extension at 72ºC for 5 min. This second PCR amplifies a fragment of 2408 bp of UL54, 
which includes known antiviral-resistance mutations sites from codons 269-1070. PCR 
products were analysed by electrophoresis in 0.5% (w/v) agarose gel stained with ethidium 
bromide and visualized under UV light – Figure 11. 
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Figure 11: Second PCR product with 2408 bp indicates the presence of the amplification product of HCMV UL54 gene. 1-8: samples; 
M-marker; C+: Positive Control; C-: Negative Control. 
3.5.2.3. Sequencing of HCMV UL97 and UL54 
UL97 and UL54 products were sequenced using overlapping primer pairs with the 
Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, 
Courtaboeuf, France) and analyzed with the automated sequencer ABI 3730 Genetic 
Analyzer (Applied Biosystems, Foster City, USA). All primers for amplification and 
sequencing are listed in Table II and III. 
 
Table II: Primers used for amplification and sequencing of HCMV full-length UL97 gene. 
Target gene Function Name Sequence (5´→3´) 
    
UL97 (2389 bp) First-round PCR (outer primers) UL97-F1 
UL97-R1 
F:CGACGCCGTCTAACAGGTAT 
R: CTCATCGTCGTCGTAGTCCA 
UL97 (2288 bp) Second-round PCR (inner primers) UL97-F2 
UL97-R2 
F: TCACGCCTCTGTTCAGATTTT 
R: CGGTGGGTTTGTACCTTCTC 
UL97 Sequence reaction UL97-A 
UL97-B 
UL97-C 
UL97-D 
UL97-E 
UL97-F 
+UL97-F2 and UL97-R2 
R: TCGTACTCGAACGACCACAT 
F: GAAACTTCGGCCATGTGGT 
R: CAGACCTCGCCGAAGGAG 
F: GACATGAGCGACGAGAGCTA 
R: AAAAGCCCAGCACGTTACC 
F: CTACGGCGTTATTGCATGTC 
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Table III: Primers used for UL54 gene amplification and sequencing. 
Target gene Function Name Sequence (5´→3´) 
    
UL54 (2576  bp) First-round PCR (outer primers) UL54-1 
UL54-11 
F: ATCTGCTGGAGCAGGGTTTT 
R: CCAATCGCTTAATGACGGCA 
UL54 (2408 bp) Second-round PCR (inner primers) UL54-2 
UL54-3 
R: TTGACGGTACAGCGAGATGT 
F: GCGTCGACTTGTGATATCGA 
UL54 Sequence reaction UL54-4 
UL54-5 
UL54-6 
UL54-7 
UL54-8 
UL54-9 
UL54-10 
+UL54-2 and UL54-3 
R:ATCCTCAAAGAGCAGCGAGA 
F:GCGCGGTTCATCAAAGACAA 
R:AAAGCGGACAAACACGCTGT 
F: TGGCTAAAATTCCGTTGCGG 
R: ACCTTTGCTGTAGTGGTTGG 
R:GCATACAGGGTACATGTCGAT 
F: TCGGCTTCTCACAACAATC 
3.6. HCMV sequence analysis  
The sequence data was observed using the 4Peaks for Mac OS X 10.3 version 1.7.2 
freeware program developed by A. Griekspoor and Tom Groothuis and available at 
http://nucleobytes.com/index.php/4peaks. 
The analysis of the sequence data from UL97 and UL54 of all patients was 
performed by the MRA – Mutation Resistance Analyzer online tool 
(http://www.informatik.uni-
ulm.de/ni/mitarbeiter/HKestler/mra/app/index.php?plugin=form) from the Universität 
Ulm, AG Bioinformatics and Systems Biology, Institute of Neural Information Processing, 
Institute of Virology. This tool compares the sequence results with the reference sequences: 
UL97 from Merlin strain (GenBank accession No: AY446894.2); and UL54 from TB40/E 
strain (GenBank accession No: ABV71585.1) – Figure 12 and 13, and Attachments III and 
IV.  
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Figure 12: UL97 sequencing analysis of codon 1 until 707 in comparison to Merlin strain. The mutations found were: T75A, N510S and 
L595W. 
 
Figure 13: UL54 sequencing analysis of codon 272 until 1069 in comparison to TB40/E strain. The mutations found were: G874R, 
L890Fand L957F. 
 
All sequence data was also compared with the HCMV genome reference strain 
AD169 (GenBank accession No: BK000394) using SeqScape v2.5 software (Applied 
Biosystems, Foster City, USA).  
Mutations were reported as resistance mutations, natural polymorphisms or 
unknown mutations.  The predicted results were also compared with the list of mutations 
published in www.ViracorIBT.com (Viracol. IBT Laboratories) and with the Attachments 
I and II that report mutations described in the literature. 
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Chapter 4  
Results 
4.1. Characteristics of the study population 
Our case series included 22 patients (9 female and 13 male), with a median age at 
allogeneic HSCT of 12 years (range: 0-60) – Table IV. The majority of the patients were 
submitted to allogeneic HSCT for acute leukemia (n=12, being n the frequency) with 
myeloblative conditioning regimen (n=15), and were transplanted with peripheral blood 
stem cells (n=11). All patients were seropositive for HCMV (positive for Immunoglobulin 
G (IgG) at the date of the transplant and received stem cells from both HCMV seropositive 
(n=10) or seronegative donors (n=12).  
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Table IV: Characteristics of the study population. 
Variable  
Gender n  
   Female 9 
   Male 13 
Age, median (range) years old 12 (0-60) 
Underlying disease n  
   Acute leukemia 12 
   Chronic myeloproliferative diseases  1 
   Chronic lymphoproliferative diseases 2 
   Myelodysplatic/Myeloproliferative diseases 1 
   Aplastic anemia 3 
   Others 3 
Stem cell source n 
   Cord Blood 8 
   Bone Marrow 3 
   Peripheral Blood 11 
Conditioning regimen n  
   Reduced Intensity 7 
   Myeloblative 15 
Donor n  
   Match/Related   5 
   Mismatched or Unrelated   17 
HCMV Donor/Recipient status n  
   D-/R+ 12 
   D+/R+ 10 
n, frequency; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D+, Positive 
Donor; R+, Positive Recipient; D-, Negative Donor; R-, Negative Recipient. 
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4.2. HCMV Infection  
Table V summarizes the information regarding time to infection (TTI) and duration 
of infection (DOI) of HCMV, for each patient. Considering the TTI, 22 patients developed 
early HCMV infection (≤100 days post-transplant) with median TTI of 20.5 days (range 0-
42) and median DOI of 108.5 days (range: 10-294).  
 
Table V: Analysis of HCMV infection among allogeneic HSCT recipients. 
Patient 
Number 
Gender 
Age  
(years old) 
HCMV D/R 
status 
TTI 
 (days) 
DOI  
(days) 
1 Male 0 D-/R+ 0 98 
2 Male 24 D+/R+ 28 39 
3 Female 7 D-/R+ 36 140 
4 Male 1 D-/R+ 16 187 
5 Male 1 D-/R+ 22 21 
6 Male 10 D+/R+ 39 31 
7 Female 5 D+/R+ 25 227 
8 Male 2 D+/R+ 42 53 
9 Male 60 D+/R+ 22 38 
10 Female 49 D-/R+ 18 273 
11 Female 18 D-/R+ 34 119 
12 Male 49 D-/R+ 18 168 
13 Female 2 D-/R+ 7 127 
14 Female 2 D-/R+ 19 196 
15 Male 37 D+/R+ 40 143 
16 Male 41 D-/R+ 7 84 
17 Female 23 D+/R+ 12 63 
18 Male 1 D-/R+ 17 14 
19 Female 54 D+/R+ 7 183 
20 Male 30 D+/R+ 32 10 
21 Female 6 D+/R+ 17 294 
22 Male 14 D-/R+ 28 70 
HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D+, Positive Donor; R+, 
Positive Recipient; D-, Negative Donor; R-, Negative Recipient; TTI, Time to Infection; 
DOI, Duration of Infection. 
 
The evolution of HCMV infection with detailed viral information for each patient is 
shown in Attachment V. 
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4.3. Genotypic Analysis of UL97 and UL54 genes 
4.3.1. UL97 sequencing results 
Table VI contains the summary of sequencing data (resistance mutations, 
polymorphisms and unknown mutations) of UL97 for each patient by comparing the 
sequence information with Merlin and AD169 strains. Despite our efforts in the laboratory, 
there are 13/22 patients on which no complete sequence data was achieved, nevertheless, 
the missing data is outside the regions which have shown resistance mutations – 
Attachment I. 
Overall, our data showed that five of the tweny two (23%) patients have been found 
with harbored HCMV resistance mutations (C592G, A594V, L595W and C603W) in 
UL97, being these mutations in bold in Table VI. The common polymorphisms, identified 
in our series, were: Q19E, N68D, S108N, L126Q, I244V, P247S and N510S. By 
comparing the sequence data with Merlin and AD169 strains, we have observed that there 
are a number of common unknown mutations found in our patients (S7Y, V96G, S135L, 
S155L, D167G, G188D, G242V, D269E, M330T, E333D, D422G, D430N, V466A, 
Y491H, R514H, V559A and A619S). We have found some unknown mutations that are 
strain specific (Merlin Strain: T75A, A104S, D122E, D290E and D422E), and indeed, all 
patients were mutant for T75A when compared with the Merlin strain. Only one unknown 
mutation was found in AD169 strain (E115K).  
To summarize the frequency (n) of found mutations we have considered the 
reported mutations compared with AD169 strain: five known UL97 resistance mutations, 
namely A594V (n=2), C592G (n=1), L595W (n=1) and C603W (n=1) were found; seven 
polymorphism, namely I244V (n=21), N68D (n=20), L126Q (n=10), Q19E (n=4), S108N 
(n=4), P247S (n=1) and N510S (n=1); and eighteen unknown mutations with the majority 
of the patients harboring more than one unknown mutation. 
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Table VI: Resistance mutations, polymorphisms and unknown mutations detected in UL97 by Merlin and AD169 strains. 
Patient 
Number 
Merlin strain AD169 strain 
Resistance Polymorphism Unknown Resistance Polymorphism Unknown 
1 L595W N510S T75A L595W 
N68D, L126Q,  
I244V, N510S 
- 
2 1) - - T75A - N68D, I244V - 
3 2) - Q126L T75A  - N68D, I244V - 
4 3) C592G - 
T75A, G242V, 
D422G, A619S 
C592G 
N68D, L126Q,  
I244V 
G242V, 
D422G,  
A619S 
5 -  Q126L T75A  - N68D, I244V - 
6 - - 
T75A, V96G, 
E333D 
- 
N68D, L126Q,  
I244V 
V96G, 
E333D 
7 - 
Q19E, S108N, 
Q126L 
T75A - 
Q19E,  N68D,  
S108N, I244V 
- 
8 - - T75A - N68D, I244V - 
9 4) - N510S 
T75A, D122E, 
S135L, G188D, 
D269E 
- 
N68D, L126Q,  
I244V 
E115K, 
S135L, 
G188D, 
D269E 
10 5) A594V - 
T75A, D422E, 
V466A, Y491H 
A594V 
N68D, L126Q,  
I244V 
V466A, 
Y491H 
11 6) A594V 
D68N, 
Q126L, V244I  
T75A, S155L A594V - S155L 
12 7) C603W Q126L  T75A C603W N68D, I244V - 
13 8) - - 
T75A, D167G, 
M330T, V559A 
- 
N68D, L126Q,  
I244V 
D167G, 
M330T 
V559A 
14 - 
Q19E, S108N, 
Q126L 
T75A - 
Q19E, N68D,  
S108N, I244V 
- 
15 - - T75A, D290E - 
N68D, L126Q,  
I244V 
- 
16 9) - - T75A, R514H - 
N68D, L126Q, 
 I244V 
R514H 
17 10) - 
Q126L, 
P247S 
T75A - 
N68D, I244V,  
P247S 
- 
18 - 
Q19E, S108N, 
Q126L 
T75A - 
Q19E,N68D,  
S108N, I244V 
- 
19 - - T75A - 
N68D, L126Q, 
 I244V 
- 
20 11) - - 
S7Y, T75A, 
D430N 
- 
N68D, L126Q,  
I244V 
S7Y,  
D430N 
21 12) -  D68N T75A, A104S - I244V - 
22 13) - 
Q19E, S108N, 
Q126L 
T75A - 
Q19E, N68D, 
S108N, I244V 
- 
1) Missing information of codon 149-151; 2) Missing 149-152, 336-339; 3) Missing 144-152, 336-339, 552-556; 4) Missing 146-152; 
5) Missing 552-556; 6) Missing 149; 7) Missing 144-152; 336-339; 552-556; 8) Missing 135-152; 9) Missing 149-152, 336-339; 10) 
Missing 149-152, 336-339; 11) Missing 149-152, 336-339, 449-508; 12) Missing 105-133, 152-166, 334-341; 13) Missing 334-342, 
548-558.  
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4.3.2. UL54 sequencing results 
Table VII contains the summary of sequencing data (resistance mutations, 
polymorphisms and unknown mutations) of UL54, for each patient by comparing the 
sequence information with TB40/E and AD169 strains. All patients were efficiently 
sequenced for UL54. 
Of the studied patients, two out of twenty two (9%) harbored HCMV resistance 
mutations (P522S and L957F) in UL54, being these mutations in bold in Table VII. The 
common polymorphisms, identified in our series, were: A614S, S655L, F669L, S676G, 
N685S, A688V, G874R, A885T, ins885S, L890F, S897L and N898D. By comparing the 
sequence data with TB40/E and AD169 strains, we observed that there are only a few 
common unknown mutations found in our patients (S306I, S306T, L394F, Y477D and 
K493N). Moreover, there are two unknown mutations that are TB40/E strain specific 
(A559V and L845V) while only one was found in AD169 strain (S656L).  
To summarize the frequency (n) of found mutations we have considered the 
reported mutations compared with AD169 strain: two resistance mutations P522S and 
L957F were found in one patient each; 12 polymorphisms, being A885T (n=18), N898D 
(n=14), S655L (n=9), N685S (n=9) and S897L (n=7) the most frequent; and 6 mutations of 
unknown significance (S306I, S306T, L394F, Y477D, K493N and S656L) were found 
with equal frequency (n=1). 
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Table VII: Resistance mutations, polymorphisms and unknown mutations detected in UL54 by TB40/E and AD169 strains. 
Patient 
Number 
TB40/E strain AD169 strain 
Resistance Polymorphism Unknown Resistance Polymorphism Unknown 
1 - 
L655S, S685N,  
S897L, D898N 
- - - - 
2 - 
L655S,  S685N,  
S897L 
- - S897L, N898D - 
3 - A614S L394F - 
A614S, S655L, 
N685S, A885T, 
N898D 
L394F 
4 - F669L - - 
S655L, F669L, 
N685S, A885T, 
N898D 
- 
5 - ins885S, D898N - - 
S655L, N685S, 
A885T, ins885S 
- 
6 P522S - - P522S 
S655L, N685S, 
A885T, N898D 
- 
7 - 
L655S, S685N,  
T885A, D898N, 
K493N - - K493N 
8 - F669L 
S306T, 
A559V 
- 
S655L,  F669L, 
N685S, A885T, 
N898D 
S306T 
9 - 
L665S, S685N,  
A688V, S897L 
- - 
A688V, A885T, 
N898D 
- 
10 - G874R, L890F - - 
S655L, N685S, 
G874R, A885T,  
L890F, N898D 
- 
11 - F669L - - 
S655L, F669L, 
N685S, A885T, 
N898D 
- 
12 - 
L655S, S685N,  
S897L 
- - 
A885T, S897L, 
N898D 
- 
13 - 
L655S, S685N, 
 S897L, D898N 
S306I, 
Y477D 
- A885T, S897L S306I,Y477D 
14 - 
L655S,  S676G,  
S685N, S897L 
L845V - 
S676G, A885T,   
S897L, N898D 
- 
15 - 
L655S,  S685N,   
S897L, D898N 
- - A885T, S897L - 
16 - - - - A885T, N898D S656L 
17 - 
L655S, S685N,  
S897L 
- - 
A885T, S897L, 
N898D 
- 
18 - 
L655S, S685N,  
T885A, D898N 
- - - - 
19 - - - - 
S655L, N685S, 
A885T, N898D 
- 
20 - 
L655S, S685N,  
S897L, D898N 
- - A885T, S897L - 
21 L957F G874R, L890F - L957F 
S655L, N685S, 
A885T,  L890F, 
N898D 
- 
22 - 
L655S, S685N,  
T885A, D898N 
- - A885T - 
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4.4. Characteristics of patients with resistance mutations 
Table VIII contains the characteristics of the seven patients where resistance 
mutations were identified, being these mutations in bold. The first five patients had 
resistance mutations in UL97 and the last two had resistance mutations in UL54. 
Additionally, this table also contains the polymorphisms and the unknown mutations that 
were found on each gene, for each patient, comparing with AD169 strain.  
Among the seven out of the twenty two (32%) patients with resistance mutations, 
five of them contained resistance mutations in UL97 (one patient each), and only two (one 
patient each) contained resistance mutations in the UL54. Patients with resistance 
mutations in UL97 did not have resistance mutations detected in UL54. Within the five 
patients with resistance mutations in UL97, three are males and two are females; three 
patients were diagnosed with different underlying disease and two patients were diagnosed 
with acute myeloid leukemia; and all, except for one patient, were submitted to 
myeloblative conditioning regimen. The stem cell source was different: two received cord 
blood; two received peripheral blood and one received bone marrow. Curiously, all 
patients were transplanted with HCMV seronegative unrelated HLA-identical donor. 
Patients with resistance mutations in UL54 did not have resistance mutations detected in 
UL97. The two patients with resistance mutations in UL54 (one male and one female), 
were diagnosed with different underlying diseases: acute myeloid leukemia and 
Myelodysplatic/myeloproliferative disease, respectively. Both were submitted to 
myeloblative conditioning regimen, and received stem cells from peripheral blood (male) 
and from cord blood (female), both from an HCMV seropositive unrelated HLA-identical 
donor – Table VIII. 
Regarding the outcome, all patients, except one which contains the UL97 A594V 
resistance mutation, are dead – Table VIII. 
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Table VIII: Characteristics of patients with resistance mutations in the UL97 and UL54. 
 
Bold, Resistance Mutations; HLA, Human Leukocyte Antigen; HCMV, Human Cytomegalovirus; D, Donor; R, Recipient; D+, Positive 
Donor; R+, Positive Recipient; D-, Negative Donor; R-, Negative Recipient. 
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4.5. Analysis of HCMV infection and treatment in patients 
with resistance mutations  
All patients included in this study were treated with preemptive treatment as 
described previously in the Material and Methods chapter. This subchapter describes each 
patient characteristics, HCMV monitoring and antiviral treatment (drug, dose and duration 
of the treatment) of the seven patients identified with resistance mutations in UL97 and 
UL54. The first five patients (Patient 1, 4, 10, 11 and 12) had mutations in UL97 and the 
last two (Patient 6 and 21) had resistance mutations in UL54. 
The detailed information for all other patients is shown in Attachment V. 
4.5.1. Patient 1 
Patient 1 was a male with less than twelve months old, diagnosed with primary 
immunodeficiency submitted to myeloblative conditioning regimen, which received 
allogeneic HSCT cord blood from a HCMV seronegative unrelated HLA-identical donor.  
 
HCMV monitoring 
 
Antiviral Treatment 
Day +0 – FOS 288 mg 8h/8h 35 days;   
Day +41 – FOS 648 mg 1x/day 19 days;   
Day +60 – FOS 432 mg 8h/8h 28 days;  
Day +89 – FOS 648 mg 1x/day 2 day;  
Day +91 – CDV 35 mg 1x/day 8 days. 
Figure 14: HCMV monitoring and antiviral treatment of patient 1. The arrow points to the sample that was selected for mutations 
analysis. 
 
The first episode of HCMV infection was detected on the day of the transplant (day 
+0). The treatment was initiated with FOS at day +0 until day +91. During this period of 
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treatment, a decrease of viremia was observed after day +22, but was not achieved 
remission of infection, with an increase and persistence of viremia after day +60. Therapy 
was then switched to CDV, which was maintained during 8 days with the maintenance of 
infection – Figure 14.  
In this patient, at day +8 after transplantation, we have identified the UL97 L595W 
GCV/VGCV resistance mutation and four different polymorphisms in UL97 (N68D, 
L126Q, I244V and N510S), but no mutations were found in UL54 – Table VIII. 
4.5.2. Patient 4 
Patient 4, was a male with one year old diagnosed with acute Lymphoid Leukemia 
B lineage underwent myeloblative conditioning regimen, which received allogeneic HSCT 
cord blood from HCMV seronegative unrelated HLA-identical donor.  
 
HCMV monitoring 
 
Antiviral Treatment 
Day +22 – GCV 44 mg 12h/12h 23 days;  
Day +22 – FOS 504 mg 8h/8h 23 days;  
Day +35 – GCV 43 mg 12h/12h 57 days;  
Day +51 – FOS 520 mg 8h/8h 41 days;  
Day +101 – GCV 40 mg 12h/12h 70 days;  
Day +114 – FOS 480 mg 8h/8h 57 days;  
Day +185 – FOS 508 mg 8h/8h 32 days. 
Figure 15: HCMV monitoring and antiviral treatment of patient 4. The arrow points to the sample that was selected for mutations 
analysis. 
 
The first episode of HCMV infection was detected in day +16 after the transplant. 
Preemptive therapy was initiated with the combination of GCV and FOS at day +22 until 
day +45. A slight decrease of the viremia was observed at the beginning of this treatment, 
but quickly increased until day +37, from when occurred a decrease of the viremia and the 
therapy was switched to GCV at day +45. At day +51, FOS was added to GCV until day 
+92 with a decrease of the number of positive cells and subsequent elimination in day +86. 
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During the follow up, a reactivation occurred at day +94 and was treated with GCV (day 
+101 to day +114), which was replaced by therapy with GCV and FOS (day +114 to day 
+171). During the period of the treatment with GCV, the viremia increased, but with the 
administration of the combination of GCV and FOS therapy, the viral load/positive cells 
slightly decreased. The viral load/positive cells increased again, but decreased after the 
administration of FOS therapy from day +185 with subsequent elimination of HCMV (0 
positive cells) at day +209 – Figure 15.  
At day +111 after transplantation, we identified, in UL97, the C592G GCV/VGCV 
resistance mutation, three different polymorphism (N68D, L126Q and I244V) and three 
unknown mutations (G242V, D422G and A619S); while in UL54 five different 
polymorphism were found (S655L, F669L, N685S, A885T and N898D) – Table VIII. 
4.5.3. Patient 10 
Patient 10 was a 49 years old female with acute myeloid leukemia submitted to 
myeloblative conditioning regimen, which received allogeneic HSCT peripheral blood 
from HCMV seronegative unrelated HLA-identical donor.  
 
HCMV monitoring 
 
Antiviral Treatment 
Day +30 – VGCV 900 mg 12h/12h 44 days;  
Day +103 – VGCV 900 mg 12h/12h 13 days;  
Day +120 – VGCV 900 mg 12h/12h 5 days;  
Day +131 – VGCV 900 mg 12h/12h 55 days;  
Day +186 – FOS 3288 mg 8h/8h 25 days;  
Day +211 – VGCV 450 mg 12h/12h 6 days;  
Day +251 – GCV 250 mg 12h/12h 16 days;  
Day +252 – FOS 3288 mg 8h/8h 22 days; 
Day +276 – GCV 280 mg 12h/12h 15 days; 
Day +276 – FOS 3360 mg 8h/8h 15 days. 
Figure 16: HCMV monitoring and antiviral treatment of patient 10. The arrow points to the sample that was selected for mutations 
analysis. 
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The first episode of HCMV infection was detected in day +18 after the transplant, 
and the preemptive treatment was initiated with VGCV (day +30 to day +74). At the 
beginning of the treatment with VGCV it was observed an increase of the number of 
positive cells until day +41, from this day forward was observed a decrease, and 
subsequent elimination, at day +57 (0 positive cells). At day +97, it was detected a new 
episode of infection, and the therapy was initiated with VGCV from day +103 until day 
+186. At day +186, the therapy was switched to FOS and the viremia decreased until 
elimination at day +209. A reactivation was identified at day +210 and the number of 
positive cells increased but with the administration of combination therapy, GCV and FOS, 
the number of positive cells slightly decreased. The continuous therapy with FOS leads to 
a decrease of the number of positive cells. The therapy was again switched to a 
combination of GCV and FOS, which was maintained until the patient died – Figure 16. 
In this patient, at day +120 after transplantation, we have identified the A594V 
GCV/VGCV resistance mutation, three different polymorphism (N68D, L126Q and 
I244V) and two unknown mutations (V466A and Y491H) in UL97; and six different 
polymorphism in UL54 (S655L, N685S, G874R, A885T, L890F and N898D) – Table VIII. 
4.5.4. Patient 11 
Patient 11 was an 18 years old female with a medullary aplasia underwent a 
reduced intensity regimen, which received allogeneic HSCT bone marrow from HCMV 
seronegative unrelated HLA-identical donor. 
The first episode of HCMV infection was detected in day +34 after the transplant. 
Preemptive treatment was initiated with VGCV, from day +42 until day +86. No 
significant change in viremia was observed under VGCV therapy. Indeed, after inclusion 
of FOS (day +115) in combination with VGCV, followed by FOS therapy alone there was 
a significant decrease of HCMV viremia and subsequent elimination, at day +139.  The 
therapy was then switched to GCV (day +139 to day +149), which kept the number of 
positive cells in a low level – Figure 17.  
In this patient, we have identified, at day +115 after transplant, the A594V 
GCV/VGCV resistance mutation and one unknown mutation, S155L, in UL97, and five 
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different polymorphisms, S655L, F669L, N685S, A885T and N898D, in UL54 – Table 
VIII. 
 
HCMV monitoring 
 
Antiviral Treatment 
Day +42 – VGCV 900 mg 12h/12h 41 days;  
Day +84 – VGCV 450 mg 12h/12h 2 days;  
Day +98 – VGCV 900 mg 12h/12h 24 days;  
Day +115 – FOS 2640 mg 12h/12h 3 days;  
Day +119 – FOS 4080 mg 8h/8h 2 days;  
Day +122 – FOS 3360 mg 12h/12h 4 days; 
Day +123 – FOS 4080 mg 1x/day 8 days;  
Day +132 – FOS 2688 mg 12h/12h 1 day;  
Day +133 – FOS 4080 mg 1x/day 6 days;  
Day +139 – GCV 300 mg 1x/day 2 days;  
Day +142 – GCV 170 mg 1x/day 7 days. 
Figure 17: HCMV monitoring and antiviral treatment of patient 11. The arrow points to the sample that was selected for mutations 
analysis. 
4.5.5. Patient 12 
Patient 12 was a 49 years old male with an acute myeloid leukemia submitted to 
myeloblative conditioning regimen, which received allogeneic HSCT peripheral blood 
from HCMV seronegative unrelated HLA-identical donor 
The first episode of HCMV infection was detected in day +18 after the transplant 
and was treated with GCV therapy, from day +19 until day +25 and changed to VGCV 
under maintenance therapy. At day +119, a new episode of infection started, with HCMV 
viremia increasing significantly under VGCV therapy and remaining high until 
administration of FOS at day +159. Afterwards there was a slightly decreased in viremia 
without elimination under FOS therapy – Figure 18. 
In this patient, it was observed, at day +159 after transplant, the UL97 C603W 
GCV/VGCV resistance mutation, two different polymorphisms (N68D and I244V) in the 
UL97, and three different polymorphisms, A885T, S897L and N898D, in UL54 – Table 
VIII. 
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HCMV monitoring  
 
Antiviral Treatment 
Day +19 – GCV 450 mg 12h/12h 6 days;  
Day +28 – VGCV 900 mg 2 days;  
Day +39 – VGCV 900 mg 4 days;  
Day +54 – VGCV 450 mg 6 days;  
Day +77 – VGCV 900 mg 57 days;  
Day +159 – FOS 3600 mg 8h/8h 20 days;  
Day +172 – FOS 3120 mg 12h/12h 15 days. 
Figure 18: HCMV monitoring and antiviral treatment of patient 12.  The arrow points to the sample that was selected for mutations 
analysis. 
4.5.6. Patient 6 
Patient 6 was a 10 years old male with an acute myeloid leukemia submitted to 
myeloblative conditioning regimen, which received allogeneic HSCT peripheral blood 
from HCMV seropositive unrelated HLA-identical donor.  
The first episode of HCMV infection was detected in day +39 after the transplant, 
when the patient was already being administered with VGCV therapy. The viremia 
increased significantly, under VGCV therapy, until day +57, when FOS was administered. 
During the therapy with FOS it was observed a decrease of the viral load/positive cells and 
subsequent elimination, at day +64 – Figure 19.  
In this patient, it was observed, at day +54 after transplant, the UL54 P522S 
mutation, known to be associated with a cross-resistance to GCV/VGCV and CDV, four 
different polymorphisms S655L, N685S, A885T and N898D, in UL54 and three different 
polymorphisms, N68D, L126Q and I244V, and two unknown mutations, V96G and E333D 
in the UL97 – Table VIII. 
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HCMV monitoring 
 
Antiviral Treatment 
Day +28 – VGCV 450 mg 12h/12h 29 days; 
Day +57 – FOS 1848 mg 8h/8h 32 days; 
Day +75 – FOS 2808 mg 1x/day 16 days; 
Day +91 – FOS 1224 mg 8h/8h. 
Figure 19: HCMV monitoring and antiviral treatment of patient 6. The arrow points to the sample that was selected for mutations 
analysis. 
4.5.7. Patient 21 
Patient 21 was a 6 years old female with a myelodysplatic/myeloproliferative 
disease underwent myeloblative conditioning regimen, which received allogeneic HSCT 
cord blood from HCMV seropositive unrelated HLA-identical donor. 
 
HCMV monitoring 
 
Antiviral Treatment 
Day +32 – FOS 1080 mg 8h/8h 17 days; 
Day +50 – FOS 1344 mg 8h/8h 16 days;  
Day +85 – FOS 1121 mg 8h/8h 24 days;  
Day +109 – GCV 100 mg 12h/12h 4 days;  
Day +114 – GCV 50 mg 12h/12h 19 days;  
Day +133 –GCV 50 mg 1x/day 16 days;  
Day +215 – GCV 52.5 mg 12h/12h 6 days;  
Day +221 – GCV 16 mg 1x/day 7 days;  
Day +228 – GCV 50 mg 1x/day 4 days;  
Day +232 – FOS 220 mg 8h/8h 9 days. 
Figure 20: HCMV monitoring and antiviral treatment of patient 21. The arrow points to the sample that was selected for mutations 
analysis. 
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The first episode of HCMV infection was detected in day +17, after the transplant. 
The preemptive treatment was initiated at day +32 with FOS, which was extended until 
day +66. During the FOS therapy, the number of positive cells decreased leading to its 
subsequent elimination (0 positive cells) at day +42. A new HCMV episode occurred and 
was treated with FOS, during day +85 until day +109. Therapy was then switched to GCV, 
from day +109 until day +149, during when, the infection remained absent, with only one 
positive result for HCMV by quantitative PCR, at day +133. During the interval when no 
therapy was administered, from day +154 until day +211, the viremia was inconstant, with 
some episodes of positivity by quantitative PCR. At day +215, GCV therapy was initiated 
until day +232 with a slightly decreased of HCMV infection. Afterwards, the therapy was 
changed to FOS and the infection was eliminated at day +238 for a short period – Figure 
20. 
In this patient, it was observed, at day +196 after transplant, the UL54 L957F 
mutation, known to be associated with a resistance to GCV/VGCV, five different 
polymorphisms, S655L, N685S, A885T, L890F and N898D, in UL54 and one 
polymorphism, I244V, in UL97 – Table VIII. 
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Chapter 5  
Discussion 
The development of HCMV drug resistance in the transplanted population appears 
to vary widely depending on the type of patients, and remains relatively rare for 
hematopoietic stem cell transplanted (HSCT) patients [74, 79, 142]. Indeed, there are some 
retrospective and prospective studies, to analyze HCMV drug-resistant mutations on 
allogeneic HSCT (allo-HSCT) patients worldwide but not from Portugal [73, 93, 103, 142, 
145, 167]. In this study, we have retrospectively analyzed a population of patients 
submitted to allo-HSCT with diagnosed HCMV infection on which we have attempted to 
identify drug-resistant mutations. 
5.1. Correlation of HCMV resistance mutations with 
antiviral treatment response 
In the population in study we have identified seven patients with resistance 
mutations. Of the seven patients, the first five (patient 1, 4, 10, 11 and 12) had resistance 
mutations in UL97 and the last two (patient 6 and 21) had resistance mutations in UL54. 
The correlation of HCMV resistance mutations with the antiviral treatment response, for 
each one of these patients, will be discussed in the following lines. 
5.1.1. Patient 1 
This patient was diagnosed with a HCMV infection at the day of transplant (day 
+0) being treated with FOS. At day +8 we identified the UL97 L595W mutation, which is 
known to confer a moderate GCV/VGCV resistance [108, 123]. As this mutation confers 
resistance to GCV/VGCV it was expected a decrease and subsequent elimination of the 
infection, however, the remission of the infection was not achieved. Besides the 
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identification of four UL97 polymorphisms (N68D, L126Q, I244V and N510S) we have 
not identified any mutation in UL54. Considering that patient’s response to FOS was not 
complete, we hypothesize that other HCMV strains may coexist, which may contain FOS 
resistance mutations. Indeed, it has been reported that the continuous administration of a 
drug can lead to the accumulation of multiple drug resistance mutations, which may 
explain the increase and persistence of viremia after day +60 [74, 96, 99, 100]. Therapy 
was then switch to CDV, which seemed to be effective, although the patient has died. The 
use of CDV as a second-line therapy is indicated especially to rescue patients failing 
antiviral therapy with GCV, FOS or both [62, 90].  
5.1.2. Patient 4 
In this patient, HCMV infection was detected at day +16 with very high HCMV 
levels and the treatment was initiated at day +22 with the combination of GCV and FOS, 
only after two consecutive positive results. Despite it has been reported that high viral 
load/positive cells at the start of the therapy may contribute to the emergence of resistance, 
the combination of GCV and FOS has been used with high effectiveness in patients with a 
high viral load [19, 73, 90, 91]. Indeed, there was a decrease of viremia and its subsequent 
elimination in day +86. Nevertheless, a reactivation occurred immediately at day +94, with 
an increase in the viremia. The treatment was then initiated with GCV and afterward 
combined with FOS at day +114. At day +111 we identified the UL97 C592G mutation, 
which is reported to confer a low level of resistance to GCV/VGCV and preferentially 
selected in situations where the virus is exposed to low GCV concentrations [55, 112]. In 
addition, this mutation may have emerged from prolonged antiviral therapy. Even though 
this mutation confer low resistance, it is likely to be responsible for the viral persistence. 
Hence, the decrease and subsequent elimination of HCMV viremia, at day +209 is likely to 
be conferred by FOS. We have also found polymorphisms in UL97 (N68D, L126Q and 
I244V) and UL54 (S655L, F669L, N685S, A885T and N898D), and some unknown 
mutations in UL97 (G242V, D422G and A619S) that may play an important role in the 
emergence of antiviral resistance.  
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5.1.3. Patient 10 
In this patient, the infection was detected at day +18 and the treatment initiated with 
VGCV at day +30, leading to the elimination of the HCMV infection episode at day +57. 
However, a new HCMV episode started at day +97 and despite the therapy with VGCV, 
the infection was not eliminated. Indeed, we have detected the UL97 A594V mutation at 
day +120. This mutation is known for being frequent and for confer high resistance to 
GCV/VGCV [112, 137, 153]. Additionally, several polymorphisms were found in UL97 
(N68D, L126Q and I244V) and in UL54 (S655L, N685S, G874R, A885T, L890F and 
N898D).Two unknown mutations in UL97 (V466A and Y491H) were also observed. 
Curiously, despite VGCV resistance, the number of positive cells remained relatively low 
under VGCV until day +155. However, this mutation is likely to be responsible for the 
viral persistence and for the increase of the number of positive cells, which occur at day 
+155 until day +186. In this day, the treatment was changed to FOS and lead to undetected 
levels of HCMV until day +209. Nevertheless, a reactivation occurred at day +210, which 
persisted for a long period even with a combination therapy of GCV and FOS. This 
persistence may be due to possible GCV and FOS resistance developed during the long 
period of treatment [99]. 
5.1.4. Patient 11 
Patient 11 was detected with HCMV infection at day +34 and treated with VGCV, 
which was responsible for the decrease of infection until day +83. Nevertheless, the 
HCMV levels increased by day +91 and the therapeutics were combined with FOS at day 
+115. In this day we have identified the UL97 A594V mutation, known to confer high 
resistance to GCV/VGCV [112, 137, 153]. This resistant strain, which may have emerged 
from a prolonged therapy with VGCV, could have been the cause of the increase and 
persistence of the viral replication. Additionally, several polymorphisms (S655L, F669L, 
N685S, A885T and N898D) were found in UL54, and one unknown mutation (S155L) in 
UL97. After the combination of FOS with VGCV, followed by FOS therapy alone, there 
was a significant decreased of HCMV viremia and subsequent elimination at day +139, 
probably due to the effect of FOS. Afterwards, the therapeutics changed to GCV and the 
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infection was maintained under low levels, which may be the result of the emergence of 
GCV resistance strains.  
5.1.5. Patient 12 
This patient was positive for HCMV at day +18, whom had the therapy initiated 
with GCV and then changed to VGCV with elimination of the infection by day +34. A new 
HCMV episode started at day +77 and was eliminated at day +91, with VGCV therapy. 
Nevertheless, under VGCV therapy, a new infection occurred at day +119 with increasing 
HCMV viremia and the therapeutics was changed, at day +159, to FOS. In this day, we 
detected the UL97 C603W mutation, which is known to be associated with a high 
GCV/VGCV resistance [101, 153] and might be the result of prolonged therapy with 
VGCV and the responsible for the increase of HCMV viremia under VGCV therapy. We 
have also found the following polymorphisms: N68D and I244V in UL97, and A885T, 
S897L and N898D in UL54, which may modulate the resistance level conferred by this 
mutation [100, 136]. However, with the introduction of the FOS therapy the viremia has 
decreased, but without remission of the infection, and so other strains with FOS resistant 
mutations may co-exist. 
5.1.6. Patient 6 
In this patient, the HCMV infection was detected at day +39 after the transplant, 
when the patient was already being administered with VGCV. The viremia increased, 
under the therapy with VGCV, until day +57. This increase is likely to have resulted from 
the resistant strain that emerged at day +54, with a UL54 P522S mutation, which is known 
for confer dual low-grade GCV-CDV resistance [74, 156]. Additionally, we have detected 
polymorphisms in UL54 (S655L, N685S, A885T and N898D) and in UL97 (N68D, L126Q 
and I244V), which may modulate the drug-resistance level provided by resistance mutation 
[100, 136], and two unknown mutations (V96G and E333D) in UL97, which may be of 
potential interest. Hence, with the switch of therapy to FOS at day +57, we observed a 
significant reduction and subsequent elimination of the HCMV infection by day +64. 
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5.1.7. Patient 21 
In this patient, the infection was detected at day +17, but the therapy was only 
initiated at day +32 with FOS, when HCMV viremia was already high. It has been reported 
that high viral load/positive cells at the start of the therapy may contribute to the 
emergence of resistance [19, 73]. However, despite the therapy started while the viremia 
was high, the infection was eliminated with FOS at day +42. New HCMV infection 
episodes and reactivations occurred from day +68 until day +191 that were eliminated by 
the treatment or possibility by the host immune response of the individual. During the 
interval when no therapy was administered, a reactivation occured at day +196, when we 
have identified the UL54 L957F mutation, which is known to confer low resistance to 
GCV/VGCV [98, 105]. Additionally, the following polymorphisms were found: S655L, 
N685S, A885T and N898D in UL54 and I244V in UL97. Under the therapy with GCV, 
despite occuring a slight reduction of the HCMV infection, which may be due to the fact 
that this mutation confers low resistance to GCV, this mutation is likely to be responsible 
for the viral persistence, that ends up by being eliminated with the switch of the therapy to 
FOS. 
5.2. Overall Discussion 
This is the first study in Portugal to characterize both HCMV UL97 and UL54 
sequences and to identify HCMV drug-resistance mutations in allogeneic HSCT patients. 
The majority of the studies use AD169 reference strain, to analyze mutations in both genes. 
In our study, in addition to the AD169 strain, we also used the Merlin and TB40/E strains, 
which were used to analyze mutations on genes UL97 and UL54, respectively. Even 
though we had our focus on the results obtained by the AD169 strain, there were identified 
mutations that are specific to Merlin or TB40/E strains, which may be relevant for the 
emergence of HCMV resistance.  
Our study was developed with twenty two patients on whom we have been able to 
identify seven (32%) with resistance mutations: five (23%) with resistance mutations in the 
UL97 (one patient each); and two (9%) with resistance mutations in UL54 (one patient 
each). In immunocompromised patients, such as HSCT, the treatment of HCMV 
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infection/disease often require prolonged administration of antiviral therapy [96] and it has 
been shown that prolonged treatment (e.g. several months) can promote the development 
of resistant HCMV strains resulting in an impaired response to the therapy [98, 99]. In our 
study, some drug-resistant HCMV mutations were first detected 2-3 months after antiviral 
therapy. It is known that the occurrence of drug resistance during the first six weeks of 
therapy is unusual, although this has been reported to occur [129, 168]. In our study, some 
drug-resistant HCMV mutations were first detected during the first six weeks of therapy. 
Moreover, the continuous administration of a drug to which resistance was observed in 
some patients can lead to accumulation of multiple drug resistance mutations [74, 99, 100]. 
Additionally, it has also been reported that suboptimal antiviral concentrations due to poor 
compliance or low drug absorption and limited oral bioavailability are others risk factors in 
the emergence of HCMV drug resistance [45, 68, 73, 96].  
Ganciclovir/Valganciclovir (GCV/VGCV) resistance in HCMV is usually caused 
by mutations in the UL97 kinase gene, which impair the initial phosphorylation of the drug 
that is necessary for its antiviral activity [58, 62]. The GCV/VGCV resistance mutations in 
UL97 that were found in this study were C592G, A594V, L595W and C603W. By revising 
the literature, these amino acid changes belong to the most frequently detected mutations 
with a known confirmed GCV/VGCV resistant [108-110, 131]. Additionally, these 
mutations are clustered in the codon segment 590–607 (non-functional region), which is 
dispensable for viral replication [19, 40, 55, 77, 81]. Nevertheless, a considerable diversity 
of mutations, in this region, has been linked to varying degrees of GCV/VGCV resistance, 
which impair the recognition of GCV as a substrate while preserving the normal biological 
function [19, 55]. Of the four resistance mutations identified in our patients, the A594V 
mutation was the most frequent and has been frequently found in several other studies 
[116, 137, 153], being the one conferring more resistance to GCV/VGCV (IC50=8.3) [101, 
112]. Except for C592G, which confers low-grade resistance (IC50=2.9), the L595W 
(IC50=5.1) and C603W (IC50=8.0) confer moderate to high-grade resistance [55, 101, 112]. 
Additionally, we observed that patients with GCV/VGCV-resistant UL97 mutations had no 
UL54 resistance mutations, which is in accordance with the literature since the major 
contribution for GCV/VGCV resistance is on UL97 [73, 99, 116, 153]. 
In contrast with UL97, UL54 resistance mutations are less common and can confer 
resistance to any, or all, of the current HCMV antivirals (GCV, VGCV, FOS and CDV) 
[75, 76, 97]. The UL54 P522S mutation, located on exonuclease domains (N-terminal 
Ana Bela Saraiva de Campos 
Master Degree Course in Medical and Molecular Oncology 
 
CHARACTERIZATION OF CYTOMEGALOVIRUS RESISTANT 
STRAINS IN HEMATOPOIETIC STEM CELL TRANSPLANTED PATIENTS   
 
Page 
71 
 
 
extremity of ∂-region C), was observed in one patient and has shown to confer low-grade 
resistance to GCV/VGCV (IC50=3.1) and to CDV (IC50=3.6) [40, 77, 98, 140, 156]. This 
mutation is located in a region of frequent mutations that confer resistance to GCV/VGCV 
and CDV and is among the most frequent mutations, in UL54, associated with drug 
resistance [77, 99]. The other UL54 mutation found in our study was the L957F, which is 
known to confer low resistance to GCV/VGCV (IC50=2.7) [98, 105]. This mutation is one 
of the few UL54 mutations that confer resistance only to GCV/VGCV and, until now, was 
only reported on laboratory strains [98, 105] and despite the fact that the majority of the 
resistance mutations in UL54 occur within the conserved regions, this mutation occurs 
outside of these regions [19]. Our study showed that patients with resistance mutations in 
UL54 did not have resistance mutations in UL97, and although uncommon this has been 
reported previously [138, 139]. Nevertheless, we have found, in one patient with UL54 
resistance mutation, that there were UL97 mutations of unknown significance, which may 
be of potential interest. 
The level of resistance is a very important factor that influences patient’s outcome 
[93, 147]. In our study, we observed that of the seven patients with resistant mutations, 
only one is alive, and he had a high resistance mutation. Indeed, patients with mutations 
that conferred low-resistance had the same outcome (death) as the others. The only patient 
alive was submitted to a bone marrow transplant with reduced intensity regimen. Thus, in 
our study, the immunosuppression regimens and the source of stem cells may have 
influenced the clinical outcome. Moreover, most HCMV drug resistance clinical reports 
have shown the more severe outcomes, because the same host factors that predispose to 
drug resistance are also associated with more severe HCMV disease [19]. A recent study 
showed that HCMV drug resistance mutations were not associated with a poor outcome 
[73]. This leads us to think that other factors other than the level of resistance of the 
mutations may be important to define the clinical outcome.  
UL97 and UL54 variants, known in literature as natural polymorphisms, were also 
observed in seven patients with resistance mutations. The UL97 observed variants were: 
N68D, L126Q, I244V and N510S, being I244V (n=6), N68D (n=5) and L126Q (n=4) the 
most frequent. Except for the N510S polymorphism, all others occur outside the region 
where UL97 polymorphisms are usually found (on codon range 460-607) [136] and all of 
these polymorphisms were also found in other studies [55, 93, 101, 136, 169].  The UL54 
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observed variants were: S655L, F669L, N685S, G874R, A885T, L890F, S897L and 
N898D. These variants occur at residues outside the conserved regions, such as the 
majority of the polymorphisms found in this gene, and all of them were also found in other 
studies [19, 78]. The A885T (n=6), N898D (n=6), S655L (n=5) and N685S (n=5) variants 
were the most frequently found, such as observed in others studies [73, 82, 93, 94, 116, 
146, 156]. It has been reported that some natural polymorphisms may modulate the drug-
resistance level provided by other mutations [100, 136]. In our study, these 
polymorphisms, identified in UL97 or in UL54, were found in combination with UL97 and 
UL54 resistance mutations. Other recent studies also showed that the polymorphisms 
identified in the UL97 or in the UL54 are found in combination with resistance mutations 
[73, 82, 93, 94, 116]. For example, the N510S polymorphism, which was found in just one 
patient, was found in a HCMV isolate resistant to GCV with a deletion of UL97 codons 
591-594 [108]. In our study, this polymorphism was detected in a HCMV isolate resistant 
to GCV, with a L595W mutation. Thus, the role of these mutations, found in UL97 and 
UL54, as polymorphism or compensatory mutation remains unclear and needs further 
investigation. 
Moreover, eight new mutations of unknown significance (V96G, S155L, G242V, 
E333D, D422G, V466A, Y491H and A619S) found in UL97 were observed in three 
patients with UL97 resistance mutations and in one patient with UL54 resistance mutation. 
The D422G and A619S unknown mutations, found in the patient with the UL97 C592G 
mutation, and V466A and Y491H found in one patient with the UL97 A594V mutation, are 
located between different conserved regions of the protein and are clustered in the codons 
segment (342-708) where all known GCV/VGCV-resistance mutations have been 
described [97, 107]. In addition, the majority of the UL97 resistance mutations are found 
outside the conserved kinase domains, which are more likely to be critical to the overall 
kinase function [19, 40, 55, 77, 108-110]. Some amino acid positions of UL97 can be 
involved in both natural polymorphisms and antiviral resistance [136]. Additionally, the 
V466A unknown mutation occurs at the same position as a previous established 
GCV/VGCV resistance-associated substitution (V466G) and natural polymorphism 
(V466M) and, therefore, its role needs further investigation. The V96G and E333D found 
in patient with UL54 P522S mutation, the G242V found in the patient with the UL97 
C592G mutation and S155L found in one patient with the UL97 A594V mutation, occur at 
a region of the gene where, until now, resistance mutations to GCV/VGCV were not 
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found. However, a recent study found the F342S mutation in the region I of the gene, 
which confers a moderate resistance to GCV/VGCV, where, until then, resistance 
mutations to GCV/VGCV had not yet been described in these regions [117]. In addition, 
studies describe the UL97 natural polymorphisms mainly focused on codon range 460-607, 
where all known GCV/VGCV resistance mutations are localized [55]. Nevertheless, 
phenotypic studies are required to ascertain the true nature of these new mutations.  
The clinical courses of HCMV infection are influenced by multiple risk factors as 
well as by the presence of an antiviral-resistance mutation [93]. Our patients met some 
critical risk factors for the emergence of HCMV resistance: the majority were high-risk 
patients for HCMV infection with HCMV D-/R+ serostatus; some received stem cells from 
cord blood; and, except for one patient, all were submitted to myeloblative conditioning 
regimen [40, 73, 93]. High viral load/positive cells at the start of the therapy and recurrent 
HCMV infections were other risk factors, which may have contributed to the emergence of 
resistance in some of these patients [19, 77, 93]. The patients where UL97 resistance 
mutations were found were transplanted with HCMV seronegative unrelated HLA-
identical donor while patients with UL54 resistance mutations were transplanted with 
HCMV seropositive unrelated HLA-identical donors. Curiously, UL97 resistance 
mutations that confer low to moderate resistance to GCV/VGCV appeared on the patients 
that were transplanted with cord blood while the ones conferring high resistance appeared 
on the patients transplanted with peripheral blood or bone marrow. In UL54, the L957F 
mutation, which confers low resistance to GCV, appeared on the patient transplanted with 
cord blood while the P522S mutation appeared on the patient transplanted with peripheral 
blood. This observation leads us to presume that different factors may have contributed to 
the emergence of different resistance mutations. 
In the patients where resistance mutations were not found, we have found unknown 
mutations in both UL97 and UL54, which may have influenced the development of 
resistance. In UL97, the majority of mutations occur at a region of the gene where, until 
now, resistance mutations to GCV/VGCV were not found: S7Y, E115K, S135L, D167G, 
G188D, D269E and M330T. Nevertheless, D430N, R514H and V559A mutations, are 
located between different conserved regions of the protein and all them are clustered in the 
codons segment (342-708) where all known GCV/VGCV-resistance mutations have been 
described and where UL97 polymorphisms are usually found [55, 97, 107]. In UL54, the 
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L394F, K493N and S306T/I mutations are located within the exonuclease domains where 
other resistance mutations to GCV/VGCV and CDV are more frequent [40, 77, 98], 
including the mutation found in this study (P522S). Because of their location inside the 
conserved domains, all of these mutations are likely considered to be associated to antiviral 
resistance, rather than to polymorphisms. Additionally, UL54 Y477D and S656L 
mutations, due to their location outside the conserved regions, are likely considered to be 
associated with polymorphism, rather than to resistance mutations. Despite this 
assumption, more studies are required to ascertain the true nature of these new mutations.  
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Chapter 6  
Conclusions and Future Directions 
The emergence of HCMV resistance to one or more antiviral agents, which is 
influenced by multiple risk factors as well as by the presence of antiviral-resistance 
mutations, is associated with treatment failure and progression of HCMV disease in 
immunocompromised patients, complicating therapeutic and clinical management. In our 
study we have found HCMV drug-resistance mutations, in both UL97 and UL54, leading 
to an impaired response to the therapy.  
Our results confirm predominant role of UL97 mutations in HCMV resistance to 
GCV/VGCV, which are in accordance with previous studies [73, 94, 99]. In this gene, we 
have detected the C592G, A594V, L595W and C603W mutations, which belong to the 
most frequently detected mutations. UL54 gene was less frequently mutated than UL97, 
and the detected mutations were the P522S and L957F in the absence of mutations in 
UL97. UL54 P522S mutation is located in a region of frequent mutations that confer 
resistance to GCV/VGCV and CDV and is among the most frequent UL54 mutations 
associated with drug resistance. Furthermore, to our knowledge, this was the first study 
describing the L957F mutation among immunocompromised patients. Until now, this 
mutation was only reported on laboratory strains. These mutations confer different 
resistance levels and, based on the clinicopathological data for each patient, we conclude 
that different factors may have contributed to the emergence of mutations with different 
levels of resistance. Moreover, we also conclude that other factors other than the level of 
resistance of the mutations may be important to define the clinical outcome. Additionally, 
several polymorphisms were found in both genes, in combination with UL97 and UL54 
resistance mutations, which may modulate the drug-resistance level provided by resistance 
mutations. Unknown mutations in UL97 and/or in UL54 were also found and they may 
play an important role in the emergence of antiviral resistance. However, further 
investigation is required to understand the role of these mutations as polymorphisms or 
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compensatory mutations and phenotypic studies are required to ascertain the true nature of 
the unknown mutations. 
Given the frequency of resistance mutations found in this study (n=7, 32%), we 
conclude that it is important to implement protocols for a rapid detection of HCMV 
mutations in cases of clinical and laboratory suspicion, improving the management of 
patients. The establishment of guidelines for HCMV treatment, including genotyping 
information of viral genes, is important to improve the management of allogeneic HSCT 
patients with alternative treatments. 
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Attachments 
Attachment I: Mutations in viral phosphokinase (UL97) gene associated with 
GCV/VGCV resistance in laboratory and clinical isolates confirmed by marked transfer. 
 
Mutation 
Amino acid change Viral 
Phenotype a) 
GCV/VGCV IC50 
References 
Wild type (Wt) Mutant 
F342S F S R (7.8) [117] 
del355 K del 1 R (16) [117] 
V356G V G R (5.5) [117] 
L405P  L P R (2.5) [101] 
D456N D N R (12) [118] 
M460I  M I R (5) 
[73, 96, 104, 108, 116, 134, 144, 157, 
159, 170, 171] 
M460L M L NA [129] 
M460T  M T R (9.3) [96, 101] 
M460V M V R (8.3) 
[74, 75, 82, 93, 96, 99, 100, 108, 112, 
116, 122, 134, 137, 138, 142, 145, 
153, 155, 170-172] 
V466G V G R (3.5) [96, 122] 
C480R D R R (9) [118] 
C518Y C Y R (12) [123] 
H520Q H Q R (10) [74, 96, 108, 134, 137, 138, 153] 
P521L P L R (17) [117] 
del591-594  b) ACRA del 4 R (6) [96, 108, 137, 173] 
del590-600 AACRALENGKL del 11 R (6.3) [119] 
del590-603 
AACRALENGKL
THC 
del 14 NA [174] 
del591-607  
ACRALENGKLT
HCSDAC 
del 17 R (6.2) [96, 108] 
C592F C F R (31.5) [120] 
C592G C G R (2.9) 
[73, 74, 93, 94, 96, 101, 108, 111, 
112, 116, 122, 138, 141, 145, 153, 
155, 157] 
A594E  A E R (3.0) [96, 101] 
A594G A G R (13.5) [124] 
A594P A P R (2.9) [73, 96, 113, 134, 145, 158] 
A594T A T R (2.7) 
[73, 94, 96, 99, 108, 116, 134, 137, 
138, 167, 170] 
A594V A V R (8.3) 
[73, 74, 82, 83, 94, 96, 99, 101, 103, 
104, 108, 112, 116, 134, 137, 138, 
140, 145, 153, 155, 158, 159, 167, 
170-172] 
del594-595 AL del 2 NA [131] 
L595F L F R (15.7) [96, 108, 116, 122, 145, 163, 171] 
L595S L S R (9.2) 
[73-75, 83, 94, 96, 99, 104, 108, 112, 
116, 134, 137, 138, 145, 153, 157, 
159, 167, 170-172] 
L595T L T R (2.2) [116] 
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L595W L W R (5.1) [83, 96, 108, 123, 134, 153] 
del595 L del 1 R (13.3) [96, 153, 175] 
del595-603 LENGKLTHC del 9 R (8.4) [96, 114, 176] 
del596 E del 1 NA [132] 
E596G E G R (2.3) [73, 95, 96, 108] 
E596Y  E Y R (6.4) [95] 
G598S G S NA [96, 127, 177] 
K599E K E NA [132] 
K599T  K T R (5.3) [96, 115] 
del600 L del 1 r (1.9) [96, 108, 153] 
del601 T del 1 NA [128, 153] 
del601-603 THC del 3 R (11) [96, 142] 
T601M T M NA [133] 
C603R C R R (3.6 - 8.3) [96, 101, 122, 134] 
C603S C S r (1.9) [96, 101, 134] 
C603W C W R (8) 
[73, 74, 96, 99, 101, 104, 108, 111, 
116, 134, 137, 145, 153, 157] 
C607F C F r (1.9) [74, 96, 108, 137] 
C607T C T R (12.5) [121] 
C607Y C Y R (12.5) [96, 108, 134, 137, 140, 144] 
I610T  I T R (2.6) [95] 
A613V  A V R (2.3) [125] 
del617 Y del 1 R (10) [118] 
E655K E K r (1.7) [126] 
 
Boldface indicates the most common mutations conferring resistance; Deletions start at the 
designated codon and continue through the number of shown codons; R, resistant strain 
(2 fold reduction in susceptibility to GCV/VGCV); r, low-grade resistance or <2 fold 
reduction in susceptibility GCV/VGCV; NA, not available. 
a) The level of resistance of each mutation is expressed as the ratio of the half maximal 
inhibitory concentration (IC50) of the mutant to that of drug – sensitive wild-type (IC50 of 
mutant/IC50 of wild type ratio); b) Deletion of codons 591 to 594 results in the same 
mutant virus as deletion of codons 590 to 593. 
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Attachment II: Mutations in DNA polymerase (UL54) gene associated with antiviral 
resistance in laboratory and clinical isolates confirmed by marked transfer.
 
Mutation 
Amino acid 
change 
Viral 
Phenotype a) 
References 
Wild 
Type (Wt) 
Mutant 
GCV/ 
VGCV 
(IC50) 
CDV 
(IC50) 
FOS 
(IC50) 
Exo I (295 - 312) 
D301N D N R (2.6) R (3) S (0.5) [96, 143] 
Regions IV / Exo II (379 - 421 / 404 - 418) 
N408D   N D R (4.9) R (5.6) S (1.3) [96, 105, 116, 138, 140, 151] 
N408K N K R (4.2) R (21) S (0.7) [82, 96, 145, 160] 
N408S N S R (3.1) R (7.5) S (1.0) [144] 
N410K N K R (2.9) R (3) S (0.8) [96, 143] 
F412C F C R (4.2) R (18) S (1.2) [74, 96, 111, 116, 151, 157] 
F412L  F L R (4.6) R (9.4) S (1.1) [96, 98, 161] 
F412S F S R (5.3) R (13) S (0.8) [96, 98, 134, 161] 
F412V  F V R (4.3) R (15.5) S (1.1) [96, 151] 
D413A D A R (6.5) R (11) S (0.8) [96, 142] 
D413E D E R (4.8) R (4.3) S (0.8) [96, 138, 143, 145] 
D413N D N R (3.8) R (10) S (1.0) [140] 
Outside the conserved regions 
P488R  P R R (3.5) R (7.9) S (0.6) [98, 105] 
∂-Region C (492 - 588) 
N495K  N K S (1.1) S (1.1) R (3.4) [75, 96, 154] 
K500N  K N R (3.2) R (3.0) S (1.2) [98, 105] 
L501I L I R (6) R (9.1) S (1.4) [74, 82, 96, 116, 151] 
T503I T I R (2.9) R (6.1) S (0.5) [74, 96, 116, 143] 
A505V A V r (1.8) R (2) S (1.1) [146] 
K513E K E R (5) R (9.1) S (1.4) [96, 116, 151, 157] 
K513N K N R (6) R (12.5) S (1.5) [96, 164] 
K513R K R R (3.7) R (10) S (1.1) [116, 140] 
D515E D E R (2.7) NT R (4.6) [145] 
D515Y D Y R (5.6) NT R (4.6) [145] 
L516R  L R R (2.1) R (5.1) S (0.8) [96, 143] 
I521T I T R (2.1) R (5.1) S (0.8) [96, 104, 162] 
P522A P A R (3) R (4.1) S (1) [74, 96, 138, 162] 
P522S P S R (3.1) R (3.6) S (1.1) 
[74, 75, 96, 99, 134, 140, 
151, 153, 156] 
del524 C del 1 R (3.5) R (9.7) S (1.1) [144] 
V526L V L R (5.5) R (2.5) S (1.8) [126] 
ExoIII / ∂ region C (533 - 545 / 492 - 588) 
C539G C G R (3.1) R (4.4) S (1.0) [140] 
C539R  C R R (3.2) R (13.3) S (0.7) [98, 105] 
D542E  D E S (1.5) R (12) S (1.7) [148] 
L545S  L S R (3.5) R (9.1) S (1.2) [73, 96, 105, 139, 151] 
L545W L W R (4.9) R (6.3) S (1.3) [96, 98, 161] 
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∂-Region C (492 – 588) 
T552N  T N r (1.9) S (1.2) R (2.6) [98, 105] 
Q578H Q H R (3.3) R (2.3) R (4.5) [96, 98, 103, 140, 161, 178] 
Q578L Q L r (1.9) S (0.8) R (3.0) [97, 140] 
S585A  S A S (1.5) S (1.4) R (2.7) [98, 105] 
D588E D E S (1.3) S (1.1) R (2.3) [96, 116, 151] 
D588N  D N R (3.8) R (2.7) R (3.2-9) [74, 96, 155, 157, 161] 
Outside the conserved regions 
F595I  F I S (1.3) S (1.2) R (2.0) [98, 105] 
A692S A S S (1.6) S (1.7) R (3.3) [143, 153] 
Region II ( 696-742) 
T700A T A S (0.9) S (1.5) R (4.7) [93, 96, 138, 151, 159] 
V715M V M S (1.0) S (1.1) R (5.5) 
[94, 96, 134, 140, 151, 156, 
158, 159] 
I726T I T R (2.0) r (1.7) S (1.1) [146] 
I726V I V r (1.9) r (1.9) S (1.2) [146] 
Outside the conserved regions 
E756D E D S (1.2) S (0.7) R (3.4) [96, 138, 143] 
E756K E K R (2.5) R (2.2) R (>8) [96, 143, 157] 
E756Q E Q S (1.7) S (1.0) R (4.3) [96, 156] 
Region VI (771- 790) 
L773V  L V R (3.0) R (2.5) R (4.4) [140] 
L776M L M R (2.5) S (1) R (3.5) [96] 
W780V W V S (1.5) NA r (1.9) [149] 
V781I  V I R (1-4) S (1.2) R (4-5.2) 
[96, 116, 140, 151, 153, 156, 
157] 
V787A V A R (2.5) NA R (3.5) [158] 
V787L V L R (2.4) S (1) R (4.1) [96, 105, 153, 156] 
Outside the conserved regions 
L802M  L M R (1.1-3.5) S (0.9-1.8) R (3.2-11) 
[74, 96, 104, 105, 111, 116, 
145, 151, 155, 157] 
L802V  L V r  (1.8) S (1.1) S (0.9) [98, 105] 
Region III (805 – 845) 
K805Q  K Q S (1) R (2.2) S (0.18) [96, 116, 151, 152] 
A809V A V R (2.6) S (1.7) R (6.3) [96, 134, 140, 141] 
V812L V L R (2.5) R (3.2) R (2.9) [96, 105, 155, 164] 
T813S  T S R (2.5) R (2.7) R (4.9) [96, 141] 
T821I T I R (4.5) r (1.9) R (21) [96, 116, 151, 152] 
P829S  P I R (2.0) S (1.6) S (1.1) [98, 105] 
A834P A P R (5.4) R (3) R (6.4) 
[74, 82, 96, 103, 140, 145, 
160] 
T838A T A S (1.8) S (0.8) R (2.4) [96, 155] 
G841A G A R (3.2) R (2.6) R (4.3) [74, 96, 138, 141] 
G841S G S R (2.2) S (1.1) R (2.1) [146] 
M844T M T S (1.4) S (1.3) R (2.5) [150] 
M844V M V R (2.5) r (1.6) R (2.2) [150] 
Outside the conserved regions 
L862F  L F r (1.7) S (0.9) S (1.1) [98, 105] 
V946L  V L S (1.1) S (0.9) R (2.4) [98, 105] 
L957F  L F R (2.7) S (1.4) S (1.3) [98, 105] 
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Region V (978 – 988) 
del981-2  DL del 2 R (8.3) R (2.8) R (3.6) [96, 112, 140, 143, 163] 
A987G A G R (5.3) R (11.3) S (1.2) 
[74, 82, 96, 134, 145, 151, 
153] 
 
Boldface indicates the mutations conferring resistance. Deletions start at the designated 
codon and continue through the number of shown codons; R, resistant strain (2 fold 
reduction in susceptibility to antiviral drugs); r, low-grade resistance or <2 fold reduction 
in susceptibility to antiviral drugs; S, sensitive strain; NA, not available; NT, not tested. 
a) The level of resistance of each mutation is expressed as the ratio of the half maximal 
inhibitory concentration (IC50) of the mutant to that of drug – sensitive wild-type (IC50 of 
mutant/IC50 of wild type ratio); 
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Attachment III: UL97 sequencing analysis of codon 1 until 707 in comparison to the 
sequence information of the Merlin strain, for the 22 patients included in this study. 
Patient 1 
 
List of Mutations: 
 Resistance Mutation: L595W 
 Polymorphism: N510S 
 Unknown mutation: T75A 
 
Patient 2 
 
List of Mutations: 
 Unknown mutation: T75A 
Missing information of codon: del 149-151 
 
Patient 3 
 
List of Mutations: 
 Polymorphism: Q126L 
 Unknown mutation: T75A 
Missing information of codon: del 149-152, del 336-339 
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Patient 4 
 
List of Mutations: 
 Resistance Mutation: C592G 
 Unknown mutations: T75A, G242V, D422G, A619S 
 
Missing information of codon: del 144-152, del 336-341, del 552-556 
 
Patient 5 
 
List of Mutations: 
 Polymorphism: Q126L 
 Unknown mutation: T75A 
 
Patient 6 
 
List of Mutations: 
 Unknown mutations: T75A, V96G, E333D 
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Patient 7 
 
List of Mutations: 
 Polymorphisms: Q19E, S108N, Q126L  
 Unknown mutation: T75A  
 
Patient 8 
 
List of Mutations: 
 Unknown mutations: T75A 
 
Patient 9 
 
List of Mutations: 
 Polymorphism: N510S 
 Unknown mutations: T75A, D122E, S135L, G188D, D269E 
 
Missing information of codon: del 146-152 
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Patient 10 
 
List of Mutations: 
 Resistance Mutation: A594V 
 Unknown mutations: T75A, D422E, V466A, Y491H 
Missing information of codon: del 552-556 
 
Patient 11 
 
List of Mutations: 
 Resistance Mutation: A594V 
 Polymorphisms: D68N, Q126L, V244I 
 Unknown mutations: T75A, S155L 
Missing information of codon: del 149 
 
Patient 12 
 
List of Mutations: 
 Resistance Mutation: C603W 
 Polymorphism: Q126L 
 Unknown mutation:T75A 
Missing information of codon: del 149-152, del 336-339, del 552-556 
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Patient 13 
 
List of Mutations: 
 Unknown mutation: T75A, D167G, M330T , V559A 
 
Missing information of codon: del 135-152 
 
Patient 14 
 
List of Mutations: 
 Polymorphisms: Q19E, S108N, Q126L 
 Unknown mutation: T75A  
 
Patient 15 
 
List of Mutations: 
 Unknown mutations: T75A, D290E 
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Patient 16 
 
List of Mutations: 
 Unknown mutations: T75A, R514H 
 
Missing information of codon: del 149-152, del 336-339 
 
Patient 17 
 
List of Mutations: 
 Polymorphisms: Q126L, P247S 
 Unknown mutation: T75A 
 
Missing information of codon: del 149-152, del 336-339 
 
Patient 18 
 
List of Mutations: 
 Polymorphisms: Q19E, S108N, Q126L  
 Unknown mutation: T75A 
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Patient 19 
 
List of Mutations: 
 Unknown mutation: T75A 
 
Patient 20 
 
List of Mutations: 
 Unknown mutations: S7Y, T75A, D430N 
 
Missing information of codon: del 149-152, del 336-339, del 449-50 
 
Patient 21 
 
List of Mutations: 
 Polymorphism: D68N 
 Unknown mutations: T75A, A104S 
 
Single frameshift mutation: SFS148 
Double frameshift mutation: DFS102 
Missing information of codon: del 105-133, del 152-166, del 334-341 
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Patient 22 
 
List of Mutations: 
 Polymorphisms: Q19E, S108N, Q126L 
 Unknown mutations: T75A 
 
Missing information of codon: del 334-342, del 548-558 
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Attachment IV: UL54 sequencing analysis of codon 272 until 1069 in comparison to the 
sequence information of the TB40/E strain, for the 22 patients included in this study. 
 
Patient 1 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, S897L, D898N 
 
 
Patient 2 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, S897L 
 
 
Patient 3 
 
List of Mutations: 
 Polymorphism: A614S 
 Unknown mutation: L394F 
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Patient 4 
 
List of Mutations: 
 Polymorphism: F669L 
 
 
Patient 5 
 
List of Mutations: 
 Polymorphisms: ins885S and D898N 
 
 
Patient 6 
 
List of Mutations: 
 Resistance mutation: P522S 
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Patient 7 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, T885A, D898N 
 Unknown mutation: K493N 
 
 
Patient 8 
 
List of Mutations: 
 Polymorphism: F669L 
 Unknown mutations: S306T, A559V 
 
 
Patient 9 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, A688V, S897L 
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Patient 10 
 
List of Mutations: 
 Polymorphisms: G874R, L890F 
 
 
Patient 11 
 
List of Mutations: 
 Polymorphism: F669L 
 
 
Patient 12 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, S897L 
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Patient 13 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, S897L, D898N 
 Unknown mutations: S306I, Y477D 
 
 
Patient 14 
 
List of Mutations: 
 Polymorphisms: L655S, S676G, S685N, S897L 
 Unknown mutation: L845V 
 
 
Patient 15 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, S897L, D898N 
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Patient 16 
 
List of Mutations: No Mutations found 
 
 
Patient 17 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, S897L  
 
 
Patient 18 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, T885A, D898N 
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Patient 19 
 
List of Mutations: No mutations found. 
 
 
Patient 20 
 
List of Mutations: 
 Polymorphisms: L655S, S685N,  S897L , D898N 
 
Double frameshift mutation: DFS287  
 
 
Patient 21 
 
List of Mutations: 
 Resistance mutation: L957F 
 Polymorphisms: G874R, L890F 
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Patient 22 
 
List of Mutations: 
 Polymorphisms: L655S, S685N, T885A, D898N 
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Attachment V: HCMV monitoring, demographic and clinicopathological characteristics, 
and antiviral treatment of 22 patients. The arrows point to the sample that was selected for 
mutations analysis. 
Patient 1 
HCMV Monitoring 
 
Characteristics of patient Antiviral Treatment 
Gender Male 
Day +0 – FOS 288 mg 8h/8h 35 days; 
Day +41 – FOS 648 mg 1x/day 19 days; 
Day +60 – FOS 432 mg 8h/8h 28 days; 
Day +89 – FOS 648 mg 1x/day 2 day; 
Day +91 – CID 35 mg 1x/day 8 days. 
Age (months old) < 12 months 
Underlying disease Primary immunodeficiency  
Conditioning regimen Myeloblative 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, Negative Donor; R+, Positive recipient 
Patient 2 
HCMV Monitoring 
 
Characteristics of patient  Antiviral treatment 
Gender Male 
Day +7 – FOS 3360 mg 8h/8h 44 days; 
Day +23 – VGCV 900 mg 12/12h 3 days; 
Day +52 – FOS 4850 mg 1x/day 17 days; 
Day +58 – FOS 4850 mg 1x/day 2 days; 
Day +60 – GCV 70 mg 1x/day 2 days. 
Age (years old) 24 
Underlying disease paroxysmal nocturnal hemoglobinuria 
Conditioning regimen Myeloblative 
Stem cell source Peripheral Blood 
HLA status Match/Related 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor, R; Recipient; D+, Positive Donor; R+, Positive recipient 
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Patient 3 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +44 – GCV 100 mg 2x/day 21 
days; 
Day +65 – FOS 1300 mg 8h/8h 7 days; 
Day +97 – FOS 1920 mg 1x/day 4 days; 
Day +97 – GCV 100 mg 12h/12h 45 
days; 
Day +167 – GCV 100 mg 12h/12h 1 
day; 
Day +169 – GCV 50 mg 12h/12h 8 
days. 
Age (years old) 7 
Underlying disease Acute Myeloid Leukemia 
Conditioning regimen Reduced intensity 
Stem cell source Peripheral Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient, D-, Negative Donor; R+, positive recipient 
 
Patient 4 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male Day +22 – GCV 44 mg 12h/12h 23 days; 
Day +22 – FOS 504 mg 8h/8h 23 days; 
Day +35 – GCV 43 mg 12h/12h 57 days; 
Day +51 – FOS 520 mg 8h/8h 41 days; 
Day +101 – GCV 40 mg 12h/12h 70 
days; 
Day +114 – FOS 480 mg 8h/8h 57 days; 
Day +185 – FOS 508 mg 8h/8h 32 days. 
Age (years old) 1 
Underlying disease Acute lymphoid leukemia B lineage 
Conditioning regimen Myeloblative 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
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Patient 5 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male Day +28 – FOS 700 mg 8h/8h 24 
days; 
Day +53 – FOS 1176 mg 8h/8h 
11 days; 
Day +65 – VGCV 260 mg 2x/day 
14 days. 
Age (years old) 1 
Underlying disease Primary immunodeficiency 
Conditioning regimen Myeloblative 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, Negative Donor; R+; positive recipient 
 
Patient 6 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male 
Day +28 – VGCV 450 mg 12h/12h 29 
days; 
Day +57 – FOS 1848 mg 8h/8h 32 days; 
Day +75 – FOS 2808 mg 1x/day 16 days; 
Day +91 – FOS 1224 mg 8h/8h. 
Age (years old) 10 
Underlying disease Acute myeloid leukemia 
Conditioning regimen Myeloblative 
Stem cell source Peripheral Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human Cytomegalovirus; D, Donor; R, Recipient; D+, positive donor; R+, positive recipient 
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Patient 7 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +34 – FOS 1200 mg 8h/8h 27 days; 
Day +60 – FOS 1776 mg 2x/day  7 days; 
Day +66 – GCV 98 mg 12h/12h 18 days; 
Day +85 – GCV 45 mg 12h/12h 8 days; 
Day +139 – VGCV 330 mg 12h/12h 6 days 
Day +146 – FOS 920 mg 8h/8h 15 days; 
Day +161 – GCV 89 mg 12h/12h 20 days; 
Day +173 – FOS 900 mg 8h/8h 16 days; 
Day +181 – CDV 16 mg 2x/day 17 days; 
Day+189 – GCV 75 mg 12h/12h 40 days; 
Day +204 – FOS 900 mg 8h/8h 38 days; 
Day +245 – GCV 65 mg 1x/day 11 days. 
Age (years old) 5 
Underlying disease Acute lymphoid leukemia T lineage 
Conditioning regimen Myeloblative 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human Cytomegalovirus; D, Donor; R, Recipient; D+, Positive Donor; R+, positive recipient 
Patient 8 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male 
Day +61 – GCV 75 mg 12h/12h 22 days 
Age (years old) 2 
Underlying disease Medullar aplasia 
Conditioning regimen Reduced intensity 
Stem cell source Bone Marrow 
HLA status Mismatch or Unrelated 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human Cytomegalovirus; D, Donor; R, Recipient; D+, Positive Donor; R+, positive recipient 
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Patient 9 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male 
Day +24 – FOS 4728 mg 8h/8h 1 day; 
Day +25 – VGCV 400 mg 12h/12h 38 
days. 
Age (years old) 60 
Underlying disease Acute myeloid leukemia M1 
Conditioning regimen Reduced intensity 
Stem cell source Peripheral Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human Cytomegalovirus; D, Donor; R, Recipient; D+, Positive Donor; R+, positive recipient 
Patient 10 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +30 – VGCV 900 mg 12h/12h 44 days; 
Day +103 – VGCV 900 mg 12h/12h 13 days; 
Day +120 – VGCV 900 mg 12h/12h 5 days; 
Day +131 – VGCV 900 mg 12h/12h 55 days; 
Day +187 – FOS 3288 mg 8h/8h 24 days; 
Day +211 – VGCV 450 mg 12h/12h 6 days; 
Day +251 – GCV 250 mg 12h/12h 16 days; 
Day +252 – FOS 3288 mg 8h/8h 22 days; 
Day +276 – GCV 280 mg 12h/12h 15 days; 
Day +276 – FOS 3360 mg 8h/8h 15 days. 
Age (years old) 49 
Underlying disease Acute myeloid leukemia  
Conditioning regimen Myeloblative 
Stem cell source Peripheral Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
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Patient 11 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +42 – VGCV 900 mg 12h/12h 41 days 
Day +84 – VGCV 450 mg 12h/12h 2 days 
Day +98 – VGCV 900 mg 12h/12h 24 days 
Day +115 – FOS 2640 mg 12h/12h 3 days  
Day +119 – FOS 4080 mg 8h/8h 2 days 
Day +122 – FOS 3360 mg 12h/12h 4 days 
Day +123 – FOS 4080 mg 1x/day 8 days 
Day +132 – FOS 2688 mg 12h/12h 1 day 
Day +133 – FOS 4080 mg 1x/day 6 days 
Day +139 – GCV 300 mg 1x/day 2 days 
Day +142 – GCV 170 mg 1x/day 7 days 
Age (years old) 18 
Underlying disease Medullar aplasia 
Conditioning regimen Reduced Intensity 
Stem cell source Bone Marrow 
HLA status Mismatch or Unrelated 
D/R HCMV status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
Patient 12 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male Day +19 – GCV 450 mg 12h/12h 6 days; 
Day +28 – VGCV 900 mg 2 days; 
Day +39 – VGCV 900 mg 4 days; 
Day +54 – VGCV 450 mg 6 days; 
Day +77 – VGCV 900 mg 57 days; 
Day +159 – FOS 3600 mg 8h/8h 20 days; 
Day +172 – FOS 3120 mg 12h/12h 15 days. 
Age (years old) 49 
Underlying disease Acute myeloid leukemia 
Conditioning regimen Myeloblative 
Stem cell source Peripheral Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
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Patient 13 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +17 – GCV 70 mg 12h/12h 18 days; 
Day +35 – FOS 840 mg 8h/8h 12 days; 
Day +47 – FOS 1200 mg 1x/day 3 days; 
Day +67 – GCV 65 mg 12h/12h 7 days; 
Day +74 – FOS 260 mg 8h/8h 39 days; 
Day +89 – GCV 62,5 mg 12h/12h 32 days; 
Day +114 – FOS 1125 mg 1x/day 7 days; 
Day +121 – GCV 66 mg 12h/12h 9 days; 
Day +121  - FOS 1200 mg 1x/day 9 days; 
Day +130 – VGCV 240 mg 12h/12h 3 days; 
Day +134 – FOS 840 mg 8h/8h 9 days; 
Day +134 - GCV 70 mg 12h/12h 9 days. 
Age (years old) 2 
Underlying disease Acute myeloid leukemia M5  
Conditioning regimen Myeloblative 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
 
Patient 14 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +23 – FOS 792mg 8h/8h 6 days; 
Day +29 – GCV 75 mg12h/12h 35 days; 
Day +64 – VGCV 360 mg 12h/12h 26 days; 
Day +93 – VGCV 360 mg 12h/12h 4 days; 
Day +100 – VGCV 360 mg 12h/12h 4 days; 
Day +110 – VGCV 360 mg 12h/12h 3 days; 
Day +113 – FOS 840 mg 8h/8h 7 days; 
Day +120 – FOS 560 mg 8h/8h 1 day; 
Day +126 – VGCV 100 mg 12/12h 8 days; 
Day +134 – VGCV 150 mg 12h/12h 1 day; 
Day +140 – VGCV 150 mg 12h/12h 2 days; 
Day +146 – GCV 30 mg 12h/12h 9 days; 
Day +155 – FOS 792 mg 8h/8h 15 days. 
Age (years old) 2 
Underlying disease Chronic Myeloid Leukemia 
Conditioning regimen Myeloblative 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
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Patient 15 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male Day  +53 – VGCV 450 mg 2x/day 4 days; 
Day  +77 – FOS 4080 mg 8h/8h 5 days; 
Day  +82 – FOS 3048 mg 8h/8h 8 days; 
Day +126 – VGCV 900 mg 12h/12h 21 
days; 
Day +182 – FOS 2640 mg 12h/12h 8 days 
Age (years old) 37 
Underlying disease Hodgkin's disease 
Conditioning regimen Reduced intensity 
Stem cell source Peripheral Blood 
HLA status Match/Related 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D+, positive donor; R+, positive recipient 
 
Patient 16 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male Day +20 – FOS 3360 mg 8h/8h 1 day; 
Day +22 – FOS 2688 mg 8h/8h 3 days; 
Day + 26 – FOS 2472 mg 8h/8h 2 days; 
Day + 29 – FOS 2400 mg 12h/12h 3 
days; 
Day +33 – FOS 2800 mg 1x/day 3 days; 
Day  +36 – VGCV 450 mg 1x/day 3 
days; 
Day  +47 – GCV 35 mg 1x/day 7 days; 
Day +55 – GCV 140 mg 1x/day 6 days; 
Day  +62 – GCV 65 mg 1x/day 2 days; 
Day  +65 – GCV 135 mg 1x/day 1 day; 
Day +66 – GCV 67, 5 mg 1x/day 4 days 
Day +89 – VGCV 450 mg 1x/day 9 
days. 
Age (years old) 41 
Underlying disease Acute lymphoid leukemia 
Conditioning regimen Myeloblative 
Stem cell source Peripheral Blood 
HLA status Match/Related 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
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Patient 17 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female 
Day +23 – GCV 300 mg 12h/12h 8 days; 
Day +43 – VGCV 900 mg 12h/12h 4 days; 
Day +58 – VGCV 900 mg 12h/12h 12 days; 
Day +70 – GCV 300 mg 12h/12h 5 days. 
Age (years old) 23 
Underlying disease Acute lymphoid leukemia 
Conditioning regimen Myeloblative 
Stem cell source Peripheral Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor, R, Recipient; D+, positive donor; R+, positive recipient 
 
Patient 18 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male 
Day +29 – GCV 55 mg 12h/12h 15 days; 
Day +42 – FOS 600 mg 8h/8h 2 days. 
Age (years old) 1 
Underlying disease Acute myeloid leukemia M0 
Conditioning regimen Myeloblative 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
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Patient 19 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +15 – VGCV 900 mg 12h/12h 14 
days; 
Day +36 – VGCV 450 mg 1x/day 7 days; 
Day +46 – VGCV 450 mg 1x/day 5 days; 
Day +71 – VGCV 900 mg 1x/day 4 days; 
Day +75 – VGCV 450 mg 1x/day 14 days; 
Day +96 – VGCV 450 mg 1xday 14 days; 
Day +124 – VGCV 450 mg 1x/day 17 
days; 
Day +145 – VGCV 400 mg 1x/day 45 days 
Age (years old) 54 
Underlying disease Chronic Lymphoid Leukemia B lineage 
Conditioning regimen Reduced Intensity 
Stem cell source Peripheral Blood 
HLA status Match/Related 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D+, positive donor; R+, positive recipient 
 
Patient 20 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male Day +33 – VGCV 900 mg 12h/12h 15 
days; 
Day +48 – GCV 350 mg 12h/12h 4 days; 
Day +52 – FOS 4560 mg 8h/8h 6 days; 
Day +70 – VGCV 450 mg 12h/12h 6 days; 
Day +87 – VGCV 450 mg 2x/day 4 days; 
Day + 154 – VGCV 900 mg 1x/day 17 
days. 
Age (years old) 30 
Underlying disease Medullar Aplasia 
Conditioning regimen Reduced Intensity 
Stem cell source Bone Marrow 
HLA status Match/Related 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human cytomegalovirus; D, Donor; R, Recipient; D+, positive donor; R+, positive recipient 
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Patient 21 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Female Day +32 – FOS 1080 mg 8h/8h 17 days; 
Day +50 – FOS 1344 mg 8h/8h 16 days;  
Day +85 – FOS 1121 mg 8h/8h 24 days;  
Day +109 – GCV 100 mg 12h/12h 4 days;  
Day +114 – GCV 50 mg 12h/12h 19 days;  
Day +133 –GCV 50 mg 1x/day 16 days; 
Day +215 – GCV 52.5 mg 12h/12h 6 days;  
Day +221 – GCV 16 mg 1x/day 7 days;  
Day +228 – GCV 50 mg 1x/day 4 days;  
Day +232 – FOS 220 mg 8h/8h 9 days. 
Age (years old) 6 
Underlying disease myelodysplatic/myeloproliferative 
disease 
Conditioning regimen Myelobaltive 
Stem cell source Cord Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D+/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human Cytomegalovirus; D, Donor; R, Recipient; D+, positive donor; R+, positive recipient 
 
Patient 22 
HCMV Monitoring 
 
Characteristics of patient Antiviral treatment 
Gender Male 
Day +29 – GCV 300 mg 12h/12h 21 days; 
Day +50 – FOS 3480 mg 8h/8h 7 days; 
Day +58 – FOS 5184 mg 1x/day 13 days; 
Day +71 – GCV 285 mg 2x/day 1 day; 
Day +74  - GCV 140 mg 1x/day 17 days; 
Day +92 – FOS 2400 mg 8h/8h 7 days. 
Age (years old) 14 
Underlying disease Acute Lymphoid Leukemia B(L3) 
lineage 
Conditioning regimen Myeloblative 
Stem cell source Peripheral Blood 
HLA status Mismatch or Unrelated 
HCMV D/R status D-/R+ 
HLA, Human Leukocyte Antigen; HCMV, Human Cytomegalovirus; D, Donor; R, Recipient; D-, negative donor; R+, positive recipient 
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ABSTRACT  
Human cytomegalovirus (HCMV) infection is a major cause of morbidity and mortality in 
allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. In these 
immunocompromised patients, the significant clinical impact of HCMV infection and 
progression to HCMV disease has been reduced by prophylactic and preemptive treatments 
using ganciclovir (GCV), valganciclovir (VGCV), foscarnet (FOS) and cidofovir (CDV). 
GCV/VGCV resistance results from mutations of phosphotransferase UL97, the viral DNA 
polymerase UL54, or both; whereas CDV and FOS resistance results from mutations of 
UL54 only. This review will summarize the HCMV antiviral drug resistance, including the 
target genes and their functions, the mechanisms of antiviral resistance, the large number 
of mutations in UL97 and UL54 that have been identified in either clinical or laboratory 
isolates and the impact on HCMV susceptibility to drugs that it causes. 
 
Keywords: Human cytomegalovirus, (aHSCT) recipients, ganciclovir, valganciclovir, foscarnet and 
cidofovir, phosphokinase (UL97), DNA polymerase (UL54), resistance.
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Introduction 
Human Cytomegalovirus (HCMV) alternatively known as Human Herpesvirus 5 (HHV-5) 
is a ubiquitous virus that belongs to the Herpesviridae family, Betaherpesvirinae subfamily 
[1, 2]. It is considered the prototype betaherpesvirus and shares with the other 
herpesviruses the virion structure, double-stranded DNA genome, kinetics of viral gene 
expression, persistence for the lifetime of the host after primary infection and reactivation 
from latency [3-9]. HCMV genome is the largest of all herpesviruses with approximately 
230 000 base pairs (bp) containing a single origin of replication, a DNA polymerase gene 
(pUL54) and a complete package of genes required for viral DNA replication [10-14]. The 
AD169 laboratory strain was the first and the only completely sequenced HCMV strain 
and seems to have shorter genome than two laboratory strains (Towne and Toledo) and 
many clinical isolates [14, 15].  
HCMV is a common virus and its epidemiology varies in different regions of the world 
and between socioeconomic and age groups [10, 16, 17]. Generally, the prevalence of 
HCMV infection is higher in developing countries and among persons of lower 
socioeconomic status [10, 18]. HCMV infection is in the majority of cases asymptomatic, 
since the virus is maintained in a state of latency or low level shedding that is clinically 
undetectable [8, 11, 19]. Nevertheless, HCMV infection is an important concern in certain 
risk groups and its reactivation from latency is critic, especially in immunocompromised 
patients, including HIV-positive individuals and transplant recipients [1, 5-7, 16, 18, 20]. 
  
CHAPTER I – HCMV infection and stem cell transplantation 
HCMV infection is the leading viral cause of morbidity and mortality in patients who 
receive a solid organ transplant (SOT) (including kidney, liver, heart, heart-lung) or 
hematopoietic stem cell transplant (HSCT) [19, 21]. Several studies have described that 
HSCT recipients have a higher prevalence of HCMV infection and associated disease than 
SOT recipients [22, 23]. Moreover, it has been described that allogeneic-HSCT (allo-
HSCT) recipients are at greater risk when compared to autologous recipients [14, 24]. 
Indeed, the incidence of HCMV infection after allo-HSCT ranges from 32% to 70%, 
varying with the serological status of the recipient and donor [14, 19, 25-29].  
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The risk of HCMV reactivation or disease in HSCT patients can be predicted prior the 
transplant, nevertheless some risk factors are dependent on the transplant and the outcome 
of the transplant [14, 24, 26, 27, 30-33] – Table I.  
Typically, HCMV infection/reactivation appears within the first 100 days after transplant, 
both in allogeneic and autologous recipients, and affects mainly the lungs and the 
gastrointestinal tract [28, 30]. Furthermore, the increase of late-onset HCMV disease 
(occurring >100 days after transplant) may be due to antiviral prophylaxis or preemptive 
treatment during the first 100 days after transplantation [26, 31, 34-36] which inhibit the 
development of HCMV-specific T-cell lymphocyte response [24, 31, 37].  
HCMV has both direct effects resulting from viral invasion of organ systems and indirect 
effects on the immune systems of recipients [19, 38]. The direct effects of HCMV primary 
infection or reactivation are the development of end-organ diseases such as pneumonia, 
hepatitis, pancreatitis, gastrointestinal disease, retinitis, encephalitis, colitis, esophageal 
ulcers and others [8, 14, 25, 38]. The indirect effects are frequently associated with 
increased risk of other infections, acute graft rejection and graft-versus-host disease 
(GVHD) [14, 19, 20, 38]. 
 
Table I: Conditions associated with the risk of developing of HCMV infection, reactivation, or disease in each of the following phase of 
therapy in HSCT patients. Adapted from [24]. 
BEFORE TRANSPLANT AFTER TRANSPLANT 
Host factors 
 Age 
 Underlying disease 
 Seropositivy status (donor and 
recipient) 
Transplant-related factors 
 T-cell depletion 
 Autologous vs allogeneic 
 Human Leukocyte Antigen (HLA) 
(match vs non-match donors) 
 Immunosuppression 
 Source of stem cells 
(peripheral blood vs bone marrow) 
 Immunosuppression 
 
 Graft-versus-host disease (GVHD) 
 
 Immune reconstitution 
 
 Other viral infections  
 
 Opportunistic infections: 
          (parasitic, bacterial and fungal) 
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CHAPTER II – HCMV infection management 
Currently, three antiviral drugs have been shown to be effective in the prevention and/or 
treatment of HCMV infections and disease: ganciclovir (GCV), valganciclovir (VGCV), 
cidofovir (CDV) and foscarnet (FOS) [39-43]. Despite their clinical utility is limited by the 
efficacy, limited oral bioavailability, development of resistance in clinical practice, and 
associated toxicities, these drugs have been used to treat many forms of HCMV disease in 
immunocompromised patients [19, 44]. 
 
 
Figure 1: Action mechanisms of systemic antivirals approved for treatment of HCMV infections. GCV/VGC requires phosphorylation 
by the phosphokinase (pUL97). After monophosphorylation by pUL97, the cellular kinases add two additional phosphates. GCV 
triphosphate is the active form of the drug incorporated into viral DNA by the viral DNA polymerase (pUL54). CDV is a 
monophosphate analog and does not require initial viral phosphorylation. Cellular kinases add additional phosphates to produce CDV 
diphosphate, which is incorporated into the viral DNA by pUL54 leading to termination of viral DNA replication. FOS is a 
pyrophosphate analog, which does not require activation and is not incorporated into the growing viral DNA chain. It blocks directly the 
release of pyrophosphate by pUL54 and therefore resulting in chain termination. Adapted from [11, 45, 46]. 
 
 
Ganciclovir (GCV) and valganciclovir (VGCV)  
Ganciclovir (GCV) is a nucleoside analog of 2´deoxyguanosine that act by inhibiting 
effective HCMV synthesis by a multistep process dependent on both viral and cellular 
enzymes [14, 19, 45]. The UL97 gene of HCMV encodes a viral protein kinase (pUL97) 
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that phosphorylates GCV to GCV-monophosphate [5, 47-49] and two subsequent 
phosphorylation are performed by host cellular kinases that result in the formation of the 
GCV-triphosphate, which is a competitive inhibitor of the deoxyguanosine-triphosphate for 
the viral DNA polymerase encoded by UL54 [14, 19, 39, 44, 45, 47, 50] – Figure 1.  
GCV was initially approved by Food and Drug Administration (FDA) in 1989 for 
intravenous (IV) use [11, 19, 48]. GCV has been shown to reduce the severity of HCMV 
retinitis, gastrointestinal disease and, to a lesser extent, pneumonia in SOT, HSCT and 
acquired immune deficiency syndrome (AIDS) patients [14, 19, 25, 44]. Despite its high 
bioavailability and therapeutic efficacy, GCV use is limited due to the occurrence of 
hematologic side effects (neutropenia and thrombocytopenia) and it requires 
hospitalization for IV treatment [14, 19, 20, 24, 40, 51].  
GCV poor oral bioavailability (5.6%) lead to the development of valganciclovir (VGCV), a 
L-valyl ester prodrug which after oral administration is rapidly metabolized in the liver and 
intestinal wall [11, 14, 19, 33, 44, 45, 48]. The adverse effects of VGCV are similar to 
those of GCV mainly, neutropenia and thrombocytopenia [14, 19, 33], nevertheless it has 
much better bioavailability (60%) and allows treatment without hospitalization [11, 14, 19, 
33, 44, 45, 48]. Thus VGCV tends to be widely used among transplant recipients, not only 
for prophylaxis, but also for preemptive and maintenance therapy [19, 33, 40].  
Although intravenous GCV and oral VGCV have been effective as first-line agents in both 
prevention and treatment of HCMV disease, the emergence of ganciclovir-resistant HCMV 
strains has posed a more significant threat due to an aggressive disease course and a greater 
mortality risk [39, 41, 51, 52].  
 
Foscarnet (FOS) 
Foscarnet (FOS) is an organic analog of inorganic pyrophosphate that reversibly and 
noncompetitively inhibits the activity of pUL54, the viral DNA polymerase [14, 44, 45, 47, 
49, 50]. This noncompetitive inhibitor reversibly blocks the pyrophosphate binding site of 
pUL54 and inhibits the cleavage of pyrophosphate from deoxynucleoside triphosphates 
[19, 44] – Figure 1. FOS is administered as large volume IV solution since it must be 
present in high concentrations inside the cell to remain in contact with the viral DNA 
polymerase and inhibit DNA replication [5, 11, 14]. 
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FOS was FDA approved in 1991 and despite its utility, it has been associated with 
nephrotoxicity and metabolic toxicity as well as renal failure, hypocalcemia, 
hypomagnesemia and hypophosphatemia [5, 11, 14, 19]. Due to its side effects, FOS is 
considered a second-line therapy, preferred over GCV especially in patients with 
myelosupression or weak graft after HSCT; to treat patients with AIDS and HCMV reti-
nitis who are failing GCV therapy due to viral resistance; or those who cannot be treated 
with GCV due to dose-limiting neutropenia or leucopenia [14, 19, 20, 25, 51]. 
Furthermore, some studies refer that patients must be on long-term maintenance regimens 
with IV FOS to prevent the relapse or progression of HCMV disease [14, 25].  
 
Cidofovir (CDV) 
Cidofovir (CDV) is a monophosphate nucleotide analogue and does not require 
phosphorylation by pUL97 kinase, however it is dependent on diphosphorylation by 
cellular kinases converting it into CDV-diphosphate an analog of deoxycytosine [19, 44, 
47, 49]. Similarly to GCV, the incorporation of CDV-diphosphate into viral DNA triggers 
a slowing and subsequent cessation of HCMV DNA replication [45, 47, 49] – Figure 1.  
CDV was FDA approved in 1996 as an IV formulation for the treatment of a broad-range 
of DNA viruses infections, including all the herpesviruses [14, 44, 51, 53]. CDV oral 
bioavailability is less than 5% nevertheless it has a very long intracellular half-life when 
compared with GCV and FOS [11, 14, 19, 51]. CDV has excellent activity against HCMV 
and has been reported to be effective in the treatment of HCMV retinitis in AIDS patients 
and for HCMV infection and disease in allo-HSCT [14]. Despite its efficacy, there are 
some concerns regarding its poor oral bioavailability, dose-related nephrotoxicity and 
myelosuppression and therefore it is considered a third-line agent for HCMV infection [20, 
51, 53].  
 
CHAPTER III – HCMV drug-resistance analysis 
Phenotypic Methods  
There are important implications when virulent drug-resistant HCMV strains emerge in the 
clinical setting, including the need to developed laboratory methods for determining 
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susceptibilities of HCMV isolates to antiviral compounds [11, 17, 44, 46, 54, 55]. 
Phenotypic methods were the first to be developed before the establishment of genotypic 
testing, and they have been of great importance in identifying and characterizing mutations 
[11, 46]. These methods are based on determination of the drug concentration required to 
reduce viral growth [11, 45, 47, 56]. The “gold standard” method for phenotypic analysis 
of HCMV drug susceptibility has been the plaque reduction assay (PRA), where an 
inoculum of the clinical isolate is propagated in cell culture in the presence of different 
antiviral drug concentrations [44, 45]. Although the PRA assay is a simple test and directly 
assesses the IC50 (the effective dose in which a 50% plaque reduction is achieved) of a 
clinical isolate against specific antiviral agents, its standardization/reproducibility is still a 
problem, especially in context of definitions of cut-off levels for resistance [44-46, 56]. 
Other phenotypic methods have also been used for measuring HCMV drug susceptibility 
and resistance (ELISA tests, flow cytometry and DNA-DNA hybridization assays) [11, 45, 
47, 56]. Moreover, efforts have been made to develop new assays (quantitative real-time 
PCR, reported cell lines, polymerase biochemical assays and marker transfer) more 
amenable to standardization and easier to perform [44, 46]. Although of the importance of 
phenotypic assays to diagnose antiviral drug resistance, they are subject to selection bias 
introduced during the growth of mixed viral, and lack sensitivity for the detection of low-
level resistance or minor resistant subpopulations [44]. Phenotypic resistance assays are 
not commonly used to assess for resistant HCMV in clinical scenarios, however they 
remain essential for validation of genotypic assays [11].  
 
Genotypic Methods  
Genotypic assays were designed to detect mutations in UL97 and UL54 recognized to 
confer resistance to antiviral agents directly in clinical samples [45, 47]. The “gold 
standard" genotypic method for the detection of resistant HCMV strains is Sanger 
Sequencing which allow the identification of all nucleotide and amino acid substitutions 
[41]. However, this approach often fails for viral loads of <1,000 HCMV copies/ml of 
patient plasma, and it may fail in the detection of mutations that are present in <10 to 20% 
of the viral population [41]. There are other methods also used for the detection of drug 
resistance associated mutations (restriction fragment length polymorphisms and real time 
PCR assays), which have been used especially for UL97 gene [11, 46, 47]. Actually, next-
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generation sequencing (NGS) has been developing and it may allow the identification of 
drug resistance at earlier stages, prior to the predominance of drug resistant viral 
populations [41, 54, 57-59]. Indeed, NGS enable the detection of smaller viral 
subpopulations (1-3%) with suitable precautions for errors introduced during amplification.  
Genotypic analysis has proven to be fast and sensitive, providing results much sooner, 
minimizing selection bias by omitting the need to grow the virus and allowing the 
possibility to test directly on patient specimens and the [44, 60]. Nevertheless, its main 
disadvantage is that resistance mutations cannot be distinguished from sequence 
polymorphisms without prior confirmation by phenotypic analysis [45].  
 
Recombinant Phenotyping Techniques 
The discrimination between polymorphism and resistant-mutation is determined by 
recombinant phenotyping using marker transfer methodologies [55, 61]. Marker transfer 
has been developed to generate recombinant HCMV viruses and characterize the impact of 
specific genetic changes on viral susceptibility and resistance to antiviral drugs [60].  
Although recombinant phenotyping has been technically difficult because of the large size 
of the HCMV genome, its efficiency has been considerably improved in recent years using 
cotransfection and restriction ligase techniques [60-62]. However, this method presents 
some difficulties such as: the natural rate recombination during HCMV replication is low 
(and therefore inefficient); is laboring; the risk of introducing new mutations after 
propagation under drug exposure; and substitutions associated with clinical drug resistance 
do not always confer obvious reductions in phenotypic susceptibility in cell culture or 
biochemical assays [11, 44, 60, 62]. More recently, bacterial artificial chromosome (BAC) 
technology has been applied to generate clonal recombinant viruses for marker transfer 
experiments and is now becoming the method of choice for the characterization of the 
many still uncharacterized resistance-associated substitutions [11, 44, 54, 61, 62].  
 
CHAPTER IV – HCMV drug resistance 
The emergence of HCMV resistance to one or more antiviral agents in 
immunocompromised patients is associated with treatment failure and progression of 
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HCMV disease [40, 41, 63, 64]. Overall, HCMV resistance ranges between 5.0-12.5% for 
SOT recipients and <4.0% for HSCT recipients [11, 41, 44, 48].  
The rates of HCMV drug resistance vary widely dependent on type of patients, and several 
risk factors have already been identified: 1) patient and disease-related factors such as 
SOT, underlying disease, type and degree of host immunosuppression and the occurrence 
of HCMV disease [44, 54, 55, 65]; 2) treatment-related factors such as the prolonged 
antiviral therapy, suboptimal antiviral concentrations due to poor compliance or low drug 
absorption and limited oral bioavailability [19, 40, 41, 44, 51, 65-67]; and 3) viral factors 
such as the establishment of lifelong latency, which allows for late reactivations, the slow 
lytic replication cycle and higher viral load at the start of therapy [11, 40]. Indeed, drug 
resistance may be suspected if persistent or increasing plasma viral loads or overt HCMV 
disease occurs after two or more weeks of therapy [11, 41, 46, 51, 63, 65]. 
The resistance to HCMV antiviral drugs has been associated with single or multiple 
mutations in the viral phosphokinase (pUL97) and DNA polymerase (pUL54) that confer 
various levels of resistance [11, 40, 46, 47, 50, 56, 60, 65].  
 
UL97 mutations 
UL97 is a β2 delayed early gene located in the position 97 of the unique long region of 
HCMV genome and encodes for the viral phosphokinase pUL97 [11, 60, 62]. Structurally, 
pUL97 can be divided into different conserved functional regions: I, II, III, VIB, VII, VIII 
and IX [11, 44, 45, 54, 62] – Figure 2. While region I is responsible for adenosine 
triphosphate (ATP) binding, regions II, III, VIB and VII are involved in the phosphate 
transfer and region IX is essential for substrate binding [11, 46, 62]. 
pUL97 is required for phosphorylation of serine and threonine residues of various cellular 
and viral proteins, and is essential for efficient HCMV replication [11, 45, 54]. pUL97 has 
a crucial role in the phosphorylation of the GCV/VGCV, which is necessary for generation 
of its active forms and consequent inhibition of viral polymerase [44, 62]. Hence, 
mutations in UL97 that impair this phosphorylation in virus-infected cells are the preferred 
mechanism of viral resistance [26, 37].  
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Figure 2: UL97 structure and functional domains. Adapted from [11, 45, 46]. 
Approximately 95% of GCV/VGCV-resistant HCMV strains contain one or more 
mutations in UL97 [26, 47, 49, 64, 68-70]. Typically, amino acid substitutions or short (1- 
to 17-amino-acid) in-frame deletions that change the ATP binding sites or phosphate 
transfer site alter the ability of pUL97 to phosphorylate GCV/VGCV [11, 42, 46, 54, 62, 
68]. In UL97, known resistance-mutations are strongly clustered at codons 460 (region 
VIB) and 520 (region VIII), which are located at conserved kinase domains and therefore 
are essential for its function [11, 62]; and 590-607 (non functional region) which is 
dispensable for viral replication, nevertheless mutations in this region impair the 
recognition of GCV as a substrate [11, 62]. In fact, these regions encode a large variety of 
point mutations and deletions that confer different degrees of resistance to GCV/VGCV 
but do not affect susceptibility to FOS or CDV [11, 41, 44, 61, 62] – Table II.  
By revising literature regarding the UL97 mutations in immunocompromised patients, 
including transplantation recipients and patients with AIDS, it was found that mutations in 
three specific codons (460, 594, and 595) accounting for approximately 70% of GCV-
resistant HCMV strains [11, 44, 45, 49, 62, 68-70]. In fact, the most common UL97 
mutations associated with GCV resistance are M460I/V, H520Q, C592G, A594V, 
L595F/S/W, and C603W [45, 68-70]. All of these mutations have been described by 
recombinant phenotyping to confer a 5- to 16-fold increased GCV IC50 [45, 60-62, 68, 
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71], except C592G, which has been referred as preferentially selected in situations where 
the virus is exposed to low GCV concentrations [44, 45, 62, 68].  
A variety of uncommon mutations (amino acid substitutions or deletions) that were 
reported to confer at least a 2-fold reduction in susceptibility to GCV are known to occur in 
different UL97 codons – Table II. Some of these mutations (L405P, V466G, A594E/P/T, 
L595T, E596G, I610T and A613V) confer low-grade resistance (2-4x increased IC50), 
while others (F342S, del355, V356G, D456N, M460T, C480R, C518Y, P521L, del590-
600, del591-594, del591-607, C592F, A594G, del595, del595-603, E596Y, K599T, 
del601-603, C603R, C607Y/T, and del617) confer a moderate to higher GCV resistance 
(5-32x increased IC50) [46, 61, 68, 72-80]. Nevertheless, the del600, C603S, C607F, and 
E655K mutations have been shown to confer a <2-fold reduction in IC50 but have been 
reported to be clinically significant [11, 61, 68, 81].  
There are also other mutations (M460L, del590-603, del594-595, del596, G598S, K599E, 
del601, T601M) that appear to confer significant GCV resistance based on recombinant 
phenotyping [82-87] and many other (V498I, A590T, A591D, E596D, N597I, G598V, 
K599M, del600-601, del601-602, C603Y, del597-603, C606D and C607S) that despite 
found in clinical isolates have not been yet phenotyped by marker transference [60, 61, 
84]. Some of these non-phenotyped mutations were found in clinical isolates in 
combination with other mutations that confer resistance to GCV [40, 60, 61, 84, 88, 89]. 
Literature shows that there are several amino acid changes in UL97 that do not correspond 
to resistant mutations, being considered as natural polymorphisms (e.g. H469Y, A478V, 
A588V, L600I, M615V, G623S, T659I and V665I) [61, 62, 90]. Nevertheless, there are 
some amino acid positions where single-base modifications change from natural 
polymorphism to resistant-mutation: K599R has been assessed as a polymorphism [61] 
while K599T was reported to induce GCV resistance [74]; and V466G, but not V466M, 
confers resistance to GCV [61, 90, 91]. Furthermore, some natural polymorphisms may 
modulate the drug-resistance level when combined with other mutations [67, 91]. Indeed, 
some authors suggest that the D605E could “partially or totally compensate” the effect of 
the GCV resistance, conferred by M460V [55, 62, 67] or A594P [55, 72]. Similarly, 
N510S mutation has been identified in combination with 591–594 deletion which is 
associated with resistance despite it has been shown that the level of resistance was not 
higher than the clinical isolate harboring the 591-594 deletion alone [68, 91]. 
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Finally, there are some mutations described in in vitro studies (G340V, A442V, L446R, 
and F523C) that lead technically to GCV resistance, but are not expected to occur in 
clinical isolates since such mutations impair biological function by the loss of 
autophosphorylation and thus promote a severe growth deficiency [11]. 
 
Ana Bela Saraiva de Campos 
Master Degree Course in Medical and Molecular Oncology 
Page 
138 
CHARACTERIZATION OF CYTOMEGALOVIRUS RESISTANT 
STRAINS IN HEMATOPOIETIC STEM CELL TRANSPLANTED PATIENTS   
 
Table II: Mutations in viral phosphokinase (UL97) gene associated with GCV/VGCV resistance in laboratory and clinical isolates 
confirmed by marked transfer. 
Mutation 
Amino acid change 
Viral Phenotype 
GCV/VGCV 
(IC50)
a) 
References 
Wild type (Wt) Mutant 
F342S F S R (7.8) [76] 
del355 K Del 1 R (16) [76] 
V356G V G R (5.5) [76] 
L405P  L P R (2.5) [61] 
D456N D N R (12) [77] 
M460I M I R (5) [40, 65, 68, 75, 88, 92-97] 
M460L M L NA [50] 
M460T  M T R (9.3) [61, 65] 
M460V M V R (8.3) 
[41, 42, 50, 63, 65-68, 71, 
75, 88, 90, 92, 94, 98-104] 
V466G V G R (3.5) [65, 90] 
C480R D R R (9) [77] 
C518Y C Y R (12) [105] 
H520Q H Q R (10) 
[41, 65, 68, 88, 98, 101, 
102] 
P521L P L R (17) [76] 
del591-594 b) ACRA Del 4 R (6) [65, 68, 101] [106] 
del590-600 AACRALENGKL Del 11 R (6.3) [78] 
Del590-603 AACRALENGKLTHC Del 14 NA [107] 
del591-607  ACRALENGKLTHCSDAC Del 17 R (6.2) [65, 68] 
C592F C F R (31.5) [79] 
C592G  C G R (2.9) 
[40, 41, 61, 63-65, 68, 71, 
75, 90, 93, 98, 102-104] 
[108, 109] 
A594E  A E R (3.0) [61, 65] 
A594G A G R (13.5) [110] 
A594P A P R (2.9) [40, 65, 72, 88, 103] [111] 
A594T A T R (2.7) 
[27, 40, 64, 66, 68, 75, 88, 
92, 98, 101] [112] 
A594V A V R (8.3) 
[40, 41, 50, 52, 57, 58, 61, 
64-66, 68, 71, 75, 88, 92, 
94, 95, 97, 98, 100-104, 
111, 112] 
del594-595 AL Del 2 NA [85] 
L595F L F R (15.7) 
[65, 68, 75, 90, 94, 103] 
[113] 
L595S L S R (9.2) 
[40-42, 52, 64-66, 68, 71, 
75, 88, 92-95, 97, 98, 100-
103, 112] 
L595T L T R (2.2) [75] 
L595W L W R (5.1) [52, 65, 68, 88, 102, 105] 
del595 L Del R (13.3) [65, 102] [114] 
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del595-603 LENGKLTHC Del 9 R (8.4) [65, 73, 115] 
del596 E Del 1 NA [86] 
E596G E G R (2.3) [40, 65, 68] 
E596Y E Y R (6.4) [46] 
G598S G S NA [65, 82] [116] 
K599E K E NA [86] 
K599T  K T R (5.3) [27, 74] 
del600 L Del r (1.9 [65, 68, 102] 
del601 T Del NA [83, 102] 
del601-603 THC Del 3 R (11) [65, 99] 
T601M T M NA [87] 
C603R C R R (3.6 - 8.3) [61, 65, 88, 90] 
C603S C S r (1.9) [61, 65, 88] 
C603W C W R (8) 
[40, 41, 61, 65, 66, 68, 75, 
88, 93, 97, 101-103, 109] 
C607F C F r (1.9) [41, 65, 68, 101] 
C607T C T R (12.5) [80] 
C607Y C Y R (12.5) [58, 65, 68, 88, 96, 101] 
I610T I T R (2.6) [46] 
A613V  A V R (2.3) [117] 
del617 Y Del 1 R (10) [77] 
E655K E K r (1.7) [81] 
 
Boldface indicates the most common mutations conferring resistance; Deletions start at the 
designated codon and continue through the number of shown codons; R, resistant strain 
(2 fold reduction in susceptibility to GCV/VGCV); r, low-grade resistance or <2 fold 
reduction in susceptibility to GCV/VGCV; NA, not available. 
a) The level of resistance of each mutation is expressed as the ratio of the half maximal 
inhibitory concentration (IC50) of the mutant to that of drug – sensitive wild-type (IC50 of 
mutant/IC50 of wild type ratio); b) Deletion of codons 591 to 594 results in the same 
mutant virus as deletion of codons 590 to 593; 
 
 
 
Ana Bela Saraiva de Campos 
Master Degree Course in Medical and Molecular Oncology 
Page 
140 
CHARACTERIZATION OF CYTOMEGALOVIRUS RESISTANT 
STRAINS IN HEMATOPOIETIC STEM CELL TRANSPLANTED PATIENTS   
 
UL54 mutations 
The UL54 gene is a β2 delayed early gene located on the position 54 of the unique long 
region of HCMV genome which encodes for the viral DNA polymerase (pUL54) [60]. 
Both DNA and amino acid sequence analysis revealed that this protein has significant 
homology to the pol genes of other herpesviruses but also with DNA polymerases encoded 
by a wide range of organisms [49, 60]. There are two functions extremely important in 
viral polymerases: the 3´-5´ exonuclease activity (Exo I through III) and polymerization (I 
through VII). In addition, the Delta-region (∂-region) C has also been suggested to 
participate in 3´-5´ exonuclease activity of pUL54 [11, 45] and there is an overlap of Exo 
II with polymerization region IV and of Exo III with ∂-region C [11, 45] – Figure 3.  
 
 
Figure 3: UL54 structure and functional domains. Adapted from [11, 45, 46]. 
 
pUL54 is the central enzyme involved in viral DNA replication and the primary drug target 
for current therapies (GCV/VGCV, FOS and CDV) [42, 43, 60]. The mechanisms of 
resistance postulated for either GCV-triphosphate or CDV-diphosphate are: 1) decreased 
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affinity of the enzyme for the inhibitor; 2) decreased selective incorporation of the 
inhibitor into the elongating DNA chain; or 3) enhanced selective excision from the DNA 
chain of the incorporated inhibitors [11, 45]. Furthermore, as FOS is not incorporated into 
the DNA the resistance if often associated with decreased affinity of the enzyme [11, 45].  
Mutations in UL54, despite less common than mutations in the UL97, are clustered over a 
much larger area of the gene and the positions of known resistance-conferring mutations 
are more varied [44, 50, 57]. Although uncommon, it has been reported the appearance of a 
resistance UL54 mutations in the absence of a UL97 mutation [11, 47]. Indeed, the 
combination of amino acid substitutions in pUL97 and pUL54 resulted in greater reduction 
in susceptibility to GCV than in isolates with only one amino acid substitution [58, 71, 
108].  
As the majority of UL54 resistant-mutations occur within the conserved regions of 
homology the particular resistance phenotype largely correlates with its location within the 
genome [42, 44, 45, 47] – Table III. Mutations that confer resistance to GCV and CDV are 
most often found within the exonuclease domains and region V, whereas mutations located 
within the C-terminal extremity of ∂-region C and within or next to conserved regions II 
and VI, seem to be mostly involved in FOS resistance [44, 45, 47, 54]. Deletion of codons 
981-982 in region V causes resistance to GCV, CDV and FOS, while mutations within 
conserved region III can be associated with resistance to any single agent or combination 
of agents, and no drug resistance mutations have so far been detected in regions I and VII 
[11, 44, 45, 47].  
Despite of the majority of UL54 mutations that confer resistance to GCV/VGCV also 
confer it to CDV and/or FOS [11, 50, 57, 65, 66] are there others that confer only to GCV 
or CDV or FOS [54, 97, 118]. The D542E and K805Q is the single mutation which confers 
resistance only to CDV [65, 75, 119, 120]; while L802V, P829S, L862F and L957F are the 
mutations which confers resistance only to GCV [54, 97, 118, 121]; and N495K, S585A, 
D588E, F595I, A692S, T700A, V715M, E756D/Q, W780V, T838A, M844T and V946L 
confer resistance only to FOS [15, 42, 54, 58, 65, 75, 95, 102-104, 118, 122, 123].  
As in UL97, the impact on drug resistance of each mutation in UL54 is variable and has 
been demonstrated by several recombinant phenotyping studies – Table III. There are 
several mutations (Q578H, E756K, L773V, T813S, A834P, G841A and del 981–982) that 
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confer a ≥2-fold reduction for all three drugs, with A834P and Q578H to be the most 
frequently found [41, 50, 57, 58, 65, 103, 104, 118, 124].  Nevertheless, some (T821I and 
M844V) do not confer a ≥2-fold reduction to all of three drugs [11, 46, 60, 108, 113, 118, 
119, 122, 124-126]. Cross-resistance between GCV and CDV has been reported more 
frequently than between the GCV and FOS [11, 46, 47, 56, 60, 65] and the most frequent 
mutations are P522S, A987G, L545S and T503I [40, 41, 50, 58, 65, 75, 88, 102, 103, 127, 
128]. Among mutations that confer ≥2-fold resistance to GCV and CDV (D301N, 
N408D/K/S, N410K, F412C/L/S/V, D413A/E/N, P488R, K500N, L501I, T503I, 
K513E/N/R, L516R, I521T, P522A/S, V526L, C539G/R, L545S/W, V812L, A987G and 
del524) the majority to exhibit greater resistance to CDV than to GCV [11, 46, 60, 96, 118, 
119, 122, 124, 125, 129]. Similarly, there are several mutations with cross-resistance (≥2-
fold reduction) to GCV and FOS (D515E/Y, D588N, V776M, V781I, V787A/L, L802M, 
A809V and G841S), being the most frequent D588N, V781I, L802M and A809V, and with 
the majority to confer greater resistance to FOS than to GCV [46, 58, 65, 75, 88, 102, 103, 
108, 109, 119-121, 124, 128, 130].  
The mutations that confer higher rate of GCV-resistance are D413A, L501I, K513N and 
deletion of codons 981 to 982 which have been associated with a 6- to 8-fold increased 
resistance [11, 46, 60, 71, 113, 119, 122]; while for CDV are N408K, F412C/S/V, 
D413A/N, K513N/R, C539R, D542E and A987G which have been associated with a 10- to 
21-fold decrease in susceptibility [11, 118, 119, 124, 125]; and for FOS are V715M, 
E756K, L802M, A809V, T821I and A834P which confer 5.5- to 21-fold increased 
resistance [108, 118-120, 122, 124, 125]. In addition, there are several mutations (A505V, 
T552N, Q578L, I726T/V, W780V, L802V, T821I, M844V and L862F) that confer a <2-
fold reduction in susceptibility to HCMV-antiviral drugs in phenotypic assays and have 
been found in both laboratory and clinical isolates and lack more evidences [54, 58, 60, 
118, 126, 130].  
Despite of some UL54 mutations have little direct impact on HCMV susceptibility to 
drugs; they may augment the effect of other mutations, either by directly enhancing 
resistance or indirectly by increasing viral fitness [54, 60, 118, 120, 125]. For example, 
K805Q seem to improve the viral fitness (replication kinetics) of T821I which is associated 
with high resistance to FOS [120]. N408K in combination with A834P also partially 
reconstituted the replication impairment of recombinant virus containing only A834P 
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[125]. This suggests that perturbation of both polymerization (A834P) and exonuclease 
(N408K) activities contributes to increased GCV and CDV resistance ([125]). Others 
combinations, such as N408D/L957F, L545S/P829S and L957F/T552N showed FOS 
resistance whereas the single mutations did not [54, 118]. Moreover, some studies 
suggested that the occurrence of mutations within conserved regions contribute to FOS 
resistance due since it is associated with a slower replication of HCMV [95, 104, 123, 
131].  
Two polymorphisms laying in conserved regions (E506K in ∂-Region C and R785S in 
region VI) thought to be associated with resistance are described in a position with high 
variability amongst herpesviruses DNA polymerase, supporting the theory that they may 
be natural variants [127]. Nevertheless, polymorphisms in UL54 occur frequently outside 
the conserved regions and are relatively common which makes more complicated to 
distinguish them from true resistance mutations [11, 47]. For example, the P522L 
polymorphism, located at the same position as confirmed resistance-associated mutation 
(P522S), and  the E315D, D879G and A972V polymorphisms have also been observed in 
patients failing treatment or prophylaxis [40, 60]. Furthermore, there are several other 
amino acid substitution (i.e. M393R/K, L501F, L516M, P608S, T610M, A614S, G629S, 
I722V, Y751H, S880L, S897P and R1052C) found in clinical isolates that have not been 
phenotyped by marker transfer yet [40, 56, 75, 97, 103, 132]. A number of other mutations 
observed after in vitro or in vivo drug exposure have not been confirmed, and they 
illustrate the potential diversity and distribution of pol mutations, which may not be the 
same in laboratory strains as in clinical isolates [11].  
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Table III: Mutations in DNA polymerase (UL54) gene associated with antiviral resistance in laboratory and clinical isolates confirmed 
by marked transfer. 
Mutation 
Amino acid change Viral Phenotype a) 
References Wild type 
(Wt) 
Mutant GCV (IC50) CDV (IC50) FOS (IC50) 
Exo I (295 - 312) 
D301N D N R (2.6) R (3) S (0.5) [65, 122] 
IV / Exo II (379 - 421 / 404 - 418) 
N408D N D R (4.9) R (5.6) S (1.3) 
[50, 58, 65, 75, 98, 103, 
118, 119, 125] 
N408K N K R (4.2) R (21) S (0.7) [50, 65, 103, 125] 
N408S N S R (3.1) R (7.5) S (1.0) [96] 
N410K N K R (2.9) R (3) S (0.8) [65, 122] 
F412C F C R (4.2) R (18) S (1.2) [41, 65, 75, 93, 109] 
F412L  F L R (4.6) R (9.4) S (1.1) [54, 65, 124] 
F412S F S R (5.3) R (13) S (0.8) [54, 65, 88, 124] 
F412V F V R (4.3) R (15.5) S (1.1) [65, 119] 
D413A D A R (6.5) R (11) S (0.8) [65, 99] 
D413E D E R (4.8) R (4.3) S (0.8) [65, 98, 103, 122] 
D413N D N R (3.8) R (10) S (1.0) [58] 
Outside conserved region 
P488R  P R R (3.5) R (7.9) S (0.6) [54, 118] 
∂-Region C (492 - 588) 
N495K  N K S (1.1) S (1.1) R (3.4) [42, 65, 123] 
K500N K N R (3.2) R (3.0) S (1.2) [54, 118] 
L501I L I R (6) R (9.1) S (1.4) [41, 50, 65, 75, 119] 
T503I T I R (2.9) R (6.1) S (0.5) [41, 65, 75, 122] 
A505V A V r (1.8) R (2) S (1.1) [130] 
K513E K E R (5) R (9.1) S (1.4) [65, 75, 93, 119] 
K513N K N R (6) R (12.5) S (1.5) [65, 131] 
K513R K R R (3.7) R (10) S (1.1) [58, 75] 
D515E D E R (2.7) NT R (4.6) [103] 
D515Y D Y R (5.6) NT R (4.6) [103] 
L516R L R R (2.1) R (5.1) S (0.8) [65, 122] 
I521T I T R (2.1) R (5.1) S (0.8) [65, 97, 129] 
P522A P A R (3) R (4.1) S (1) [41, 65, 98, 129] 
P522S P S R (3.1) R (3.6) S (1.1) 
[41, 42, 58, 65, 66, 88, 
102, 119, 128] 
del524 C del1 R (3.5) R (9.7) S (1.1) [96] 
V526L V L R (5.5) R (2.5) S 1.8) [81] 
ExoIII / ∂ region C (533 - 545 / 492 - 588) 
C539G C G R (3.1) R (4.4) S (1.0) [58] 
C539R  C R R (3.2) R (13.3) S (0.7) [54, 118] 
D542E D E S (1.5) R (12) S (1.7) [133] 
L545S L S R (3.5) R (9.1) S (1.2) [40, 65, 118, 119, 127] 
L545W L W R (4.9) R (6.3) S (1.3) [54, 65, 124] 
∂-Region C (492 – 588) 
T552N T N r (1.9) S (1.2) R (2.6) [54, 118] 
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Q578H Q H R (3.3) R (2.3) R (4.5) 
[54, 57, 58, 65, 124] 
[134]  
Q578L Q L r (1.9) S (0.8) R (3.0) [58, 60] 
 S585A S A S (1.5) S (1.4) R (2.7) [54, 118] 
D588E D E S (1.3) S (1.1) R (2.3) [65, 75, 119] 
D588N D N R (3.8) R (2.7) R (3.2-9) [41, 65, 93, 104, 124] 
Outside conserved region 
F595I  F I S (1.3) S (1.2) R (2.0) [54, 118] 
A692S A S S (1.6) S (1.7) R (3.3) [102, 122] 
Region II ( 696-742) 
T700A T A S (0.9) S (1.5) R (4.7) [63, 65, 95, 98, 119] 
V715M V M S (1.0) S (1.1) R (5.5) 
[58, 64, 65, 88, 95, 111, 
119, 128] 
I726T I T R (2.0) r (1.7) S (1.1) [130] 
I726V I V r (1.9) r (1.9) S (1.2) [130] 
Outside conserved region 
E756D E D S (1.2) S (0.7) R (3.4) [65, 98, 122] 
E756K E K R (2.5) R (2.2) R (>8) [93, 122] 
E756Q E Q S (1.7) S (1.0) R (4.3) [128] 
Region VI (771- 790) 
L773V L V R (3.0) R (2.5) R (4.4) [58] 
L776M L M R (2.5) S (1) R (3.5) [65] 
W780V W V S (1.5) NA r (1.9) [126] 
V781I V I R (1-4) S (1.2) R (4-5.2) 
[58, 75, 93, 102, 119, 
128] 
V787A V A R (2.5) NA R (3.5) [111] 
V787L V L R (2.4) S (1) R (4.1) [102, 118, 128] 
Outside conserved region 
L802M L M R (1.1-3.5) S (0.9-1.8) R (3.2-11) 
[41, 75, 93, 97, 103, 104, 
109, 118, 119] 
L802V L V r  (1.8) S (1.1) S (0.9) [54, 118] 
Region III (805 – 845) 
K805Q K Q S (1) R (2.2) S (0.18) [75, 119, 120] 
A809V A V R (2.6) S (1.7) R (6.3) [58, 88, 108] 
V812L V L R (2.5) R (3.2) R (2.9) [104, 118, 131] 
T813S  T S R (2.5) R (2.7) R (4.9) [108] 
T821I T I R (4.5) r (1.9) R (21) [75, 119, 120] 
P829S P I R (2.0) S (1.6) S (1.1) [54, 118] 
A834P A P R (5.4) R (3) R (6.4) [41, 50, 57, 58, 103, 125] 
T838A T A S (1.8) S (0.8) R (2.4) [104] 
G841A G A R (3.2) R (2.6) R (4.3) [41, 98, 108] 
G841S G S R (2.2) S (1.1) R (2.1) [130] 
M844T M T S (1.4) S (1.3) R (2.5) [135] 
M844V M V R (2.5) r (1.6) R (2.2) [135] 
Outside conserved region 
L862F  L F r (1.7) S (0.9) S (1.1) [54, 118] 
V946L  V L S (1.1) S (0.9) R (2.4) [54, 118] 
L957F L F R (2.7) S (1.4) S (1.3) [54, 118] 
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Boldface indicates the mutations conferring resistance; Deletions start at the designated 
codon and continue through the number of shown codons; R, resistant strain (2 fold 
reduction in susceptibility to antiviral drugs); r, low-grade resistance or <2 fold reduction 
in susceptibility to antiviral drugs; S, sensitive strain; NA, not available; NT, not tested. 
a) The level of resistance of each mutation is expressed as the ratio of the half maximal 
inhibitory concentration (IC50) of the mutant to that of drug – sensitive wild-type (IC50 of 
mutant/IC50 of wild type ratio); 
 
Region V (978 – 988) 
del981-2  DL Del 2 R (8.3) R (2.8) R (3.6) [58, 71, 113, 122] 
A987G A G R (5.3) R (11.3) S (1.2) 
[41, 50, 88, 102, 103, 
119] 
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CHAPTER V – New strategies for HCMV management 
New treatment options for HCMV infection in immunocompromised patients are urgently 
needed because the currently available drugs have major limitations, illustrated by their 
toxicities (hematotoxicity for VGCV, nephrotoxicity for FOS and CDV) and the 
phenomenon of drug resistance. Given the paucity of current antivirals drugs, the 
emergence of HCMV resistance to antivirals constitutes a rising therapeutic challenge. 
Moreover, multidrug resistant HCMV infections remain a clinically challenging 
complication [136, 137]. 
In allo-HSCT recipients, the high level of cellular immunosuppression, including a deficit 
in number and function of HCMV-reactive T cells, deeply impairs the host response 
towards HCMV active infection and constitutes a risk factor for the emergence of HCMV 
drug resistance [138]. In this context, adoptive transfers of HCMV-specific T-cell could 
constitute a beneficial strategy, but still remains logistically complicated [139, 140]. 
Three novel oral drugs targeting HCMV replication are being evaluated in clinical trials. 
Brincidofovir (hexadecyloxypropyl-CDV; CMX001), the lipid conjugate of CDV, has 
been reported to be less nephrotoxic than CDV [141] and to prevent efficiently the 
incidence of HCMV events in HSCT recipients [142]. Maribavir (MBV) is a 
benzimidazole riboside that impairs viral encapsidation and nuclear egress of viral particles 
through the direct inhibition of HCMV UL97 phosphotransferase. Despite promising 
previous results, a low-dose phase III MBV study failed to prevent HCMV disease in allo-
HSCT recipients [143]. However, few reports suggest some efficacy of high-dose MBV 
treatment as salvage therapy [144, 145]. MBV has completed a phase II trial for the 
treatment of resistant or refractory HCMV infections in transplant recipients, but results 
are still unknown (clinicaltrials.gov NCT01611974). Letermovir (AIC246, MK-8228) is a 
highly selective anti-HCMV agent that inhibits the viral terminase complex [146, 147]. 
Two successful phase II clinical studies demonstrated the efficacy of letermovir for HCMV 
prevention in transplant recipients [148, 149]. However, one letermovir resistance mutation 
has been evidenced in a case of HCMV breakthrough during prophylaxis [150]. 
Letermovir has recently entered a phase III study for the prevention of HCMV infection in 
adult allo-HSCT recipients (clinicaltrials.gov NCT02137772).  
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The use of drugs targeting cellular pathways, rather than HCMV replication, may 
constitute an alternative for the treatment of HCMV infections. The antimalarial agent 
artesunate has an anti-HCMV activity through the downregulation of NF-kB and Sp1 
signaling pathways [151]. Artesunate has been used in salvage situations with mixed 
results [152]. Leflunomide, an immunosuppressive agent used for the treatment of 
rheumatoid arthritis, inhibits HCMV replication by preventing tegument acquisition by 
viral nucleocapsids [153]. This drug, alone or in combination, has potential utility in the 
treatment of complex HCMV syndromes [154]. Finally, the use of immunosuppressive 
agents mTOR inhibitors (i.e., sirolimus and everolimus) in transplant recipients has been 
associated with a lower incidence of HCMV infections [155]. These molecules seem to 
inhibit the later stages of HCMV replication [156]. Moreover, mTOR inhibitors may be 
beneficial in transplant recipients with GCV-resistant HCMV [157]. However, no 
systematic evaluation of these different drugs targeting cellular pathways has been 
performed for HCMV treatment.  
The development of novel anti-HCMV molecules with improved efficacy and lower 
toxicity, targeting different viral proteins, together with the possibility of alternative 
options involving cellular metabolic pathways, will provide new possibilities of 
combination therapy. This strategy, that has proven to be highly effective for the treatment 
of HIV or HCV infections, is now required for the therapeutic management of HCMV 
infection in transplant recipients, since the incomplete viral suppression obtained with a 
single agent may not be supplied by the host immune system.  
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